GENE EXPRESSION PROFILES REVEAL ALTERNATIVE TARGETS OF THERAPEUTIC INTERVENTION FOR THE TREATMENT OF DRUG-RESISTANT NON-SMALL CELL LUNG CANCERS by Krentz Gober, Madeline J.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Pharmacy College of Pharmacy 
2017 
GENE EXPRESSION PROFILES REVEAL ALTERNATIVE TARGETS 
OF THERAPEUTIC INTERVENTION FOR THE TREATMENT OF 
DRUG-RESISTANT NON-SMALL CELL LUNG CANCERS 
Madeline J. Krentz Gober 
University of Kentucky, madeline.krentz@uky.edu 
Author ORCID Identifier: 
https://orcid.org/0000-0001-7761-6741 
Digital Object Identifier: https://doi.org/10.13023/ETD.2017.309 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Krentz Gober, Madeline J., "GENE EXPRESSION PROFILES REVEAL ALTERNATIVE TARGETS OF 
THERAPEUTIC INTERVENTION FOR THE TREATMENT OF DRUG-RESISTANT NON-SMALL CELL LUNG 
CANCERS" (2017). Theses and Dissertations--Pharmacy. 78. 
https://uknowledge.uky.edu/pharmacy_etds/78 
This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It 
has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Madeline J. Krentz Gober, Student 
Dr. Esther P. Black, Major Professor 
Dr. Dave Feola, Director of Graduate Studies 
GENE EXPRESSION PROFILES REVEAL ALTERNATIVE TARGETS OF 
THERAPEUTIC INTERVENTION FOR THE TREATMENT OF DRUG-
RESISTANT NON-SMALL CELL LUNG CANCERS 
 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment of the  
     requirements for the degree of Doctor of Philosophy
     in the College of Pharmacy at the 
                            University of Kentucky 
 
By: 
Madeline J. Krentz Gober  
Lexington, Kentucky 
Director:   
Dr. Esther P. Black, Ph.D., Professor of Pharmaceutical Science 
Lexington, Kentucky 
2017 
Copyright © Madeline Krentz Gober, 2017 
  
 DISSERTATION
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
GENE EXPRESSION PROFILES REVEAL ALTERNATIVE TARGETS OF 
THERAPEUTIC INTERVENTION FOR THE TREATMENT OF DRUG-
RESISTANT NON-SMALL CELL LUNG CANCERS 
 
More than 80% of lung cancer patients die from drug-resistant, metastatic 
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strategies to improve outcomes for this majority of lung cancer patients. We aimed 
to satisfy the need for new treatment approaches by leveraging the information 
gained from the development of two multigene biomarker predictors of Epidermal 
Growth Factor Receptor Inhibitors (EGFRI) response in Non-Small Cell Lung 
Cancer (NSCLC). From these data, we first identified TGFβ signaling as a possible 
modulator of EGFRI resistance and I hypothesized that TGFβ signaling 
participates in the development and maintenance of erlotinib-resistance and -
sensitivity and regulates the gene expression of the miRNA comprising the 
signature of response. To identify novel putative treatment strategies for 
overcoming EGFRI resistance, we leveraged the raw data used to build the 
EGFRI-response predictors of NSCLC cells with divergent EGFRI responses using 
mathematical and protein-protein interaction modeling to identify a network of 
deregulated proteins in EGFRI-resistant cells. From this analysis, we identified a 
drug combination that is kills EGFRI-resistant NSCLC cells and further study will 
confirm if this novel strategy translates into a clinically utilizable option for the 
treatment of EGFRI-resistant NSCLC. 
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CHAPTER 1 
A. LUNG CANCER OVERVIEW 
Overview of Cancer 
Cancer is a group of genetic diseases that are caused by DNA damage and epigenetic 
changes. These changes result in cells that are characterized by uncontrolled growth, 
unchecked survival, and invasion into surrounding and distant tissues.  
Cancers are classically characterized by six hallmarks with an additional two hallmarks 
and two tumor-enabling characteristics that are increasingly recognized (1):  
1) Growth signal autonomy: Normal cells require direction of external growth
factors to drive replication. Cancers circumvent this need by mutational loss of 
growth factor pathway regulation and sometimes autonomous secretion of and 
response to growth factors. 
2) Genomic instability: This is a tumor-enabling characteristic. Tumor cells
gain increasing numbers of mutations and epigenetic changes that are selected 
for by pressure over successive generations.   
3) Evasion of growth and proliferation inhibitory signals: The majority of the
body’s healthy cells are not actively dividing. This is due to their response to growth 
inhibitory signals that are required to maintain homeostasis and prevent unwanted 
growth. Cancers develop acquired mutations to evade these inhibitory signals. 
4) Tumor promoting inflammation: This is another tumor-enabling
characteristic. Pathways that respond to signals from the immune system that are 
intended to induce cell death are co-opted by tumors to enhance tumorigenesis 
and progression. 
5) Evasion of apoptosis, or programmed cell death: Normal cells undergo
apoptosis in response to events like DNA damage. Cancer cells evade apoptosis 
generally through loss of apoptotic regulators. 
6) Avoiding immune destruction: The immune system can play a role of
identifying and destroying emerging neoplasias. Tumors develop methods of 
locally disabling immune surveillance mechanisms.  
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7) Gain of unlimited replication potential: Normal cells are programmed to stop 
dividing (senesce) or undergo apoptosis following too many rounds of DNA 
replication and subsequent cell division events. 
8) Angiogenesis, or the formation of new blood vessels: All cells require blood 
vessels to supply oxygen and nutrients and cancer cells induce the formation of 
new blood vessels in order to supply their rapidly growing numbers. 
9) Deregulated cellular energetics: The perpetual proliferation of tumor cells 
requires increased energy metabolism from a variety of sources (e.g., 
carbohydrates or lipids) to produce additional ATP demand to fuel growth. They 
also require larger amounts of cellular building blocks like nucleotides. Tumor cells 
adjust cellular metabolism pathways to meet increased energy requirements by 
the tumor. 
10) Invasion and metastasis: The healthy cells only migrate for the purposes 
of development and wound healing. Cancer cells exploit the pathways that regulate 
these processes in order to invade surrounding tissues with the ultimate goal of 
colonizing tissues at distant sites from the initial, primary tumor site. 
 
Cancers are driven by a series of two types of mutations: 1) gain-of-function 
mutations including amplification events resulting in oncogenic drivers, also known as 
oncogenes, and 2) loss-of-function mutations resulting in loss of genes responsible for 
regulating proliferation and survival, known as tumor suppressors (1). Proto-oncogenes, 
or genes that can become oncogenic with a gain-of-function mutation in one copy of the 
gene, are often involved in growth and proliferation pathways. Tumor suppressor genes 
require the loss-of-function of at least one (for haploinsufficiency and lower gene dose), 
but more often two copies of the gene (complete loss) in the genome. Tumor suppressors 
are most often growth inhibitors, responsive to growth inhibitors, or related to DNA repair 
or cell cycle check points (2). Cancers were initially described as having an “oncogene 
addiction” when cell survival is dependent on the constant over-activation of oncogenic 
signaling pathways (3, 4). However, it is growing increasingly evident that tumors are 
incredibly heterogeneous. Therapeutically targeting only the “oncogene addiction” leads 
to resistance arising from the selection of tumor cells that have alternative means of 
functioning around the inhibited oncogene (4). Moreover, not all tumors have an evident 
single “oncogenic addiction” and it is clear that successful tumor treatment will require the 
therapeutic-targeting of multiple oncogenic drivers and sources of resistance 
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simultaneously or sequentially (4). These specific aberrations in the cancer genome are 
paramount to cancer genesis, adaptability and progression and will be described in depth 
later in this chapter. 
 
Cancer progression is marked by the extent of primary tumor invasion into the 
surrounding tissues. In the later stages, after heavily invading surrounding tissues, tumor 
cells gain the potential to survive beyond the stroma. This process primes them to enter 
nearby blood vessels (intravasation) and be transported to distant organs via the 
circulatory or lymphatic system (5). Following transport, cancer cells exit blood vessels by 
a process called extravasation and either lie dormant or begin colonizing near the site of 
exit (5). The colonization of distant organs is called metastasis and is a hallmark of the 
latest stages of the disease most often resulting in death (1, 5). Lung cancers are 
particularly deadly because the majority of patients present in the later stages of the 
disease where metastatic colonization is already in progress or distant lesions have 
already been confirmed (6).  
 
Lung Cancer Epidemiology 
 
Lung and bronchial cancers represent a significant health issue both in the United 
States as well as abroad and are the number one cancer killer in the world (7). Around 
14% of cancer diagnoses each year are lung and bronchial cancers (6, 8). Lung and 
bronchial cancers are second in the number of diagnoses in both men and women in the 
U.S. each year behind the gender specific cancers, prostate and breast (6, 8). However, 
26-28% of the cancer deaths each year are attributable to lung and bronchial cancers in 
both men and women, which exceeds that of any other cancer (6, 8). The high incidence 
of lung cancer mortality correlates with the fact that 80-85% of patients present in the later 
stages of the disease (6, 8). 
 
The Commonwealth of Kentucky has one of the highest incidences of lung cancer 
in the U.S. with an exceptionally high rate of lung cancer diagnoses in the rural, 
underserved, Appalachian communities (9). Eighty-two percent of lung cancer deaths are 
directly attributable to smoking (10). Frequent indirect smoke exposure also contributes to 
lung cancer development (10). The Commonwealth of Kentucky has one of the highest 
smoking rates in the U.S. (6, 7). Kentucky agriculture has historically relied heavily on 
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tobacco as a major state crop. The federal deregulation of tobacco occurred in the mid-
2000s causing many local farmers to stop growing the crop while the local economy 
suffered accordingly. Many Kentucky smokers still consider smoking to be a form of 
boosting the local economy despite the decrease in working tobacco farms. Other 
environmental sources of carcinogen exposure leading to lung cancer include radon, 
chloromethyl ethers, asbestos, arsenic and other outdoor pollution namely by industry and 
vehicles (11). Of these, high radon levels are also commonly seen in Kentucky (12). 
Moreover, reliance on the rural industry of coal mining exposes many residents of 
underserved Appalachia to additional industrial carcinogens including increased radon 
levels and heavy metal exposure at jobsites (11, 13). The mining industry also introduces 
these carcinogens into the environment where they are commonly found in the air, soil 
and in water runoff further compounding the problem (13).  
 
Lung cancers present as different histological subtypes that are broken down into 
two broad categories: 1) Small Cell Lung Cancers (SCLC) and 2) Non-Small Cell Lung 
Cancers (NSCLC) which encompass adenocarcinomas, bronchioalveolar carcinomas, 
squamous cell carcinomas, and large cell carcinomas. Adenocarcinomas represent the 
largest percentage of lung cancer cases (14).     
 
Common Driver Mutations in Lung Tumors  
 
 Tobacco smoke is the main contributing factor to DNA mutagenesis leading to lung 
cancer pathogenesis, but other environmental factors including radon, occupational lung 
carcinogens and indoor and outdoor pollution contribute to lung cancer development (11). 
The carcinogenic activity of tobacco smoke is largely caused by three specific groups of 
chemicals: 1) tobacco-specific nitrosamines, 2) polycyclic aromatic hydrocarbons, and 3) 
aromatic amines (15). As lung cancers are largely driven by carcinogen exposure resulting 
in DNA damage and epigenetic alterations, they are highly heterogeneous and have one 
of the highest numbers of somatic mutations among cancers (16, 17). This high level of 
heterogeneity among lung tumors complicates molecular testing efforts for drug 
assignment and leads to quick cancer evolution in response to treatment (18). 
 
In recent years, an increasing number of driver mutations in lung cancers have 
been identified. Growth promoting drivers of lung cancers currently known include Kirsten 
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rat sarcoma viral oncogene homolog (KRAS), the epidermal growth factor receptor 
(EGFR), BRAF, MEK-1, HER2, MET, multiple members of the PI3K/AKT/mTOR 
pathways, ALK, ROS1, and rearranged during transfection (RET) (19). Prominent tumor 
suppressors found to be inactivated in lung cancers that are currently known include p53, 
phosphatase with tensin homology (PTEN), members of the p16INK4A/RB pathway and 
STK11. Other less prevalent oncogenes currently being studied in NSCLC include 
fibroblast growth factor receptor 1 (FGFR1), discoidin domain receptor 2 (DDR2), MYC 
family member amplification, and amplification of BCL2 (19). 
 
 
The Oncogenic Drivers of the Hallmarks of Cancer in Lung Tumors 
 
 Most lung adenocarcinomas harbor known oncogenic driver mutations (20). The 
activation of proto-oncogenes into oncogenes often occurs by gene amplification, 
structural rearrangements forming fusion proteins with other genes, deletions and point 
mutations (19). Signaling by oncogenes often results in “oncogene addiction”, making 
those proteins ideal candidates for targeted therapy (3, 4). Unfortunately, the signaling 
pathways regulated by oncogenes and tumor suppressors are commonly interconnected 
and the mutational evolution of tumors in response to disease progression and/or 
therapeutic selection pressure adds complexity to this increasingly intricate relationship 
(19).  
 
 KRAS is a member of the RAS family of proto-oncogenes that include KRAS, 
NRAS, and HRAS. RAS family members encode G-proteins that bind guanosine 
diphosphate (GDP) in inactive form. Upon activation of an upstream receptor tyrosine 
kinase (RTK), they switch to bind guanosine triphosphate (GTP) allowing the activation of 
many downstream pathways (19). These pathways include the mitogen-activated protein 
kinase (MAPK) pathway through ERK and phosphoinositol-3-kinase (PI3K)/AKT/mTOR 
pathway (21). Activation mutations in KRAS are the result of mutations that alter the 
GTPase function of the protein hindering KRAS-GTP from being inactivated into KRAS-
GDP (19, 21). KRAS activation mutations occur in 25-40% of lung adenocarcinoma tumors 
making them the most common oncogenic alterations in lung adenocarcinomas (19, 22). 
Meta-analyses have shown that KRAS mutated tumors are resistant to EGFR inhibitors 
(EGFRI) as KRAS signaling is downstream of the EGFR RTK (23). Mutations in HRAS  
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Figure 1.1: Oncogenic driver mutations and percentage of occurrence in lung 
adenocarcinomas.  
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and NRAS are rare in lung adenocarcinomas (24). KRAS mutations are more common in 
western populations, males and smokers (25, 26). KRAS driver mutations very rarely 
occur in lung adenocarcinomas concurrently with EGFR activation mutations (27).  
 
 BRAF is a serine/threonine protein kinase that is downstream of KRAS signaling 
in the MAPK-ERK signaling pathway (28). Activated BRAF activates MEK1/2, and MEK1/2 
subsequently activates ERK1/2 which regulates transcription factors including c-Jun and 
ELK1 (28). BRAF mutations only occur in about 3% of NSCLC with mutual exclusivity from 
KRAS and EGFR mutations (19, 27). Similar to what is observed in melanoma and 
colorectal cancers, 50-75% of BRAF mutations in lung adenocarcinomas are the V600E 
activation mutation in the kinase domain of the protein (19, 29). Other BRAF mutations 
observed in the kinase domain include D594G and L596R and mutations also occur in the 
activation domain (G-loop) of the protein including G465V and G468A (28, 30).  
 
 MEK1 (also known as MAPK1) is a serine/threonine kinase downstream of RAS in 
the MAPK-ERK signaling cascade (31). Somatic mutations resulting in activation of MEK1 
are rare and found in less than 2% of lung adenocarcinomas. MEK mutations are most 
often activation mutations in exon 2 that is not part of the kinase domain (32). Importantly, 
NSCLC harboring these MEK1 mutations have been shown to be sensitive to anti-MEK 
therapies (32). 
 
 Human epidermal growth factor receptor 2 (HER2/ERBB2) is a member of the 
ERBB/EGFR family of receptor tyrosine kinases. HER2 does not commonly bind ligand 
directly as most ligands have a low affinity for the HER2 receptor (33). Instead, HER2 
binds to other ligand bound receptors of the same family and is a preferential 
heterodimerization partner by other ERBB family receptors (33, 34). HER2 signals through 
a variety of downstream signaling pathways including STAT, PI3K/ATK/mTOR, and 
MAPK-ERK (35). HER2 mutations in NSCLC are observed as an overexpression in 20% 
of cases, as an amplification in 2%, and activation mutations are only observed in 1-4% 
of NSCLC (36, 37).   
 
 MET, also known as hepatocyte growth factor receptor, is a proto-oncogene that 
encodes a membrane-spanning tyrosine kinase receptor (38). Like many other RTKs, 
MET binds its ligand and homodimerizes, which results in the activation of the tyrosine 
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kinase domain. It is able to activate Ras-MAPK-ERK, PI3K-AKT, and c-SRC pathways 
(38). MET amplification is a common mechanism of acquired resistance to EGFR inhibitor 
(EGFRI) treatment and is observed in ~20% (39, 40). MET amplifications are observed in 
treatment naïve patients in approximately 1-7% of tumors (40, 41). MET amplification 
occurrence has been reported as high as 21% in one study of a treatment-naïve cohort of 
western Europeans (all non-Asian), 93% of whom were smokers (42). MET amplification 
leading to acquired EGFRI resistance occurs by aberrant or unregulated PI3K-AKT 
signaling. Tumors harboring a MET amplification have been shown to drive and maintain 
the PI3K/AKT signaling cascade thereby bypassing EGFRI blockade (19). For this reason, 
one of the mechanisms proposed to overcome acquired EGFRI resistance in NSCLC is 
co-treatment with EGFRI and MET inhibitors (39). 
 
 The phosphoinositol-3-kinase (PI3K)/AKT and mTOR signaling pathways are 
responsible for cell survival, proliferation, differentiation, adhesion and motility and are 
also frequently mutated in NSCLC (43). Many of the receptor tyrosine kinases are able to 
activate this pathway including EGFR, MET, HER2, insulin-like growth factor receptor, 
platelet-derived growth factor receptor, and transforming growth factor receptor beta 
(TGFβ) (44). Activated RTKs recruit PI3K to the membrane where it is responsible for the 
phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 
3,4,5-triphosphate (PIP3). Active PIP3 recruits AKT to the membrane where it can be 
phosphorylated by PI3K and/or mTOR (45). RAS family members have been shown to be 
able to activate PI3K directly contributing to the cross talk between PI3K/AKT/mTOR and 
MAPK-ERK signaling cascades (45). The PI3K/AKT/mTOR signaling pathway is 
commonly deregulated in NSCLC, and other cancers, with 50-70% of NSCLC harboring 
PI3K pathway member mutations (22, 44). Oncogenic mutations in PI3K and AKT have 
been reported with amplification of the PIK3CA gene, which encodes the alpha isoform of 
the PI3K catalytic subunit, most commonly observed (44). PIK3CA mutations largely 
involve the catalytic domain and occur in 1-3% of NSCLC (22). Mutations in AKT are rare, 
only being reported in 0.5-2% of NSCLC (22). Loss of PI3K regulation by the tumor 
suppressor component, PTEN, also occurs and will be discussed further below (45). 
 
 ALK is a receptor tyrosine kinase found commonly with a gain-of-function mutation 
in NSCLC resulting in constitutively active ALK signaling (46). ALK mutations are most 
commonly rearrangement mutations resulting in a fusion of the intracellular kinase domain 
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with a different gene, echinoderm microtubule associated protein-like 4 (EML4) (47, 48). 
ALK-EML4 fusion proteins come in a number of variants, but the most commonly 
described is the fusion of exons 1-13 of EML4 joined to ALK exons 20-29 (47, 49). Other 
partner genes besides EML4 have been described recently, but are less common (50). 
Active ALK signaling results in cell proliferation and apoptotic evasion mediated by 
JAK3/STAT3, RAS/MAPK-ERK, and PI3K/AKT signaling pathways (51). Oncogenic ALK 
mutations are susceptible to ALK inhibition by crizotinib (52) and have been found in 
approximately 4-8% of NSCLC (53). ALK rearrangements generally occur exclusively from 
EGFR and KRAS alterations, but instances of ALK rearrangements occurring 
concomitantly with EGFR mutations have been reported as a mechanism for EGFRI 
resistance (20, 47). 
 
 ROS1 is a proto-oncogene encoding a transmembrane receptor tyrosine kinase. 
Its kinase domain has high homology with that of ALK (54). Similar to ALK, ROS1 
mutations are most commonly gene rearrangements resulting in fusion proteins and are 
found in 1-3% of NSCLC (55, 56). A variety of fusion partners have been identified 
including, FIG, KDELR2, TPM3, SDC4, LRIG3, EZR, SLC34A2, and CD74 (50, 56). Early 
clinical evidence has suggested that NSCLC harboring ROS1 rearrangements are 
sensitive to the ALK/MET kinase inhibitor, crizotinib (55). 
 
 Rearranged during transfection (RET) is a proto-oncogene activated by 
chromosomal rearrangement resulting in oncogenic fusion RTK signaling (57). RET is 
most commonly found fused with KIF5B and RET fusions have been identified in 1-2% of 
NSCLC (58). Tumors harboring RET rearrangements are sensitive to several multi-kinase 
inhibitors, and recent in vitro evidence suggests that tumors harboring KIF5B-RET fusions 
are sensitive to RET inhibition (59).  
 
 
The Tumor Suppressors Commonly Lost in Lung Cancer  
 
 Tumor suppressor genes are important negative regulators of cell growth and 
proliferation, and a normal functioning cell requires two copies of these genes to function 
(60). Tumor suppressor genes were famously described as “anti-oncogenes” by Alfred 
Knudson in 1993 where he outlined a “two-hit” hypothesis describing how the loss of two 
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copies of a tumor suppressor gene resulted in carcinogenic activity (60). The first allele is 
most often lost by an inactivation mutation, epigenetic silencing or other aberrations, while 
the second allele is most commonly lost by loss of heterozygosity (LOH) when a region of 
a chromosome is lost by deletion, mitotic recombination, or non-reciprocal translocation 
(19). The most common tumor suppressor genes inactivated in NSCLC are TP53, PTEN, 
the p16INK4A/RB cell cycle regulating pathway, and serine/threonine kinase 11 (STK11). 
Others have been noted, FHIT and RASSF1A, but they are less prevalent in NSCLC than 
those listed and are discussed elsewhere. 
 
 The most commonly occurring gene mutation found in lung cancers is TP53. TP53 
mutations are found in up to 80-100% of small cell lung carcinomas and in up to 65% in 
non-small cell lung cancers, although a consensus on frequency varies (19, 61, 62). p53, 
the protein product of the TP53 gene, is responsible for making cell fate decisions in 
response to damaged DNA by upregulating genes responsible for DNA repair or apoptosis 
accordingly (63). It is also a transcription factor for a host of other genes (19). In healthy 
cells, DNA damage or other carcinogenic stress induces p53 expression, which promotes 
DNA repair or cell cycle arrest by inducing the expression of cyclin-dependent kinase 
inhibitors (64). For this reason, p53 plays a crucial role in determining cell fate between 
whether to repair DNA damage or undergo apoptosis (65). TP53 loss is most commonly 
due to a hemizygous deletion of the chromosomal locus in which it resides (19). TP53 loss 
of function also occurs when missense mutations in the DNA binding domain occur (62). 
TP53 mutations in NSCLC correlate with a history of smoking or environmental exposure 
to smoke (64, 66). TP53 mutations can occur concomitantly with EGFR and KRAS 
mutations (67). 
 
 A second commonly mutated tumor suppressor is phosphatase with tensin 
homology (PTEN). As discussed earlier, PTEN is a lipid and protein phosphatase 
responsible for inhibiting PI3K/AKT/mTOR signaling. It does this by dephosphorylating 
PIP3 back into PIP2 (68). 
 
STK11 (also known as LKB1) is a serine/threonine kinase responsible for inhibiting 
mTOR (69). As described above, components of the AKT/mTOR signaling pathway have 
been found to be deregulated in around 30% of lung adenocarcinomas (22). STK11 
activity is inhibited by a variety of deletion or other somatic mutations leading to inactive,  
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Figure 1.2: Tumor suppressors that are commonly lost in lung adenocarcinomas. 
Percentage of lung adenocarcinomas with each tumor suppressor loss. Occurrence laid 
over the oncogenic driver mutations in lung adenocarcinomas.    
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truncated proteins (70). Inactivation of STK11 specifically occurs in 11-30% of lung 
adenocarcinomas (22, 70, 71). STK11 inactivation mutations comprise the third most 
common mutation observed in lung adenocarcinomas behind p53 and KRAS (19, 70). It 
has been suggested that STK11 mutations correlate to smoking history. STK11 loss has 
also been correlated with the existence of KRAS mutations. Smoking status, KRAS 
mutations, and STK11 mutations are mutually exclusive of EGFR mutations (70, 71). 
 
 The p16INK4A/cyclin D1/CDK4/RB pathway is responsible for cell cycle progression 
between G1 and S phase and members of the pathway are commonly mutated in lung 
cancers (19). Retinoblastoma protein (Rb), encoded by the RB1 gene, mediates the G1/S 
transition of the cell cycle by sequestering the E2F1 transcription factor required for S-
phase entry until its phosphorylation (72). RB1 was the first tumor suppressor gene 
described in lung cancer (73). It is found to be inactivated in around 90% of lung 
carcinomas, but it is only inactivated in 10-15% of NSCLC (17). In NSCLC, perturbations 
in this pathway most commonly come from members upstream of RB resulting in hyper-
phosphorylation of the protein leaving the G1-S transition to occur unchecked. In NSCLC, 
these alterations occur in cyclin D1, CDK4 and the cyclin-dependent kinase inhibitor, 
p16INK4A (74). In normal signaling, p16INK4A is responsible for inhibiting phosphorylation of 
RB by cyclin D1 halting the cell cycle. p16INK4A is inactivated in approximately 80% of 
NSCLC (75, 76). Overexpression of cyclin D1 by gene amplification, epigenetics, or 
transcriptional upregulation is found in ~40% of NSCLC (77). 
  
Targeted Therapies in NSCLC 
 
 Targeted therapies are quickly becoming standard of care for lung cancers 
harboring oncogenic mutations. The majority of NSCLC patients present with tumors in 
the advanced stages of the disease (78). Until very recently, patients with advanced stage 
NSCLC were most often placed onto platinum-based chemotherapy regimens (29). 
Clinical trials examining the efficacy of various platinum-doublet combinations have 
revealed that improving the therapeutic benefit of conventional chemotherapies has hit a 
plateau. This has spurred forward the development of therapies that target specific 
oncogenic mutations to improve outcomes (29, 79). Several targeted therapies have 
become the standard of care for advanced NSCLC harboring specific mutations and they 
are described below. When paired with the development of diagnostic or companion 
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biomarkers, these targeted therapies have greatly improved treatment for some patients 
while the remainder are treated with the appropriate cytotoxic agents (29). Importantly, 
EGFR is commonly targeted in lung adenocarcinomas and will be covered more in depth 
in the EGFR section of this chapter. A discussion of the hallmarks of cancer with current 
FDA-approved drugs targeting them in lung cancer is presented below.  
  
Targeting Growth and Proliferation in NSCLC 
 
 Oncogenic KRAS mutations occur in 25-40% of NSCLC and are common in 
pancreatic, colorectal, serous ovarian and thyroid cancers, making them a desirable 
therapeutic target (80). Mutant KRAS is also an attractive target because it tends to occur 
exclusively of other driver mutations (e.g., EGFR, ALK) (81). Over the last three decades, 
attempts at targeting KRAS have been largely unsuccessful, and there are currently no 
KRAS inhibitors approved or in trials. Current methods of “targeting” mutant KRAS involve 
targeting the members of downstream pathways to eliminate oncogenic KRAS signal 
through them (81). These include inhibitors of MAPK-ERK and PI3K/AKT/mTOR pathways 
among others, and the FDA approved inhibitors of each of these targets are outlined below 
(81).    
 
Oncogenic ALK rearrangement mutations (described in the oncogenes discussion 
above) were first described in 2007 and have been found to occur in around 4-8% of 
adenocarcinoma patients (82). The first generation ALK inhibitor, crizotinib, was approved 
in 2011 for use in patients with advanced NSCLC harboring a confirmed ALK 
rearrangement mutation (83). A second generation ALK inhibitor, ceritinib, is 20 times 
more potent than crizotinib and has demonstrated promise in patients who progressed on 
crizotinib or were intolerant of crizotinib. It has also performed well in ALK-inhibitor-naïve 
patients (84). The other second generation ALK inhibitor, alectinib, has shown activity 
against the crizotinib resistance mutation (L1196M), reducing the size of both previously 
treated and untreated brain metastases (29). Both of the second generation ALK-inhibitors 
are indicated for use in patients who progressed on or were intolerant of crizotinib (29). 
Importantly, NSCLC that harbor ROS1 rearrangements have also been shown to be 
sensitive to crizotinib treatment, which suggests a possible dual role for the ALK inhibitor 
although it is not currently FDA-approved for use in ROS1 rearrangements (29). 
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 BRAF mutations occur in approximately 2-3% of NSCLC and are also a therapeutic 
target in lung cancers. Approximately 50-75% of the BRAF mutations observed in lung 
cancer are the V600E mutation that also occurs commonly in melanoma (85). V600K also 
occurs in 6-30% of melanomas (86), but it is very uncommon in NSCLC. Of the approved 
BRAF inhibitors, vemurafenib and dabrafenib have demonstrated significant activity in 
BRAF V600E and V600K mutant melanomas, so they are being explored for efficacy in 
NSCLC both alone and in conjunction with the MEK inhibitor, trametinib (29). Initial Phase 
II trials of trametinib combined with dabrafenib revealed an overall response rate of 63% 
(29). Vemurafenib has also demonstrated activity in NSCLC patients harboring a BRAF 
V600E mutation as a single agent (87, 88). While vemurafenib and dabrafenib are in trials, 
none are currently FDA approved specifically for the treatment of NSCLC. 
 
 The tissue-type specific drug approval by the FDA for targeted therapies has 
limited our ability to best match patients to targeted therapies (e.g., BRAF in lung). Off-
label use occurs, but this limits payment options leaving the majority of patients unable to 
receive these therapies unless they have been specifically designated for their specific 
tumor type and mutation status. An ongoing NCI trial, Molecular Analysis for Therapy 
Choice (MATCH), is currently working to identify whether actionable variants of 143 genes 
associated with cancer that match to 20 drugs in the study work in a non-tissue-specific 
manner (89). The study specifically aims to assign targeted therapies independent of 
anatomical tumor locations in any advanced or solid tumors or lymphomas that are 
refractory or with no standard therapy (89). Of the drugs described above, crizotinib is 
included for ALK and ROS1 rearrangements, while dabrafenib in conjunction with 
trametinib and trametinib alone are included for BRAF mutations. The EGFR/HER2 
inhibitor, afatinib (described in depth below), is also included for the treatment of 
EGFR/HER2 mutations (89). Other oncogenic mutations found commonly in lung cancers 
that are included are AKT and PIK3CA. Hopefully, this endeavor will end the “off-label” 
use of targeted therapies across tissue types. This would allow patients whose tumors 
harbor specific mutational statuses responsive to targeted therapies to receive them.    
 
Targeting Angiogenesis in NSCLC 
 
 As stated earlier, loss of growth and proliferation regulation is not the only 
commonality between tumors that allow them to grow and invade unchecked. One of the 
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drivers of lung cancer currently being targeted clinically is angiogenesis. Angiogenesis is 
the process by which cancer cells stimulate surrounding blood vessels to grow into and 
around a tumor supplying the oxygen and nutrients rapidly proliferating cells need to grow 
– it is also imperative for the development of metastatic lesions (1). The development of 
anti-angiogenesis therapies have been aimed at inhibiting the vascular endothelial growth 
factor (VEGF) receptor on local endothelial cells. These inhibitors intentionally target 
normal tissues is to prevent them from responding to stimuli coming from the tumor. 
Importantly, the opportunity to target the healthy cells to minimize tumor growth is a 
promising option because healthy cells are significantly less likely to develop resistance 
to a drug. There are currently two FDA-approved drugs that target the VEGF receptor in 
lung cancers: bevacizumab and ramucirumab. Both are monoclonal antibodies targeting 
the extracellular, ligand-binding domain of the VEGF receptor (29).    
 
Targeting the Immune Evasion Mechanisms of NSCLC 
 
 Immune evasion is also a commonality among tumors. In the past few decades, it 
has grown increasingly evident that the role of the tumor microenvironment, namely the 
interaction of the tumor cells with circulating immune cells, is critical for cancer growth and 
progression (90). Therapeutic targeting of tumor cell immune evasion has recently gained 
a lot of momentum as a first-line clinical option for patients with high PD-L1 expression 
(90). Inhibiting both of these interactions between the tumor and its surroundings are 
imperative to cutting tumors off from their resources and self-preservation methods. 
Evasion of the immune system is a key step in cancer development, specifically for 
NSCLC. Tumors overcome the immune responders (activated T cells, B cells, natural killer 
cells monocytes and dendritic cells) by over-expressing PD-L1 or PD-L2 ligand on their 
cell surface (90). The immune responder cells, CD4, CD8 and pro-B cells, express the 
receptor (PD-1) on their surface. The interaction between the receptor on the immune cell 
and the ligand on the tumor cell suppresses the anti-tumor immune response. This 
process is also known as T-cell exhaustion (90). By blocking the interaction of PD-L1 with 
the PD-1 receptor on immune cells, T-cell exhaustion is overcome allowing immune cells 
to maintain their tumor-cell killing function (91).  
 
There are currently three approved monoclonal antibodies targeting this interaction 
between immune cell receptors and the tumor cell blockade of immune response:   
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Drug Target 
Specific 
Mutations 
Stage 
Drugs Targeting Growth and Proliferation 
Crizotinib ALK/ROS1 Rearrangements in both 
Approved for 
ALK 
Ceritinib ALK Rearrangements Approved 
Alectinib ALK Rearrangements Approved 
Vemurafenib BRAF V600E and V600K Clinical trials 
Dabrafenib BRAF V600E and V600K 
Clinical trials 
alone and in 
combination 
with trametinib 
(MEK inhibitor) 
Gefitinib EGFR EGFR Exon 19 Deletion or L858R Approved 
Erlotinib EGFR EGFR Exon 19 Deletion or L858R Approved 
Afatinib EGFR/HER2/HER4 
EGFR Exon 19 
Deletion or L858R/ 
EGFR T790M 
Approved 
Dacomitinib EGFR/HER2/HER4 EGFR T790M Clinical trials 
Neratinib EGFR/HER2 EGFR T790M Clinical trials 
Osimertinib EGFR T790M EGFR T790M Approved 
Necitumumab EGFR None 
Approved in 
combination 
with 
gemcitabine 
and cisplatin 
Cetuximab EGFR None Clinical trials 
Drugs Targeting Angiogenesis 
Bevacizumab VEGFR None Approved 
Ramucirumab VEGFR None Approved 
Drugs Targeting Immune Evasion Mechanisms 
Nivolumab PD-1 High PD-L1 Expression Approved 
Pembrolizumab PD-1 High PD-L1 Expression Approved 
Atezolizumab PD-L1 High PD-L1 Expression Approved 
 
Table 1.1: Targeted therapies in NSCLC.  
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nivolumab, pembrolizumab, and atezolizumab. Pembrolizumab (marketed as 
Keytruda) is an IgG4 isotype humanized monoclonal antibody targeting PD-1 molecules 
expressed on the surfaces of the immune cells (92). Nivolumab (marketed as Opdivo) is 
also a monoclonal antibody targeting PD-1 molecules on immune cell surfaces. It is a fully 
humanized IgG4 isotype antibody (93). The final immune checkpoint inhibitor currently 
approved for use in NSCLC is atezolizumab (marketed as Tecentriq) (90). Atezolizumab 
is a fully humanized IgG1 isotype monoclonal antibody targeting the PD-L1 ligand on the 
tumor surface rather than the PD-1 receptor on the surface of the immune cells (94). PD-
L1 expression levels are being investigated as a predictive biomarker with success in 
some tumor subgroups, but it does not appear that PD-L1 levels have prognostic value 
(90).  
B. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 
 
As stated earlier, EGFR is a common oncogenic driver of NSCLC. This body of work 
stems from the Black laboratory’s work in identifying predictive biomarkers of EGFR 
inhibitor success in NSCLC, and for this reason I have described it in depth below. 
 
 
EGFR Activation and Signaling 
 
EGFR is a transmembrane, receptor tyrosine kinase (RTK) that includes an 
extracellular ligand binding domain and an intracellular tyrosine kinase domain (95). EGFR 
is a member of the ErbB family of RTKs that are structurally similar.  They consist of an 
extracellular, ligand binding domain, a lipophilic membrane-spanning domain, and a 
cytoplasmic tyrosine kinase domain (96). EGFR and other members of the ErbB RTK 
family have varying affinities for multiple ligands. The extracellular growth factors with 
which they interact include epidermal growth factor (EGF), transforming growth factor 
alpha (TGFα), heparin-binding epidermal growth factor (HB-EGF), amphiregulin (AREG), 
epiregulin (97), and betacellulin (BTC) (98). Binding of the ligand results in receptor 
homodimerization or heterodimerization with other members of the EGFR/ErbB family of 
receptors resulting in autophosphorylation of the tyrosine residues of the kinase domain 
(96, 99, 100).  
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EGFR signal transduction occurs through MAPK-ERK, PI3K/AKT/mTOR, and 
STAT signaling pathways (99, 100). Importantly, signal transduction through these 
signaling pathways is not exclusively driven by EGFR in normal cells. Rather, EGFR 
belongs to a network of other RTKs that can activate common effectors (101). The 
complexity of these networks is growing constantly and the phenomenon is being 
described as ‘crosstalk’ amongst the signaling pathways and RTKs (102). This improves 
our understanding of compensatory signaling routes and the development and 
maintenance of targeted therapy-resistance. However, it also underscores the need for 
developing novel methodologies targeting multiple sources of tumor driving and drug 
resistance generating pathways. 
 
One of the pathways stimulated by EGFR activation is the MAPK-ERK pathway, 
with members RAS/RAF/MEK/ERK. The MAPK/ERK signaling pathway is specifically 
responsible for growth and proliferation, which is why it is commonly mutated in cancer 
(28, 67). EGFR activates this cascade by phosphorylating the KRAS GTPase using 
mediator proteins (e.g., SOS and GRB2) (103). Phosphorylated KRAS then 
phosphorylates BRAF, which in-turn phosphorylates MEK1/2, and finally MEK1/2 
phosphorylates ERK1/2. Phosphorylated ERK then translocates into the nucleus where it 
activates transcription factors associated with growth and proliferation (e.g., ELK1 and 
ETS1) (104). The MAPK-ERK pathway is ultimately responsible for regulating the 
expression of genes that drive growth and proliferation of the cell (e.g., MYC and JUN) 
(105, 106).  
 
EGFR signaling also activates the PI3K/AKT signaling pathway. The initial steps 
in PI3K/AKT signaling are described more in depth in the oncogenes and tumor 
suppressor sections above. The important thing to note about this signaling pathway is 
that AKT is able to activate a number of independent downstream pathways. In normal 
signaling, one role of AKT is the phosphorylation of the Bcl-2 family member, Bad, which 
ultimately leads to caspase activation and the induction of apoptosis (107). AKT can also 
signal through the mammalian target of rapamycin (mTOR), sometimes referred to as 
mechanistic target of rapamycin, which is responsible for regulating cell size and 
proliferation in non-cancerous cells (108). 
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Figure 1.2: EGFR Signaling Pathways.  
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A third signaling pathway driven by EGFR is the signal transducers and activators 
of transcription signaling pathway mediated by a family of STAT molecules (109). Until 
rather recently, STAT signaling was believed to be activated only by cytokine signals (e.g., 
interferon and interleukin family members) with its activation being mediated by the Janus 
Kinase (JAK) (110, 111). We now know that STAT proteins can also be indirectly activated  
by EGFR via SRC-mediated phosphorylation (112). Phosphorylation of a STAT molecule 
results in a homodimerization with a STAT family member of the same type, resulting in 
translocation of the complex into the nucleus and gene expression regulation (112). STAT 
family members are responsible for regulating the expression of genes promoting survival, 
growth and proliferation, immune response, angiogenesis and wound healing (113, 114). 
 
Importantly, these three signaling pathways do not encompass all of the signaling 
events regulated by EGFR, just those that are best characterized and are relevant to the 
contents of this dissertation. 
 
EGFR Mutations in Non-Small Cell Lung Cancers (NSCLC) 
 
 EGFR action as an oncogene impacts many cellular functions including 
proliferation, differentiation, invasion, survival, neovascularization and metastasis (100). 
EGFR mutations are found in a number of tumor types including NSCLC (19). In lung 
cancers, the majority of EGFR mutations occur in lung cancers of the adenocarcinoma 
histological subtype (25, 67) and are also most commonly found in younger patients who 
are female with no history of smoking (22, 115, 116). EGFR activation mutations have 
been identified in 10-15% of unselected western patients (20, 25). However, EGFR 
activating mutations occur more commonly in Asian populations and are observed in 30-
40% of lung tumors (67, 115). EGFR oncogenic mutations result in constitutive tyrosine 
kinase activation (117).   
 
In NSCLC, oncogenic mutations in the EGFR gene occur in the exons (18-24) that, 
when translated, comprise the tyrosine kinase domain of the protein (19). The most 
common of these mutations are the exon 19 frame deletion mutations, of which there are 
over twenty different variants that account for around 45% of the EGFR mutations in 
NSCLC (19). The second most common type of EGFR mutations are missense mutations, 
most commonly L858R in exon 21, accounting for approximately 40% of EGFR mutations 
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in NSCLC (67). Less common EGFR mutations (~5-10% of EGFR mutations in NSCLC) 
leading to EGFR inhibitor (EGFRI) resistance often involve in-frame duplications of 
insertions into exon 20 (26). Variant-III (EGFRvIII) mutations also occur (~3% of NSCLC) 
where the extracellular binding domain of EGFR is deleted, which prevents the EGF ligand 
from binding, but still results in aberrant downstream signaling (118). EGFRvIII, gene 
duplication mutations, and over-expression of EGFR protein occur more commonly in 
squamous cell carcinomas than in adenocarcinomas (119). 
 
Acquired resistance mutations are most often selected for in patients undergoing 
EGFRI treatments which lead to resistance. The most common of these is the T790M 
point mutation in exon 20, which results in an amino acid change from a threonine to a 
methionine. This interferes with the binding of reversible EGFRIs (120). The T790M 
mutation is found in approximately 50-60% of patients who develop acquired resistance 
to EGFRIs (120). Importantly, T790M mutations have been observed in treatment-naïve 
patients, so they are not exclusively driven by EGFRI treatment (20). Other common 
routes of EGFRI resistance occur through the activation of PI3K-AKT signaling pathway 
and this is most commonly achieved by amplification of MET (39). 
 
Mutations in EGFR are not the only mechanism by which aberrant EGFR signaling 
occurs in lung cancer. EGFR has also been found to be over-expressed, generally as a 
result of a genomic amplification event, with increased EGFR copy number observed in 
up to 50% of lung cancers (121). EGFR over-expression can also occur as a result of 
increased promoter activity or a decrease or loss of transcriptional or translational 
regulation mechanisms (122). EGFR over-expression results in increased EGFR activity 
with and without activating mutations present suggesting that the increased activity is likely 
due to the high volume of receptors in the membrane spontaneously dimerizing with one 
another at the cell surface (122, 123). Increased expression or cleavage-processing to 
mature form of ErbB family ligands has also been linked to increased EGFR stimulation 
through autocrine (cell to self) and paracrine (cell to immediate surrounding cells) dosing 
of growth-inducing ligands (124, 125). Finally, it has been suggested that EGFR 
heterodimerization to other ErbB RTK family members could be a contextual contribution 
to oncogenic signaling in tumors (122). Specifically, EGFR-ErbB3 heterodimerization has 
been described in NSCLC as a possible source of EGFR targeted therapy resistance (39, 
126). EGFR-ErbB3 dimers are imperative for EGFR regulation of PI3K/AKT. Specifically, 
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the ErbB3 tyrosine kinase domain differs from EGFR which allows the docking of PI3K 
directly to the kinase (127). EGFR-ErbB3 dimers are dissociated by EGFRIs, but the 
resultant under-activation of AKT signaling leads to compensatory over-expression of 
ErbB3. This shifts the receptor equilibrium, thereby reducing EGFRI response (127). 
 
Inhibition of EGFR in Lung Cancer Therapy 
 
 There are currently two main classes of drugs targeting EGFR (EGFRI) in cancer: 
1) small molecule inhibitors of the tyrosine kinase domain of EGFR (EGFR-TKIs) and 2) 
monoclonal antibodies that bind the extracellular ligand binding domain preventing the 
binding of EGF or other ErbB family ligands and activation of the receptor. Currently, only 
the small molecule inhibitors of EGFR are used in lung cancers and a review of EGFR-
targeting monoclonal antibodies in lung cancer and why they are not currently used is 
provided below. 
 
Small Molecule Inhibitors of EGFR 
 
Preclinical work in the development of EGFR inhibitors demonstrated that point 
mutations in the ATP binding pocket of EGFR could eliminate its tyrosine kinase activity 
(128-130). This led to the development of two competitive, reversible, ATP binding pocket-
targeting small molecules as the first generation of EGFR-TKI inhibitors: gefitinib (Trade 
name: Iressa) and erlotinib (Trade name: Tarceva) (130, 131). Early trials of the first 
generation EGFR-TKIs revealed that patients with no smoking history, Asian ethnicity and 
a tumor of adenocarcinoma histology were most likely to respond to treatment (132). It 
was determined later that patients exhibiting these clinical characteristics most often 
harbored the EGFR exon 19 deletion or exon 21 L858R activation mutations (3, 133). Due 
to these observations, the prospective Phase 3 trial was performed specifically in patients 
exhibiting these clinical characteristics in Asia (134). Mok et al. demonstrated that patients 
with a confirmed EGFR mutation had a significantly higher overall response rate and 
longer progression free survival when treated with gefitinib compared to the platinum-
based chemotherapy arm (134). They also demonstrated the gefitinib treatment arm of 
patients without an EGFR mutation had significantly lower overall response and a shorter 
progression free survival (134). This study established EGFR mutation status as a 
biomarker for EGFR-TKI patient selection (29, 135). Since then, a number of studies 
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comparing the first generation EGFR-TKIs, gefitinib and erlotinib, as well as second 
generation, afatinib, to platinum-doublet chemotherapies have consistently demonstrated 
superior overall response rates, progression-free survival, and quality of life in the targeted 
therapy arm (136-140). Retrospective analysis of some of these studies suggested that 
afatinib treatment offered greater overall survival in exon 19 deletion tumors over L858R 
tumors. However, the more recent LUX-Lung 7 trial designed to confirm prior study results 
did not observe the same effect (141, 142). Erlotinib was FDA-approved in 2004 for the 
treatment of NSCLC as a second or third line therapy. It was most recently redesignated 
in October 2016 for the treatment of locally advanced or metastatic NSCLC harboring 
EGFR exon 19 deletions or exon 21 L858R substitution mutations (143, 144). Notably, 
gefitinib received conditional FDA approval following Phase II trials in 2003, but approval 
was later withdrawn after negative Phase III results in unselected patients (145). In 2015, 
gefitinib was FDA-approved a second time, but only as a first line therapy in patients with 
metastatic, EGFR mutant NSCLC, and not in populations harboring other mutations (146). 
Importantly, a majority of patients on first-line EGFR-TKIs do progress between 10-15 
months following the start of treatment (29, 147). 
 
 The most common reason for progression is the development of secondary 
resistance mutations in EGFR. For this reason, the second generation of EGFR-TKI 
development has been largely centered around overcoming secondary mutations in 
EGFR. Selecting the treatment following progression on EGFRI relies heavily on being 
able to identify the source of resistance (147). Importantly, not all EGFR-TKI resistance 
mechanisms arise due to mutations in EGFR. Bypass-signaling by other RTKs (e.g., 
HER2 and ALK), downstream mutations (e.g., BRAF and PIK3CA), and phenotypic 
changes (e.g., EMT) are also sources of EGFR-TKI resistance (147, 148). As previously 
stated, T790M mutations are the most common acquired EGFR-TKI resistance mutations 
in NSCLC accounting for 50-60% of treatment-induced resistance (120). Because of this, 
the second generation of EGFR-TKIs aimed to comprehensively target this acquired 
resistance mutation (T790M) and other resistance sources (e.g., HER2, HER4) (145). 
Second generation small molecule inhibitors, afatinib, dacomitinib, and neratinib, are each 
irreversible inhibitors of the EGFR tyrosine kinase domain (147). Each targeted T790M 
mutations, had some overlap in the EGFR sensitivity conferring mutations, and all include 
some binding to the HER2/HER4 receptors which represent an additional source of 
potential resistance (147). While the in vitro study of each of these three drugs appeared 
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promising, clinical trials of the second-generation EGFR-TKIs in patients resistant to either 
of the first generation EGFR-TKIs only demonstrated a response rate of around 10% (149-
151). Additionally, adverse side effects were observed at drug concentrations too low to 
inhibit T790M mutated EGFR molecules in vivo (149-151). Currently, afatinib is the only 
second generation, small-molecule EGFR-TKIs approved for the treatment of advanced 
NSCLC harboring an exon 19 deletion mutation or an exon 21 L858R EGFR activation 
mutation (152). 
 
 The third generation of small molecule EGFR-TKIs are being designed specifically 
to target the T790M mutation more effectively than the second generation small 
molecules. Rather than targeting both mutant and wild-type EGFR and other conserved 
receptors (e.g., HER2 and HER4), these specifically target mutant EGFR (T790M, exon 
19 deletion, and exon 21 L858R substitution) with minimal impacts on wild-type EGFR 
(147). Importantly, this would theoretically limit adverse events, but minimal activity 
against wild-type EGFR highlights that these inhibitors will not be utilizable in patients with 
amplified/overexpressed EGFR. All third generation EGFR-TKI small molecule inhibitors 
are irreversible inhibitors of EGFR (147). Of them, only one (osimertinib) has been 
approved for the treatment of metastatic NSCLC with the EGFR T790M mutation (153). 
The rocelitinib study has been paused in Phase II/III trials due to side effects, and olmutinib 
is only approved in Asia. ASP8273 is in Phase III trials, and nazartinib, PF-06747775, 
avitinib, and HS-10296 are all in Phase I/II trials (147). As with first and second generation 
small molecule EGFR-TKIs, third generation inhibitors select tumor cells with novel or rare 
point mutations (e.g., C797S in exon 20 or L798I/Q in cis with T790M) leading to 
resistance (154-156). Most importantly, additional mechanisms of EGFR-independent 
resistance to third generation EGFR-TKIs are being reported (147). Activating mutations 
in NRAS (e.g., E63K) as well as amplification of wild-type NRAS and KRAS have been 
reported in osimertinib resistance. These mutations were also observed in gefitinib and 
afatinib resistance (157). It has been suggested that loss of the T790M population of cells 
led to the over-growth of cell populations with HER2 amplifications, PIK3CA mutations or 
BRAF V600E at the time of progression (158). Amplifications of HER2 and MET genes 
have also been described as mechanisms for overcoming T790M-targeting EGFR-TKIs 
(155). All of the resistance mechanisms described above in response to single-agent 
EGFR-TKIs underscore the need to target other pathways concurrently or sequentially 
with EGFRI-TKIs to minimize or eliminate resistance mechanisms. Very importantly, the 
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third generation of EGFR-TKIs are much better tolerated than the first and second 
generations and this observation has opened them to be explored as co-therapeutics with 
new studies and clinical trials currently in the planning stages (147). 
 
Targeting EGFR with Monoclonal Antibodies 
 
 Another therapeutic route for antagonizing EGFR signaling in NSCLC is the use of 
EGFR-targeting monoclonal antibodies. Anti-EGFR monoclonal antibodies work by 
targeting the ligand binding domain of EGFR and competitively block the interaction of 
EGFR with any of its ligands (159). Complexes of EGFR and anti-EGFR monoclonal 
antibodies are then internalized and degraded leading to a decrease in cell surface EGFR 
(160). It has also been suggested that this action could lead to antibody-dependent cellular 
cytotoxicity (161). EGFR-directed monoclonal antibodies currently being investigated are 
cetuximab, matuzumab, panitumumab, and necitumumab, but others are in development 
(160).  
 
Cetuximab has been studied in Phase II and III trials in combination with first-line 
chemotherapy in advanced NSCLC (162-164). Two Phase III trials, FLEX and BMS099, 
were opened to compare the combination of chemotherapy with cetuximab. The FLEX 
trial demonstrated improved overall survival with the combination treatment versus 
chemotherapy alone whereas BMS099 did not demonstrate an improvement in 
progression free survival (165, 166). Importantly, only the FLEX trial analyzed and 
considered EGFR expression levels as a point of comparison in survival computations. 
Patients expressing high EGFR levels that were treated with the combination of cetuximab 
and chemotherapy had a median survival of 12 months compared to 9.8 months in 
patients expressing low levels of EGFR, although this difference was not found to be 
statistically significant (121, 167). Though demonstrated in colorectal cancers, KRAS 
mutation status does not predict response rate, progression-free survival, or overall 
survival in NSCLC (168, 169). Necitumumab was analyzed in two Phase III trials as well: 
INSPIRE tested activity in advanced non-squamous cell NSCLC, and SQUIRE tested 
efficacy in squamous NSCLC (170, 171). The INSPIRE trial was prematurely closed due 
to an increased number of adverse events, grade 3 or higher, including fatal 
thromboembolic events and sudden/unexplained death (170). The SQUIRE trial 
demonstrated improved overall survival in the combination necitumumab arm compared 
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to chemotherapy alone (171). Currently, only necitumumab in combination with 
gemcitabine and cisplatin is FDA approved for use in lung cancer, specifically only in 
squamous histological subtype NSCLC (172, 173).  
 
 
C. TRANSFORMING GROWTH FACTOR BETA (TGFβ) BIOLOGY AND 
SIGNALING 
 
As stated before, the Black laboratory’s efforts have been centered on identifying 
predictive biomarkers for EGFR-TKI therapies. We also aim to leverage the genes 
comprising the biomarkers to identify novel treatment options for overcoming both inherent 
and acquired resistance to EGFR-TKIs in NSCLC. As will be described in more detail later, 
one of our gene signatures indicated TGFβ as a putative source of EGFR-TKI resistance. 
For this reason, I’ve included an in-depth look at TGFβ signaling and its role in cancer 
below. 
 
TGFβ is a ubiquitous cytokine that is active in a number of cell processes, and the 
majority of cell types contain the ability to secrete the ligand as well as the receptors to 
respond to it (174). TGFβ signaling is essential for development, cell differentiation, 
homeostasis and wound healing in adult tissues (175). TGFβ belongs to the TGFβ 
superfamily of receptors and transcription factors that has over thirty members. The TGFβ 
superfamily can be subdivided into two distinct signaling families: 1) TGFβ, activin, nodal 
and other factors and 2) growth and differentiation factors including the bone morphogenic 
proteins (BMPs) and the anti-muellerian hormone (AMH/MIS) (176-178). Other members 
of the TGFβ superfamily are responsible for embryonic stem cell differentiation, 
organogenesis, body axis formation and symmetry establishment during development 
(179). In the developed adult, TGFβ superfamily members are responsible for functions 
like gonadal regulation, muscle development, and bone growth and repair (179). TGFβ 
superfamily expression and signaling behavior is largely tissue-specific limiting their 
signaling in adult tissues (176). 
 
TGFβ Signaling 
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The Receptors  
 
TGFβ canonical signaling has three receptor types (TβR-I (type 1), TβR-II (type 2), 
and TβR-III (type 3)), three ligands (TGF-β1, TGF-β2, and TGF-β3), and three 
transcription factors (Smads 2, 3, and 4) (178, 180, 181). Importantly, TβR-III expression 
is tissue-specific and lung tissues and tumors have very low levels of the type 3 receptor 
expression (182). Outlined below are the activities of the TβR-I/II receptor complexes. The 
TGF-β1 ligand isoform has been specifically shown to activate canonical Smad (2,3,4) 
signaling via TβR-I and TβR-II interactions (183). TGF-β1 activates signaling by binding 
the type 2 receptor (175). The active, ligand-bound type 2 receptor then binds a type 1 
receptor forming a heterodimer where the type 2 receptor can transphosphorylate the type 
1 receptor (175). The active heterodimer then binds to a second type 1 and type 2 receptor 
resulting in a tetrameric complex of TGFβ receptors that can recruit, bind and activate 
Smad transcription factors (180).  
 
Canonical TGFβ Signaling 
 
The term ‘Smad’ is derived from embryonic development work in Drosophila on 
Mothers against decapentaplegic (MAD) and from SMA in C. elegans. In humans, the 
conserved equivalent is called SMA and MAD related protein, hence the name Smad. 
Smads 2 and 3, also known as the receptor Smads (R-Smads) due to their direct 
interaction with the TGFβ receptor complex, are phosphorylated by the active type 1 
receptor on the C-terminal SSXS motif contained within the MAD homology (MH) 2 domain 
(181). Phosphorylation of Smads 2 and 3 results in a conformational change of the protein. 
This reveals the MH1 domain containing the nuclear localization signal (NLS) and linker 
region by which the R-Smads can complex with Smad 4 (181). Unbound Smad 4 traffics 
between the cytoplasm and nucleus, and is the only Smad with a nuclear export signal 
(NES) (181). Active Smad heterocomplexes accumulate in the nucleus, presumably due 
to the masking of the NES on Smad 4 by the R-Smads (181, 183). Nuclear localization of 
active Smad complexes enables them to interact with various co-activators and co-
repressors resulting in either the induction or repression of TGFβ signaling pathway 
responsive genes respectively (183). Smad regulation of genes occurs specifically by their 
binding to Smad Binding Elements (SBEs) contained in the promoters of TGFβ signaling 
pathway responsive genes (181, 184). 
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Figure 1.3: TGFβ Signaling Pathways. 
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TGFβ signaling via the Smads is regulated by a variety of cellular mechanisms. 
Smad 2 and 3 must dock with the receptor for activation by TβR-I and the process of 
docking relies on several adaptor proteins including SARA, Hgs, and Dab2 (185-187). 
Activation of Smads 2 and 3 can also be blocked by the inhibitory Smad (Smad7) that 
impedes the phosphorylation of the R-Smads. Smad7 can do this with two mechanisms:  
1) It can physically bind TβR-I blocking the binding of the R-Smads (188), and 2) it recruits 
Smurf 1/2 (E3 ubiquitin ligase) to facilitate TGFβ receptor degradation (189). The R-
Smads also undergo linker region phosphorylation by other signaling effectors (e.g., ERK 
1/2, JNK, p38, Casein Kinase 1, and CDKs) that results in stabilization of active Smad 
signals (175, 190). Finally, Smad 2/3/4 complexes are disabled and disassembled by 
PPM1A phosphatase, followed by Smurf 1/2 polyubiquination, and proteosomal 
degradation (191, 192). The TGFβ receptor complex can also be regulated by proteins 
that associate with it. One of these, TGFβ-receptor-interacting protein 1 (TRIP-1), interacts 
with ligand bound TGFβ complexes and is phosphorylated by them (181). Increased levels 
of TRIP-1 represses TGFβ signaling and mutants of TRIP-1 have been shown to enhance 
TGFβ signaling (193).   
 
Normal TGFβ canonical signaling is involved in the regulation of cytostasis and 
autonomous growth suppression (175). TGFβ mediates cytostasis in the G1 Phase of the 
cell cycle by specifically initiating the downregulation of c-Myc (180, 194). Myc 
downregulation results from a complex of Smad 3, E2F4/5, and p107 bound to an SBE in 
the Myc promoter (194, 195). Smad 3 also regulates ID1 via a complex of Smad 3 and 
ATF3 bound to an ID1 promoter region SBE (196). In this context, this is a self-enabled 
activity of Smad 3 as it is also responsible for the induction of ATF3 expression (196). 
TGFβ also negatively influences cell proliferation by regulating the cyclin dependent 
kinase inhibitors p15INK4b and p21CIP (180, 194). Specifically, Smad 3 downregulation of 
Myc prevents the complex of Myc and Miz-1 from forming and thereby blocks p15 
transcription that is reliant on the Myc/Miz-1 complex (197). Then Smad 3 complexes with 
free Miz-1 and Sp1 to stimulate p15 transcription (197). TGFβ activation also results in the 
formation of Smad 2:3/Sp1/FoxO complexes that are responsible for transactivating the 
promoter of p21 (198).  
 
Non-Canonical TGFβ Signaling  
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 Like many RTKs, the TGFβ receptor is able to modulate a network of signaling 
pathways in addition to the canonical effectors. It is specifically able to activate the growth 
and proliferation pathways MAPK-ERK, MAPK-p38, and MAPK-JNK (199, 200). The role 
of TGFβ in MAPK-ERK signaling came to light after it was observed that Ras was rapidly 
activated by TGFβ ligand treatment in epithelial cells (201). The TβR-I/II complex can 
activate the MAPK-JNK and MAPK-p38 pathways via TGFβ-activated kinase 1 (TAK1). 
TAK1 can also activate the growth and survival kinases PI3K/AKT/mTOR and AKT/PKB 
as well as GTP binding effectors like RhoA, and Rac (202, 203). TGFβ signaling is known 
to repress NFκβ signaling in non-cancerous cells (204). It has also been implicated in 
mediating the activation of other kinases, including the focal adhesion kinase (FAK), Abl, 
and Src, by either direct activation or transcriptional control (205-207). 
 
 Activated TGFβ receptors can also influence signaling in many of these pathways 
via the Smads, which complicates our understanding of the TGFβ signaling network. 
Smad-mediated activation of the MAPK-p38 signaling cascade has been shown to induce 
Caspase-8 and Bid activation, resulting in apoptosis (208). TGFβ signaling can also 
induce apoptosis through other members of the mitochondrial Bcl-2 family, as well as via 
NFκβ, AKT, and MAPK-JNK intracellular moderators (209).  
 
The Role of TGFβ in Lung Cancer 
 
TGFβ Signaling Pathway Mutations in NSCLC 
 
 Mutations in the TGFβ signaling pathway members (e.g., Smads) do occur, but 
most are not commonly observed in lung cancers. Loss of TβR-III expression is commonly 
observed in lung cancers, which is not surprising as signaling via the TβR-III receptor has 
been shown to block cell motility and invasiveness in NSCLC (210). Smad 2 mutations 
are observed in 7% of lung cancers and are most commonly missense mutations 
impacting the Smad-complex-forming region of the MH2 domain or the DNA binding 
domain within the MH1 domain (211, 212).  
 
The “TGFβ paradox” 
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 As previously stated, TGFβ signaling plays an imperative role in cellular 
homeostasis and genomic stability by inducing cell cycle arrest, differentiation and 
apoptosis of cells. In the early stages of tumor development, TGFβ signaling maintains 
these roles, thus serving as a potent anti-cancer agent (213). In the later stages of tumor 
development, TGFβ signaling activity switches to promote cell growth, invasive ability, and 
ultimately metastasis. This dichotomous activity of TGFβ signaling has been rightly 
dubbed the “TGFβ paradox” (175). While many theories exist on how this switch occurs 
mechanistically, it is increasingly evident that the means by which the shift in TGFβ 
signaling activity occurs likely happens on a case-by-case contextual basis adding further 
complexity to this already enigmatic problem. Some of the mechanisms proposed to 
explain the shift in TGFβ signaling include the changes in miRNA expression such as the 
miR-106b-25 cluster (214, 215). Others have suggested that epigenetic changes altering 
TGFβ signaling activity (e.g., TGFβ receptor methylation or promoter over-activation 
depending on tissue-specific context) and target (e.g., ID1) expression result in the shift 
from anti- to pro-tumorigenic TGFβ signaling (179, 216). As further described below, TGFβ 
signaling results in the secretion of cytokine-stimuli into the tumor microenvironment and 
is activated in response to stimuli in the tumor microenvironment as well. The positive 
feedback loop between tumor cell TGFβ signaling and tumor-infiltrating immune cells that 
amplify the stimuli have also been described as a possible mechanism for the signaling 
switch to occur (217, 218). Finally, mutations in TGFβ signaling family members or 
regulators (e.g., p15INK4b deletion eliminating TGFβ regulation) have been suggested as a 
possible mechanism (213). What is evident is that there is neither a specific consensus 
across tumor models or TGFβ-paradox arms as to how the paradox arises, nor a 
methodology for accurately determining which arm is at play. This is incredibly important 
because while pro-tumorigenic TGFβ seems to be an obvious and promising target, 
unintentional targeting of anti-tumorigenic TGFβ signaling in unselected patient 
populations may be detrimental (179, 219).  
 
The Roles of TGFβ Driving the Hallmarks of Cancer  
 
1) Growth Signal Autonomy: While there is no known mechanism underlying the 
shift in TGFβ activity from growth suppressor to growth promoter, it has been 
postulated that it may be coupled to TGFβ’s ability to induce the expression of 
many cytokines, growth factors, and their receptors (175). TGFβ signaling 
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promotes the production of EGFR and PDGFR receptors as well as cytokines 
and ligands including: connective tissue growth factor (CTGF), bFGF, PDGF, 
and TGFα (175). The phosphorylation of the Smad 2/3 linker region by 
pERK1/2 is another source driving prolonged TGFβ signaling (175).   
 
2) Genomic Instability: The role of TGFβ signaling in the accumulation of genomic 
instability is more of an unintentional consequence than a direct action. 
Specifically, tumors overcome the regulation of cell cycle progression via Smad 
3 regulation of Myc, p15 and p21, which in turn impacts the DNA damage 
recognition and repair pathways as well as the cell fate decision (197, 220). 
TGFβ has also been shown to influence changes in the epigenome, which also 
lead to accumulating genomic instability. Specifically, Smad 2 has also been 
shown to complex with HDAC resulting in the silencing of targets such as p15 
(221).   
 
3) Evasion of Growth Suppressors: As stated earlier, normal TGFβ signaling 
plays a role in negative cell cycle regulation. Neoplastic mechanisms for 
overcoming cytostatic TGFβ activity include deregulated Myc expression, 
methyltransferase inactivation of p21 transcription, and aberrant PI3K/AKT 
signaling (197, 220, 222, 223). It has also been suggested that TβR-III and 
TGF-β3 likely play a role in suppressing unregulated TGFβ signaling (210). 
 
4) Tumor Promoting Inflammation: TGFβ ligands produced by cancer cells serve 
as an attractant for tumor-infiltrating monocytes and macrophages (224). 
These immuno-species are known for their ability to promote tumor invasion 
and metastasis in response to TGFβ signals from the tumor cells. They do this 
by stimulating angiogenesis and the breakdown of the extracellular matrix 
(225). They also secrete additional TGFβ ligand into the tumor 
microenvironment further stimulating the tumor and in turn more immuno-
species (225). Many other tumor microenvironment species also secrete and 
respond to TGFβ ligands (e.g., myeloid-derived suppressor cells) amplifying 
the TGFβ signal and driving TGFβ-metastasis (226). 
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5) Evasion of Apoptosis: TGFβ signaling is specifically involved in the induction 
of apoptosis in normal cells through both caspase-dependent and caspase-
independent means discussed above (209). Many of the aberrations 
characteristic of in the “TGFβ paradox” shift to pro-tumorigenic activity (e.g., 
p15INK4b loss) specifically lead to a loss in growth suppression activity by TGFβ 
(174).   
 
6) Avoiding Immune Destruction: TGFβ activity has been shown to suppress 
immunosurveillance by specifically inhibiting NK and cytotoxic T lymphocyte 
differentiation resulting in a decrease in the cytotoxic effectors they secrete, 
including: Fas ligand, perforin/granzyme, lymphotoxin-α, and interferon-γ (218, 
227-229). Moreover, TGFβ further inhibits the tumor-targeting ability of these 
two immune cell types by stimulating regulatory T cells in the tumor 
microenvironment (230). 
 
7) Unlimited Replication Potential: The shift of TGFβ signaling to pro-tumorigenic 
activity results in cell cycle regulation loss and is important to the acquisition of 
unlimited replication in cells (213). The shift also overcomes the ability of TGFβ 
to induce apoptosis using a variety of means (209). While these hallmarks of 
the “TGFβ paradox” shift do not truly result in unlimited replication potential (by 
means like telomerase overexpression), they do contribute by deregulation of 
the cell cycle and evasion of apoptosis.  
 
8) Angiogenesis: TGFβ signaling enhances tumor vascularization in a number of 
ways including the direct induction of key angiogenic factors including VEGF 
and CTGF (231, 232). TGFβ also plays a role in the maturation of new blood 
vessels. Smad 2/3 activation in response to TGFβ has been shown to correlate 
with genes involved in blood vessel maturation, including plasminogen 
activator inhibitor 1 (PAI-1) and fibronectin (233).    
 
9) Deregulating Cellular Energetics: TGFβ signaling plays a role in deregulating 
cellular energetics indirectly. TGFβ is specifically associated with the 
development of rigid tumor microenvironments that allow for the enhancement 
of cell selection and metastatic expansion (234). TGFβ signaling alters cellular 
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energetics to meet the need of a growing and changing tumor by regulating the 
expression of Lysyl oxidase (LOX) family members that are responsible for 
cross-linking extracellular matrix building-block proteins like collagen and 
elastin (175). In normal tissues, LOX family members play a role in embryonic 
development and organogenesis. Importantly, their pro- or anti-tumorigenic 
activity with respect to TGFβ signaling appears to correlate with the “TGFβ 
paradox”.  
 
10) Invasion and Metastasis: One of the best characterized role of TGFβ signaling 
in cancer is its ability to induce EMT, one of the initiating steps of metastasis. 
During EMT, cells lose their cellular polarity and adhesive properties and gain 
enhanced migratory and invasive capabilities. It has been shown that the 
induction of EMT by TGFβ relies on both Smad-dependent and Smad-
independent signals (174). TGFβ-driven EMT is associated with the expression 
of E-cadherin repressors Zeb1 and Zeb2 (235). Specifically, the Zeb proteins 
associate with other corepressors, including Smad 3 to repress the 
transcription of epithelial genes such as E-cadherin (E-cad) (236). Moreover, 
many non-canonical pathways downstream of TGFβ activation contribute to 
EMT induction in response to TGFβ signaling directly or pathway collaboration 
with TGFβ signaling. The downstream signaling pathways shown to be 
responsive to TGFβ or work in collaboration with TGFβ include MAPK-ERK, 
PI3K/AKT, Rho/ROCK, Hedgehog, and WNT signaling pathways (190, 237).  
 
Targeting TGFβ Signaling in Cancer: A Paradox Problem 
 
 Effectively targeting TGFβ signaling therapeutically in cancer without inducing side 
effects has been the unachievable goal of the TGFβ community for decades. TGFβ clearly 
plays a role in tumor progression by driving growth. However, more important when 
considering therapeutic value are the roles of TGFβ in vascularization, reciprocal immune-
stimulatory activities within the tumor microenvironment, as well as invasion and 
metastasis. As stated earlier, EMT is a process that not only complicates EGFRI 
sensitivity, but also complicates cancer treatment across tumor types (1, 147). In lung 
cancer alone, between 80-85% of patients present with a tumor that has already invaded 
nearby tissues or distally metastasized. This high percentage of advanced tumors is the 
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foremost reason why lung cancer treatments have such poor outcomes (6). For this 
reason, it is understandable why the field would aim to target one of the premiere drivers 
of tumor metastasis. Progress has been made in the last decade and a half towards 
understanding the enigma of the “TGFβ paradox” and the role TGFβ plays in driving tumor 
progression and metastasis will certainly keep it an attractive target moving forward (213). 
Unfortunately, many attempts have been made to target TGFβ clinically, and while they 
show promise in treating some tumors, they have devastating off-target effects in others 
(219). This is likely attributable to the role of TGFβ in normal cells. As stated earlier, TGFβ 
is specifically responsible for preventing cell growth, proliferation and survival in normal 
tissues following appropriate completion of development processes (175). Delineating the 
pro-tumorigenic activities of TGFβ from the anti-tumorigenic behaviors and determining 
how to identify and target them clinically is paramount to the success of TGFβ inhibitors 
(179).  
 
 Identifying which arm of the TGFβ-paradox is occurring continues to be enigmatic, 
so we need to seek out means of targeting pro-tumorigenic TGFβ signaling activities 
without targeting TGFβ directly. Recently, the activity of protein kinase CK2, also known 
as Casein Kinase 2 (CK2), has been linked to TGFβ-induced EMT as well as the 
development of acquired EGFRI resistance (238, 239). Initial clinical studies of its orally-
available inhibitor, CX-4945, suggest that treatment is well tolerated by patients unlike 
TGFβ inhibitors (240). For this reason, I explored it as an alternative avenue for 
overcoming EGFRI resistance and have compiled an overview of it below.    
 
 
D. CASEIN KINASE 2 (CK2) BIOLOGY 
 
The Kinase 
 
Casein Kinase 2 (CK2) is a protein kinase that is ubiquitously expressed in both 
healthy and cancerous cells (241). CK2 consists of two catalytic subunits (α and α’; gene 
IDs CSNK2A1 and CSNK2A2, respectively) and two regulatory subunits (both CK2β; gene 
ID CSNK2B) (241). The complete protein kinase CK2 holoenzyme can be any tetrameric 
arrangement of two α subunits and two β subunits (i.e. α2β2, αα’β2, α’2β2) (242). There is 
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also mounting evidence that CK2α and CK2α’ subunits have kinase activity in their 
monomeric forms, but the holoenzyme has a substantially higher affinity for substrates 
(243, 244). Live-cell fluorescent imaging revealed that the majority of CK2 subunits are 
not contained in holoenzyme, but are dispersed as single subunits throughout the cell 
(245). Once the formed holoenzyme, subunits are predicted to remain associated as the 
dissociation constant for the holoenzyme is incredibly low (246).  
 
CK2α and CK2β subunits have been shown to be essential for viability using 
murine knock-out studies. CK2α’ knock out mice are viable, but males of this genotype 
are sterile (247). This suggests that while CK2α may be functionally distinct from CK2α’, 
it is able to partially compensate for its loss (241). Loss of the CK2β subunit results in early 
embryonic lethality in mice (248). CK2 has been shown to play a role in spermatogenesis 
(247), organ development (248, 249), and it has been suggested that its function is 
imperative during embryogenesis (250). In adult tissues, CK2 levels have also been 
shown to increase during times of cell proliferation and return to basal expression levels 
following proliferation events (242). While CK2 is constitutively expressed in nearly all 
tissues, its basal levels are considered to be sparse compared to other kinases (251). 
Importantly, unlike CK2, most kinases are regulated by expression levels and, more 
specifically, by activation events like ligand binding. Since CK2 is constitutively active, low 
expression levels are likely important to moderating CK2 activity.   
 
What makes CK2 so unique is that unlike other proto-oncogenic kinases, CK2 is 
constitutively active without the aid of a gain-of-function mutation in both normal and 
cancer cells (252). Because CK2α subunits are constitutively phosphorylated, the source 
of regulation must be something other than an upstream kinase. One of the known 
mechanisms of CK2 regulation comes from the CK2β “regulatory” subunits, which have 
been shown to act in a stimulatory fashion unlike the name suggests in most cases (253). 
However, in very specific cases (e.g., calmodulin and MDM2), CK2β subunits have been 
shown to be potent inhibitors of CK2α phosphorylation of the substrate protein and, 
thereby, regulating the kinase activity of the α subunits (254, 255). The CK2 holoenzyme 
has very high affinity for most of its substrates compared to free subunits and it has been 
suggested that this ability to complex tightly with many of its substrates is bridged by the 
CK2 dimer portion of the enzyme (256, 257). For this reason, decreases in CK2β 
expression might lead to an imbalance of active substrates of CK2α monomeric activation  
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Figure 1.4: CK2 Signaling Pathways.  
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versus active substrates by the holoenzyme. CK2 is believed to be regulated by a 
combination of its subcellular location as well as its binding to other proteins or non-protein 
factors (255, 258). CK2 dynamically localizes to a variety of specific cellular compartments 
and/or organelles based on a diverse set of cellular conditions (259-261). Specifically, 
CK2 has been shown to shuttle between nuclear structures such as the chromatin and 
nuclear matrix in response to changes in growth stimuli (262, 263). It is also known to be 
dispersed throughout the cell during mitosis, which lends to the observation that its 
aberrant signaling is occurring in cancer cells where the mitotic process is recurring far 
more frequently than in normal cells (264). The protein degradation pathway has also been 
implicated in regulating its action (265).   
 
CK2 in Cancer 
 
 As stated earlier, CK2 expression levels are relatively stable and very small 
changes in its protein expression heavily impact the regulation of cellular homeostasis 
(242). Prior work has shown a link between CK2 subunit expression changes and the 
transformation of cells (266-268). CK2 subunits are upregulated in all cancers that have 
been profiled for its expression, including lung and bronchial, prostate, breast, colorectal, 
ovarian and pancreatic cancers (269). Increased CK2 activity from overexpression of the 
constitutively active kinase has been associated with aggressive tumor behavior (269, 
270). Additionally, CK2 has no known gain-of-function mutations that would drive 
neoplastic transformation (252). For this reason, the reigning opinion is that over-
expression of CK2 subunits leads to malignant transformation of cells, and this mechanism 
has been described as a “non-oncogene addiction” (271).  
  
 Perhaps most fascinating is that, across the literature, CK2 has been implicated 
for playing a role in the genesis and maintenance of every one of the classic as well as 
the emerging “hallmarks of cancer” (1): 
 
1) The Role of CK2 in Growth Signal Autonomy 
 
The global role of CK2 in cell signaling has been described as acting 
“horizontally” across a number of “vertical” signaling pathways both in cancer and 
in healthy cell signaling, thereby representing a means of pathway integration in 
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cancer cells (271, 272). CK2 has been shown to regulate common developmental 
signal transduction cascades known to be adulterated in tumorigenesis. 
Specifically, PTEN is phosphorylated by CK2 altering its stability and limiting its 
ability to regulate AKT signaling (273, 274). Similarly, CK2 drives AKT activation 
by phosphorylating it at a specific serine residue, Ser129, leading to 
hyperactivation of AKT signaling (275, 276). CK2 has also been shown to interact 
with the kinase suppressor of RAS (KSR) molecular scaffold required for the 
spatial regulation of MAPK-ERK signaling and its loss from that complex results in 
impaired RAF, MEK, and ERK activation (277). CK2 also influences a number of 
other signaling pathways responsible for aberrant growth and proliferation in 
tumors including JAK/STAT (278), NFκβ (279), fibroblast growth factor (FGF) (280, 
281), AKT/PKB signaling (275), Wnt signaling (279, 282), and Hedgehog signaling 
(283). Importantly, CK2 has been shown to connect many of these pathways acting 
as an intermediary effector in the network. Specifically, EGFR/ERK has been 
shown to stimulate WNT/β-catenin through CK2α (284).   
 
2) The Role of CK2 in Genomic Instability 
 
CK2 has been well described for its role in regulating the response to DNA 
damage. Perhaps the best described role of CK2 in the cell cycle is that it regulates 
the tumor suppressor, p53. It does so by CK2-mediated phosphorylation at serine 
392 in response to UV induced DNA damage (268, 285-287). Specifically, UV-
induced DNA damage induces the assembly of the CK2-hSPT16-SSRP1 complex 
(288). CK2 has also been shown to phosphorylate MDM2, which decreases its 
binding affinity for pRB and reduces its ability to direct p53 degradation (285, 289). 
Another important feature of CK2 activity that promotes the genomic instability 
fueling oncogenic transformation is that it would appear to play a crucial role in 
transcription and chromatin remodeling (290, 291). CK2 activity is also connected 
to all three RNA polymerase functions, DNA topoisomerase II, as well as a number 
of pre-mRNA transcription and splicing factors suggesting a further role in mRNA 
translation (292-295). It is believed that phosphorylation of transcription and 
splicing factors by CK2 likely changes their activity as well (296). CK2 has also 
been shown to facilitate DNA repair through phosphorylation of the XRCC1 
scaffolding protein required for single-strand break repair and base excision repair 
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(297) and plays a role in many cellular mechanisms that recognize and repair DNA 
damage and strand breaks (251). 
 
3) The Role of CK2 in the Evasion of Growth Suppressors 
 
CK2 also plays a role in the evasion of growth suppression by the negative 
regulation of tumors suppressors like PTEN and PML. PML is a tumor suppressor 
responsible for moderating the pathways involved in growth suppression, 
apoptosis and senescence, and it is most frequently lost in tumors by post-
translational mechanisms (298). CK2 promotes ubiquitin-mediated degradation of 
PML by phosphorylating it at Ser517 (298). CK2 has also been shown to 
phosphorylate the tumor suppressor PTEN at its C-terminus tagging it for 
proteasome-mediated degradation (274). Importantly, the CK2 phospho-site on 
PTEN is not the only one influencing the fate of PTEN (299). CK2 has also been 
recently identified for its ability to phosphorylate and inhibit the action of another 
member of the p53 tumor suppressor family, the TAp73 variant, promoting a 
cancer stem cell phenotype in head and neck cancers (300).   
 
4) The Role of CK2 in Tumor Promoting Inflammation 
 
CK2 has been shown to play a role in tumor-promoting inflammation 
pathways. Specifically, it has been shown to respond to reactive oxygen species 
(ROS) by interactions with p38, ultimately inducing NFκβ activation (301). Platelet 
activating factor (PAF) and tumor necrosis factor α (TNFα) also drive the activation 
of p38/CK2/NFκβ in response to ROS (301). CK2 has also been shown to 
modulate IL-6 expression in breast cancer. It has been suggested that IL-6 
stimulation induces CK2 to phosphorylate the EMT effector, TWIST, thereby 
stabilizing it (302, 303). This is an example of how CK2 can influence and respond 
to tumor microenvironment inflammation signals that promote tumor development. 
It has also been shown that CK2 interaction with JAKs is necessary for the 
induction of JAK/STAT signaling in response to inflammatory cytokines (278), and 
inhibition of CK2 prevents constitutive STAT signaling (304). Interestingly, CK2 
maintains epithelial characteristics in patients with chronic colitis preventing 
inflammation-driven apoptosis (305).  
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5) The Role of CK2 in the Evasion of Apoptosis 
 
CK2 has been implicated for globally regulating apoptotic pathways 
influencing Bid, Bad, Max, Faf1, Bcl-2 and Bcl-xL, caspase 2, caspase-inhibiting 
protein ARC, and the inhibitor of apoptosis proteins (IAPs), which include survivin 
(242, 263). Specifically, the activation of AKT/PKB signaling by CK2 has been 
shown to upregulate survivin expression by β-catenin (306). It has also been 
demonstrated that CK2 inhibition can sensitize breast tumor cells to TRAIL-
induced apoptosis mediated by the Apo2 ligand (307, 308). Moreover, targeting 
overexpressed CK2 in glioblastoma results in the suppression of pro-survival 
signaling pathways including PI3K/AKT, JAK/STAT, HSP90, Wnt, Hedgehog, and 
NFκβ (309). 
 
6) The Role of CK2 in Avoiding Immune Destruction 
 
The role of CK2 in the ability of cancer cells to avoid immune response is 
only coming to light very recently. Rather than a function in the cancer cells 
themselves, CK2 activity in regulatory T-cells (Tregcells) has been implicated for its 
role in helping tumor cells hide from immune responses. Specifically, it has been 
shown that CK2β ablation in the Tregcells of mice results in the induction of a 
cancer-killing inflammatory response called T helper type 2 (TH2) by dendrites 
responding to the differentiated Tregcells (310). CK2 is overexpressed in Tregcells, 
and its function specifically suppresses T-cell antigen receptor signaling in 
Tregcells. Ultimately, this results in the induction of the TH2 inflammatory response 
in the lungs (311). It has been suggested that global targeting of CK2 in cancer 
treatment could possibly have the secondary impact of inducing the TH2 response 
and eliciting an impactful anti-tumor immune response (311). 
 
7) The Role of CK2 in Replicative Immortality 
 
CK2 has been described as interacting with and/or phosphorylating many 
of the proteins involved in the regulation of the G1/S cell cycle checkpoint as 
described above. To date, CK2 interactions with p53 have not been shown to 
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differentiate between normal and mutant p53 as well, so it is not surprising that its 
action plays a role in replicative immortality in cancer cells expressing mutant p53 
(312, 313). It has been demonstrated in glioblastoma cells that CK2 inhibition is 
sufficient to induce p53-dependent cell cycle arrest and also results in sensitization 
of cells to TNFα-driven apoptosis (314). CK2 inhibition also resulted in increased 
telomerase activity and increased p53-dependent senescence, but importantly, 
these functions by CK2 inhibition were only observed in p53 wild-type cells (314). 
 
8) The Role of CK2 in Angiogenesis 
 
CK2 has been well described for its role in promoting angiogenesis in 
tumors. CK2 regulates hypoxia inducible factor-1α (HIF-1α), the main 
angiogenesis inducing pathway, in a variety of ways (315). It has been shown that 
inhibition of CK2 results in lower expression of HIF-1α during times of hypoxia 
because of increased p53 levels (316, 317). CK2 has also been shown to 
specifically phosphorylate Proline-Rich-Homeodomain protein (PRH) specifically 
blocking its ability to bind DNA. This action prohibits PRH from repressing VEGF 
and other components of VEGF signaling (318). FGF has also been implicated in 
angiogenesis and it is also a known binding partner of CK2β. The complex of FGF-
2 and CK2 has also been shown to drive CK2 kinase to act on nucleolin which is 
responsible for the synthesis and maturation of ribosomes (281). This relationship 
suggests that CK2 activity is likely also important for the production of FGF and 
VEGF signaling components (e.g., ligands, receptors). Finally, it has also been 
shown that PDGF signaling, a common growth factor player in angiogenesis, 
induced the expression of CK2α’ subunits.   
 
9) The Role of CK2 in Deregulating Cellular Energetics 
 
CK2 plays such an extensive role in the other hallmarks of cancer, so it is 
no surprise that it also may play a role in the metabolic reprogramming of cells 
required to compensate for the increased energy demands of developing tumors. 
Specifically, CK2 kinase activity has been described as regulating the purinosome, 
a multi-subunit complex responsible for purine synthesis in cells in response to 
changes in available nucleotides (319). CK2 has also been directly linked to the 
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hormonal regulation of carbohydrate metabolism as well as the regulation of other 
enzymes involved in carbohydrate storage and metabolism (320). Finally, CK2 
activity has been implicated in upregulating cytosolic levels of zinc, a secondary 
messenger implicated in many growth and proliferation pathways including AKT 
and ERK1/2 activation. CK2 phosphorylates the ZIP7 channel on the endoplasmic 
reticulum simulating it to open, thereby releasing stored zinc levels into the cytosol 
(321). 
 
10) The Role of CK2 in Invasion and Metastasis 
 
Recently, the greatest interest in CK2 as a tumor driver has been in its role 
in invasion and metastasis. CK2 has been shown to be an intermediate effector 
linking pERK activation by EGFR to the phosphorylation of α-catenin and the 
subsequent transactivation of β-catenin leading to invasiveness of tumor cells 
(284). CK2β down-regulation has been observed concurrently with dramatic 
changes in cell migration and adhesive properties (322). A genome-wide 
characterization of mRNA expression in CK2β-depleted breast cancer cells 
highlighted the upregulation of the core mesenchymal genes (CDH2, VIM, SNAIL1, 
TWIST1, ZEB1, ZEB2, etc.), and a down-regulation of the core epithelial genes 
(CDH1, CDH3, MUC1, etc.) (322). CK2β-depleted breast cells also demonstrated 
changes in a number of genes responsible for the necessary extracellular matrix 
and cytoskeletal alterations required for EMT (e.g., ADAM19, ADAM23, FN1, 
COL6A1) (322). 
  
Therapeutic Targeting of CK2 in Cancer 
 
 The initial trepidation in targeting CK2 came from the revelations that it interacts 
with a large fraction of the kinome, and when inhibited, might logically result in adverse 
events in patients. It has also been shown that knockouts of two of the three subunit types 
results in embryonic lethality (248, 249, 252). Despite this, the growing knowledge of the 
role of CK2 in tumorigenesis of many types of cancer led to the development of the orally-
available CK2 inhibitor, CX-4945 (Silmitatsertib), in 2010 (252). CX-4945 is in clinical 
Phase 1/2 trials in cholangiocarcinoma (240) (323). However, CK2 inhibition is currently 
not being investigated in lung cancers. 
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 CX-4945 treatment has been largely inconsequential as a single agent, likely 
because the majority of its roles in cancer can be compensated for by other kinases (252). 
Importantly, Franchin et al. demonstrated that CK2 null cells (α/α’(-/-)) still demonstrate 
pAKT S129 levels despite the fact that the Serine 129 residue is a specifically known CK2 
phosphosite (252, 324). This reinforces the notion that single-agent CK2 inhibition may 
continue to have poor efficacy as an anti-tumor therapy because compensatory signaling 
is readily activated. It also highlights that CK2 is a logical secondary signaling source that 
may be responsible for drug-resistance to current targeted therapies. A Phase 1/2 trial in 
cholangiocarcinoma is examining the combination of CX-4945 with gemcitabine and 
cisplatin (323) and combinations of CX-4945 and other targeted agents are currently being 
explored pre-clinically. 
 
 
E. PROJECT OVERVIEW 
 
The aim of our lab is to use pharmacogenomics to improve the clinical care of lung 
cancer patients. Specifically, we have used high-density genomic data generated from 
NSCLC cell lines with known sensitivities to EGFRI to do three things: 
 
1) Develop predictors of EGFRI-response in order to accurately stratify NSCLC 
patient response to EGFRI therapy. As stated earlier, clinically-utilized small 
molecule inhibitors of EGFRI are specifically designated for the treatment of 
tumors harboring specific EGFR mutations. Using single-gene mutation 
statuses to identify patient response does not encompass all putative 
responders, nor does it account for non-responders harboring the mutation of 
interest. Developing more robust predictors is paramount to accurately 
stratifying responders from non-responders. It can also identify the potential for 
resistance development in patients. 
 
2) Interrogate the deregulated genes and signaling pathways identified by gene 
expression predictors to gain a greater understanding of the biology governing 
response to EGFRI in NSCLC. Exploring the genes and pathways that indicate 
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drug-sensitivity provide essential knowledge for identifying the mechanisms by 
which resistance to therapy develops. We might also identify possible 
secondary targets for the treatment of EGFRI-resistant NSCLC.  
 
3) Leverage deregulated mRNA and miRNA genes to determine putative 
interactions that might be exploited to identify novel drug targets and 
methodologies for treating EGFRI-resistant NSCLC. We have developed a 
methodology for expanding the network in a disciplined manner to identify 
nodes connecting deregulated signaling pathways and cellular processes. 
Using this multi-faceted approach to identify deregulated networks, we are able 
to filter much of the “noise” generated by the heterogeneity among NSCLC 
lines in the genomic studies. From a translational standpoint, this is a 
particularly difficult hurdle in identifying novel drug targets and treatment 
strategies for lung tumors that harbor immense amounts of somatic mutations 
and expression level changes.  
 
The history of targeting EGFR and managing EGFRI resistance has been built on 
the philosophy of targeting “oncogene addictions” exclusively. While many NSCLC are 
reliant on overactive EGFR signaling, almost all eventually develop resistance to EGFR 
inhibitors because subpopulations of cells not requiring constitutively active EGFR 
signaling or with mutant, drug-resistant EGFR arise (29, 147). The second and third 
generations of EGFR inhibitors were built to overcome some of the resistance 
mechanisms that are acquired, but have essentially continued to monotherapeutically 
target EGFR (147). This strategy does not impact the development of other resistance 
mechanisms through other kinases and oncogenes (e.g., MET, ALK and ROS1), 
phenotypic changes (e.g., EMT), and alterations in downstream effectors (e.g., BRAF) 
(147, 148). Moreover, consecutive generations of EGFRI have also allowed the selection 
of novel resistance polymorphisms in well-characterized EGFRI antagonists (e.g., NRAS 
E63K and EGFR L798I/Q) (147, 154-156). Mechanisms of drug-resistance across every 
biological model from antibiotic-resistance in bacteria to anti-retroviral resistance among 
HIV/AIDS patients highlight that drug-resistance results from the selection of 
cells/organisms that have evolved means of bypassing drug efficacy. Complex eukaryotic 
organisms like humans have cells that possess many more avenues of circumventing 
specific nodes while achieving the same results in response to situations like genetic loss 
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or damage. While this behavior of compensatory signaling is imperative for human growth, 
development, and survival despite genetic defects, it is also exploited by tumor cells to 
overcome both innate and pharmacological anti-cancer strategies. Continuing our current 
method of simply modifying EGFR inhibitors with a focus on targeting only EGFR will likely 
always be met with resistance mechanisms that will continually evolve to overcome the 
newest anti-EGFRI. 
  
Early EGFRI-TKI efficacy prediction relied on the presence of EGFR activation 
mutations and KRAS activation status (3, 133, 143, 166, 169, 325, 326). This method of 
identifying responders did not segregate responders completely. To address this, our lab 
hypothesized that multivariate biomarkers could be used to better capture the EGFRI-
resistant and -sensitive phenotypes (327, 328). In line with our first aim to produce 
biomarker signatures of drug efficacy, the lab produced two different polygenic biomarkers 
predictive of EGFRI sensitivity, one of 180-mRNA and one of 13-miRNA genes (327, 328). 
Importantly, both are the product of larger lists of deregulated genes that distinguish the 
EGFRI-resistant and -sensitive phenotypes.  
 
The second goal of our lab is to interrogate the list of deregulated genes that stratify 
EGFRI-resistant and -sensitive cells. We do this to better understand the biology driving 
each phenotype, thereby rationally seeking alternative methods for targeting EGFRI-
resistance. Of the mRNA that were found to be deregulated for the generation of the 180-
mRNA signature, MAPK-ERK and PI3K/AKT/mTOR signaling were prominently 
represented (328). Because of this, our lab members have systematically interrogated the 
value of MEK and EGFR combinatorial therapy (329), the regulation of downstream ERK 
by deregulated dual-specificity phosphatases (DUSPs) (330), and the role of p110α 
isoform compensation in PI3K inhibitor compensation (331).  
 
The desire for a new perspective on the cellular deregulation stratifying EGFRI-
resistant and -sensitive cells led to the development of the second signature identifying 
response to the EGFR-TKI, erlotinib. Comprised of 13- deregulated miRNA genes, the 
additional signature was not only able to discriminate between EGFRI-resistant and -
sensitive cells, but was also able to distinguish clinical samples as primary or metastatic 
lesions (327). Bioinformatic analysis of the 13-miRNA genes comprising the signature 
revealed that they functionally converged on the TGFβ signaling pathway (327). As stated  
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Figure 1.5: Cross talk amongst TGFβ, EGFR, and CK2 Signaling.  
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earlier, phenotypic changes, like EMT, are sources of EGFRI resistance (148) and TGFβ 
is a known driver of the EMT program (332, 333). Moreover, many of the signature miRNA 
putatively control expression of EMT-related proteins (327). For this reason, the first 
hypothesis I proposed and tested was that the miRNA comprising the signature of 
response were transcriptionally regulated by canonical TGFβ signaling by Smad 
activation/repression (Chapter 2). Canonical TGFβ signaling by Smad activity could be 
responsible for controlling the expression of the miRNA that distinguish EGFRI-resistant 
from –sensitive cells.  
 
The second hypothesis I proposed and tested was that TGFβ signaling 
impacted EGFRI-resistance differently between EGFRI-resistant and -sensitive 
NSCLC (Chapter 3). 
 
The third aim of our lab is to leverage the gene expression data generated over 
time that is descriptive of the fundamental cellular differences between EGFRI-resistant 
and -sensitive cells using novel mathematical and computational methods. The two 
expression signatures were culled from larger lists of 1495 deregulated mRNA and 23 
deregulated miRNA genes. We chose to bolster current studies by considering inversely 
related miRNA:mRNA pairs.  The third aim I proposed and tested was whether mRNA 
and miRNA gene expression data interactions, whether physical or not, would 
identify nodes of cell signaling. These interactions and their protein-protein 
interacting partners may indicate new targets for novel treatment options (Chapter 
4). 
 
This work is a study of what we can learn about the biology of a tumor phenotype 
(e.g., EGFRI resistance status) by interrogating gene expression differences. I will 
demonstrate the value of cross-examining multiple levels of genomic data to identify 
meaningful networks of deregulated signaling. I will also demonstrate that meaningful 
therapeutic targets can be captured using basic mathematical characterization of 
“significantly deregulated genes”. Finally, I will propose a method for the targeted 
treatment of EGFRI-resistant lung tumors as identified by this new method of network 
analysis.  
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CHAPTER 2 
 
A. OVERVIEW 
 
Lung cancers are frequently diagnosed in later stages of disease progression with 
few treatment options available for patients. In the last decade, a number of targeted 
therapies have been developed against impactful oncogenic targets in lung cancer (e.g., 
EGFR, ALK, and ROS), but many tumors either lack an actionable oncogenic mutation or 
harbor an inherent resistance mutation (e.g., KRAS). Therefore, most patients receive a 
cytotoxic agent to which they may not respond (55, 83). Unfortunately, many patients with 
a targetable mutation eventually develop resistance to targeted therapy enforcing the need 
to couple or stage therapies to combat resistance. 
 
Genome scale sequencing and gene expression technologies have provided 
scientists and clinicians the tools to gather increasingly more specific insight on tumor 
heterogeneity thereby allowing for tumor-specific therapeutic decisions to be made. While 
the ability to characterize tumors at this level has revolutionized the concept of 
personalized cancer care, the breadth of information presents the dilemma of how to 
interpret molecular characteristics that are biologically relevant for treatment decisions. 
Recently, The Cancer Genome Atlas (TCGA) conducted genomic, transcriptomic, and 
proteomic profiling of 230 lung adenocarcinomas revealing that 73% of the tumors studied 
showed activation of the Ras/Raf cascade downstream of a Receptor Tyrosine Kinase 
(RTK) at the level of genomic alterations and gene expression, but only a subset of those 
tumors showed aberrant activation of this cascade at the protein level (334). This 
observation underscores the diversity within and between tumors reinforcing the need for 
multivariate predictors of drug response to overcome the failings of single biomarker 
methods of response prediction. 
 
One of the more commonly targeted oncogenic RTKs in Non-Small Cell Lung 
Cancers (NSCLC) is the Epidermal Growth Factor Receptor (EGFR). The EGFR inhibitor, 
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erlotinib, is indicated for use in patients harboring an EGFR-activating mutation (10-15% 
of patients) and is contraindicated for use in patients with mutated KRAS (25-30% of 
patients) (335). Using only these two markers to assign erlotinib treatment in NSCLC has 
yielded results that are modest at best (336). To augment the short-comings of KRAS and 
EGFR mutation status as the sole predictive metric, the Black laboratory showed that 
microRNA (miRNA) expression patterns in different cell lines could predict erlotinib 
resistance, reporting that a 13-miRNA gene signature could be used for these purposes 
(327). Our 13-miRNA gene signature of response is not only able to stratify NSCLC cells 
and tumor samples into erlotinib-sensitive and -resistant groups, but was also able to 
discriminate between primary and metastatic lesions. Understanding why the expression 
of these small RNA molecules can distinguish response to anti-EGFR therapy and 
discriminate metastatic lesions has implications for both prognostic and predictive clinical 
applications. 
 
MicroRNA are non-coding, small, RNA that regulate gene expression by pairing 
with complementary mRNA resulting in translation inhibition or degradation of the mRNA 
(337). miRNA play a role in a number of biological processes (e.g., growth, differentiation, 
and proliferation), so it is not surprising that endogenous expression levels are 
deregulated in cancer (338). Bioinformatic analysis of the 13-gene miRNA signature 
showed that many of the proposed target genes functionally converge on the TGFβ 
signaling pathway (327). For this study, we specifically focused on signature members 
miR-140, miR-141, and miR-200c due to their opposing expression between erlotinib-
sensitive and -resistant cell lines. The miR-200 family, including miR-200c and miR-141, 
is well-characterized for preventing EMT onset by targeting transcription factors (e.g., 
Zeb1 and 2) responsible for suppressing expression of epithelial characteristics, such as 
the E-cadherin (E-cad) adhesion proteins (332, 339-341). High expression of these two 
miRNA correlate with erlotinib-sensitivity in the 13-miRNA gene signature. Conversely, 
miR-140 is highly expressed in erlotinib-resistant cells and is predicted to target the TGFβ 
receptor and Smad 2 (327, 342). Importantly, these data demonstrate that opposing 
expression profiles and activities are necessary for EMT. 
 
The TGFβ signaling pathway is well documented for its role in the induction and 
potentiation of the mesenchymal phenotype in tumor cells (343). TGFβ is a ubiquitous 
cytokine that is active in a number of cell processes, and many of cell types secrete the 
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ligand and express the receptors to bind it (174). Activation of TGFβ signaling is 
accomplished by TGFβ ligands binding to the extracellular domain of TGFβII receptors. 
This allows it to recruit the TGFβI receptor and then bind a second pair of activated 
TGFβII/I receptors resulting in transautophosphorylation within the tetramer (179). 
TGFβ canonical signaling is mediated by Smads 2, 3, and 4, which bind to Smad 
Binding Elements (SBE) on DNA eliciting a transcriptional response (344). TGFβ 
potentiates the Epithelial to Mesenchymal Transition (EMT) in some cancer cells by 
signaling through a variety of other non-canonical pathways including PI3K/AKT and 
MAPK/ERK (190). Interestingly, several groups have noted that erlotinib sensitivity tends 
to correlate with the epithelial phenotype (345). Since TGFβ upregulates genes 
responsible for the activation of the EMT program (346), and because the miRNA 
signature is capable of stratifying between primary and metastatic lesions ex vivo (327), 
we hypothesize that TGFβ supports differential expression of the signature miRNA 
between erlotinib-resistant and -sensitive NSCLC. 
B. METHODS 
Cell Culture, Protein harvest, Immunofluorescence, and Western Blot 
A549, PC9, H460, and H1650 cell lines (NSCLC) were purchased from ATCC. 
They were cultured in RPMI 1640 supplemented with 10% FBS (USA Scientific) and 
maintained in a humidified incubator at 37 °C at 5% CO2. Cells were seeded in 6-well 
plates and were allowed to grow under maintenance media conditions for 48 hours prior 
to treatments. Cells undergoing 24 hours of treatment were plated 4 x 104 cells/well, and
72- and 168-hour treated samples were plated at 1 x 104 cells. Cells were treated with
SB-431542 (3 µM) (Selleck Chem) and/or TGFβ (5 ng/ml) (Cell Signaling Technologies) 
under minimal serum (1%) conditions for time frames specified. If treatment times 
exceeded 72 hours, treatment media was replenished at the 72-hour time point. Whole-
cell extracts were collected using RIPA buffer (50 mM Tris-HCl, 1% NP-40, 150 mM NaCl, 
1 mM EDTA, 0.25% DOC, 10% glycerol, in ddH2O) and protein content was quantified 
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using a BCA kit (ThermoFisher) prior to western blotting. Proteins were separated using 
SDS-PAGE and were transferred to a nitrocellulose membrane. Expression and/or 
activation of specific proteins (pSmad 2, tSmad 2, pSmad 3, tSmad 3, tSmad 4, α-tubulin, 
pERK1/2, tERK1/2, pAKT, tAKT, E-cad, Vimentin, N-cad, Zeb1) was assess by western 
analysis using antibodies purchased from Cell Signaling Technologies. 
Immunofluorescence was performed using Alexa Fluor-conjugated antibodies of the 
specific clone of E-cad and vimentin used for western blotting (Cell Signaling 
Technologies). Immunofluorescence was measured using the AMG EVOS microscope 
with built-in EVOS software (Thermo Fisher). Cell morphology images was recorded using 
the Zeiss AxioObserver Microscope and processed using the AxioVision software. 
 
Chromatin Immunoprecipitation (ChIP) 
 
ChIP assays were carried out with the Simple ChIP Plus Enzymatic Chromatin IP 
Kit (Cell Signaling Technologies) to measure Smad 4 binding to two putative SBE sites in 
the shared promoter of miRNA-141 and miR-200c at -1645/-1247 and - 1793/-1395 from 
each transcriptional start site, respectively. Cells were plated at 5 x 105 cells per dish in 
10 cm dishes for 48 hours prior to a media change to 1% FBS-containing RPMI +/- 5 ng/ml 
TGFβ1 treatment for 24 hours. After treatment, cells were cross-linked, processed, and 
digested as described in the Simple ChIP protocol (Cell Signaling Technologies). Samples 
were divided following digestion and chromatin complexes were immunoprecipitated with 
Smad 4 antibody (20 µl/ChIP) against a non-specific rabbit IgG (1 µl/ChIP) overnight and 
then pulled down with magnetic ChIP-grade protein G beads for 2 hours (Cell Signaling 
Technologies). Immunoprecipitated samples were washed, uncrosslinked, and DNA was 
prepared as described in the Simple ChIP protocol (Cell Signaling Technologies). SYBR 
Green qRT-PCRs (Applied Biosystems) were performed with negative-control α-Satellite 
and positive-control ID1 Smad 4-specific control primers against the experimental region 
containing the two putative SBEs in the shared promoter of miR-141/-200c (Forward: 
GCATTACTCAGCAAATCCTTAC; Reverse: CCCGACAGGTGATTGCC. Primers 
designed in-house and produced by IDT). Data was analyzed using the Percent Input 
method where signals from ChIP samples are represented as a percentage of the total 
chromatin input. Each individual experiment was replicated in triplicate for each primer set 
and processed using the 2% input method described in the Cell Signaling Technologies 
protocol. Data represented is for three biological replicates (n = 3). P-values were 
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generated using paired t-tests comparing each TGFβ treated sample to its respective 
untreated sample. 
 
Real-Time PCR Analysis of miRNA Expression 
 
Total small RNA was harvested from the cells using the mirVANA™ miRNA 
isolation kit (Life Technologies). cDNA was synthesized for U6, miR-140, miR-141, and 
miR-200c using the TaqMan MicroRNA Reverse Transcription kit and corresponding 
reverse transcription TaqMan primers for U6, miR-140, miR-141, and miR- 200c (Life 
Technologies). cDNA was then subjected to quantitative Real Time PCR (qRT-PCR) using 
TaqMan Mastermix II with no UNG, and corresponding TaqMan microRNA assay primers 
(Life Technologies). qRT-PCR were performed by a 7900HT Fast Real-Time PCR system 
(ABI) and all reactions were run in duplicate with corresponding positive and negative 
controls. The data was analyzed using a 5-way ANOVA following internal normalization of 
raw Ct values to the internal U6 as the normalization probe. 
 
Propidium Iodide (PI) and Flow Cytometry 
 
A549 and PC9 cells were subjected to the same treatments and time points as 
previously described. Specifically, cells were rinsed in PBS at point of harvest, trypsinized, 
and collected in a 15 ml conical tube. Cells are centrifuged at 1500 rpm and the 
supernatant is removed. Cells are washed once with cold PBS, pelleted, and the 
supernatant removed. Finally, the cell pellet was resuspended in 400 µl of cold PBS and 
then 1 ml of cold, 100%, molecular biology grade ethanol was added to each sample 
dropwise while gently vortexing and then samples were placed on ice for 30 minutes. Cells 
were pelleted by centrifugation and the supernatant removed, and then washed in cold 
PBS/1%BSA. The pellet was resuspended in 0.3 ml of PI solution (1X PBS/1% BSA/50 
µg/ml PI/0.5 mg/ml RNase A). Samples were incubated in the PI solution for at least 30 
minutes at 4 °C protected from light. Samples were assayed on the Attune Flow Cytometer 
acoustic focusing cytometer, and 10,000 cells from each sample were profiled for PI 
emission, and data was collected with the Attune-specific software provided (Applied 
Biosystems/ThermoFisher). Percentage of total cells in each phase of the cell cycle was 
determined using the cell cycle analysis platform in the FlowJo V10 software (FlowJo). 
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Statistics 
To analyze changes in endogenous gene expression data generated by qRT-PCR 
described above, a five-way ANOVA was performed using the following variables: 
treatment with TGFβ, treatment with SB-431542, time point, expression as internally 
normalized Ct values, and cell line, along with all interaction terms. The overall F-test, 
followed by partial F-tests were used to determine significant effects. Following the 
ANOVA, post-hoc comparisons were made for significant terms in the ANOVA using two-
sample t-tests to compare subgroups of interest. Tests were determined to be significant 
if p-values were less than 0.05. All analyses were performed in SAS Version 9.3 or above 
(SAS Institute Inc., Cary, NC). 
C. RESULTS 
Most Signature miRNA Promoters Contain Smad Binding Elements 
The promoter of each of the 13 signature miRNA was analyzed using 
chipMAPPER (347, 348) for putative SBEs (344, 349). Predicted SBEs were retained if 
they had conservative E-values (≤ 25) and a score greater than 3.0. SBEs matching these 
criteria were found in the promoter regions of twelve of the thirteen signature miRNA 
(Figure 2.7). The three signature miRNA genes we focused on in this study (miR-140, 
miR-141, and miR-200c) have multiple predicted SBEs within -2000 base pairs of 
transcriptional start site (Figure 2.1) (184, 344, 350). 
The activity of complexes containing Smad 2 and Smad 3 along with the DNA-
binding member, Smad 4, have been shown to have both positive and negative effects on 
transcription (351, 352). Since the signature miRNAs are differentially expressed among 
cell lines, the majority of their promoters contain putative SBEs, and the known dual 
behavior of TGFβ activity on gene expression, we hypothesized that the canonical TGFβ 
signaling pathway likely controls opposing expression levels of signature miRNA between 
erlotinib-sensitive and -resistant NSCLC lines. 
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TGFβ-mediated Smad Signaling has an Opposing Phenotype in Erlotinib Resistant 
and -Sensitive Cell Lines 
 
A549 and PC9 cell lines were selected as representative NSCLC cell lines due to 
their opposing erlotinib responses and opposing expression levels of the 3 candidate 
miRNA. A549 are inherently erlotinib-resistant because they harbor a KRAS activation 
mutation, and PC9 are erlotinib-sensitive treatment because they contain an activating 
exon 19 deletion in EGFR (328). 
 
We first examined the expression and activation of the Smad molecules, Smad 2, 
Smad 3, and Smad 4, after treatment with exogenous TGFβ ligand, an inhibitor of 
TGFβRII, SB-431542, or the combination in these cell lines (Figure 2.2A) by western blot 
to determine if these effectors could be responsible for signature miRNA regulation. In 
both A549 and PC9 after 24 hours of treatment, pSmad 2 and pSmad 3 levels are elevated 
in cells treated with TGFβ, and the effect was diminished in cells treated with SB-431542 
or the combination of SB- 431542 and TGFβ. Total Smad 2, Smad 3 and Smad 4 levels 
appear to be consistently expressed across treatments at 24 hours. There were no 
obvious levels of pSmad 2 or pSmad 3 in either cell line or in any treatment condition at 
the 72-hour treatment time point. Total Smad 2 and Smad 4 levels appear to be 
consistently expressed in both cell lines across both treatments. However, in both cell 
lines, tSmad 3 levels were diminished in cultures treated with TGFβ. 
 
At 168 hours, pSmad 2 levels were seen only in A549 treated with TGFβ. Phospho-
Smad 3 levels were not observed in either line at 168 hours. tSmad 2, tSmad 3, and Smad 
4 appear diminished in PC9 treated with TGFβ alone, and this phenotype was not 
observed in any other condition. A549 demonstrated similar expression of total Smad 
molecules across all treatment conditions. 
 
We observed the cyclical activation of Smad 2 in A549 while activation of Smad 3 
was observed early following initial stimulation, but did not return. In PC9, a different 
phenotype emerged with diminished levels of all Smad 2, Smad 3, and Smad 4 molecules 
by 168 hours. Taken together, these data suggest that the TGFβ canonical signals are 
managed differently in A549 and PC9. 
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TGFβ Treatment Induces an EMT Protein Expression Switch in A549 but not in PC9 
 
Like many, we observed that A549 cells treated with TGFβ undergo a 
morphological change with treatment and appropriately activate R-Smad proteins - a 
phenotype consistent with EMT. PC9 cells did not undergo these changes with TGFβ 
treatment, but interestingly, PC9 cells treated with the TGFβ inhibitor displayed an EMT 
intermediate phenotype known as “Metastable” (Figure 2.8) (353). For this reason, we 
assessed a panel of EMT protein markers to determine if the morphological changes 
observed were indicative of EMT progression and correlated with signature miRNA 
endogenous expression changes. 
 
A549 and PC9 were plated, treated, and harvested as described for protein 
measured by BCA assay prior to western blotting. Lysates were assessed for 
mesenchymal markers N-Cadherin (N-cad), Zeb1, and vimentin as well as the epithelial 
marker, E-cadherin (E-cad) to confirm if the morphological changes were consistent with 
EMT occurring (Figure 2.2B). As a comparison, we also profiled A549 and PC9 cells for 
E-cad and vimentin expression by immunofluorescence at 24- and 168-hour (7 days) time 
points (Figure 2.2C-F). mRNA levels of E-cadherin were examined in both cell lines at 24-
, 72- and 168-hour time points to fully capture the change in expression of this epithelial 
marker across time points (Figure 2.9I). 
 
In A549, TGFβ suppressed E-cad expression across each of the time points in the 
experiment, as expected. Conversely, vimentin expression increased over the time course 
of TGFβ treatment. N-cad and Zeb1 appear in the 72- and 168- hour time points, 
respectively, in TGFβ-treated A549. The immunofluorescence profile of E-cad expression 
at the 24 hour and 7 day –treated time points in A549 cells was consistent with the levels 
observed by western analysis. Vimentin levels increased in A549 cells also mirrored the 
western blot results (Figure 2.2C,D). 
 
In PC9, neither TGFβ stimulation nor its inhibition decreased E-cad expression or 
induced expression of the mesenchymal markers assessed. E-cad expression was 
consistent between the western and immunofluorescent assays. Vimentin expression was 
not observed by western or immunofluorescence assays (Figure 2.2E,F). Since PC9 
responded unexpectedly to treatment, we sought to determine if TGFβ directly regulated 
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the expression of two candidate miRNA genes in both A549 and PC9 by assessing if 
Smad 4 directly binds a shared putative SBE. 
 
TGFβ Induces Smad 4 Binding to Putative SBEs in the Promoter of mir-141/200c in 
Erlotinib-Sensitive Cells 
 
To test the impact of the observed deregulation of R-Smad activity in A549 and 
PC9 on candidate miRNA expression, we asked whether Smad 4 was directly binding the 
promoters of our miRNA genes. Smad 4 is the only member of the canonical-Smad family 
with a nuclear localization signal, and others have shown that it is required for any active 
Smad complex to translocate into the nucleus to regulate transcription. Direct regulation 
of gene expression by TGFβ-activated Smad complexes is expected to occur within 24 
hours of treatment (184). For these reasons, we only tested Smad 4 binding to the SBE 
locus after 24 hours of treatment by Chromatin Immunoprecipitation (ChIP). 
 
In A549 cells, TGFβ treatment induced a significant enrichment of the positive 
control, the ID1 promoter SBE, bound to Smad 4 (p = 0.0171). The mir-141/-200c promoter 
region was not significantly enriched in A549 cells in any treatment or antibody 
combination (Figure 2.3A). In PC9 cells, TGFβ treatment enriched both the positive 
control, ID1 (p = 0.0035), and the mir-141/-200c promoter containing the SBE locus (p = 
0.0006), suggesting that Smad 4 is bound to the shared promoter region in PC9 cells and 
not in A549 cells treated with TGFβ (Figure 2.3B). This observation led us to ask whether 
the observed DNA interaction between the Smad 4- containing complex and the SBE 
resulted in changes in endogenous levels of miR-141 or miR-200c. 
 
Time, Not Treatment, Alters the Expression of the Candidate microRNAs 
 
Activated Smad 2 and Smad 3 were present in both lines at 24h post-TGFβ 
treatment and pSmad 2 returned at 168h after treatment in A549. We have also shown 
that Smad 4 is expressed in all conditions and binds mir-141/200c promoter at 24 hours 
post-TGFβ treatment in PC9. For these reasons, we anticipated that differential 
expression of the signature miRNA genes would occur under these conditions as a result 
of TGFβ treatment. To explore this, A549 and PC9 were cultured and harvested as 
described and assessed for endogenous expression changes of three signature miRNA 
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genes, miR-140, miR-141, and miR-200c by qRT-PCR. Importantly, these experiments 
were performed in 1%-serum media to minimize the impact of exogenous cytokines. We 
tested each of the three miRNA profiled in the conditions indicated here in both 1% serum 
and 10% serum treatment conditions to confirm that the changes observed are not due to 
serum levels. Importantly, miRNA expression does not significantly differ between the two 
serum levels for any of these three miRNA (Figure 2.13). 
 
The miRNA expression trends did not differ significantly among treatment 
conditions, but differences across time points were observed (Figure 2.10). An initial 2-
way ANOVA comparing endogenous miRNA expression changes as internally-normalized 
Ct values within each cell line indicated that the most impactful variable governing 
endogenous expression change was the time of treatment. The 2-way ANOVA was not 
able to compare whether the expression changes correlated with other miRNA tested or 
the erlotinib- sensitivity status of a cell line. In order to capture this complexity, we used a 
5-way ANOVA to identify significant interactions between five variables: 1) miRNA 
expression (Ct values), 2) time point sample was taken, 3) TGFβ treatment addition, 4) 
SB-431542 treatment addition, and 5) cell line. All combinations of factors were 
simultaneously calculated (5-way ANOVA Input in Supplementary Table 1, Ct averages in 
supplementary file 1, Appendix I). The 5-way ANOVA revealed that treatments and miRNA 
expression levels are not related, and that the most influential experimental component 
was the time of treatment (Figure 2.4A and Figure 2.11). Figure 2.11 shows that individual 
miRNA expression follow the same trends across treatments over time. For simplicity, 
since expression trends did not differ drastically between treatments, we chose to present 
the overarching miRNA expression trends generated as averages of treatments in each 
individual cell line at each time point (Figure 2.4A). The table highlights the significance of 
endogenous expression changes among time points separated by miRNA gene in each 
cell line (Figure 2.4B). Taken together, these data demonstrate that treatment was not 
impactful in the changes in endogenous miRNA expression, but the time of treatment was. 
Importantly, individual miRNA expression changes did not correlate with the erlotinib 
sensitivity of each cell line. From these data, we hypothesized that the impact of the time 
of treatment may be directly related to the cell cycle position of the cells. 
 
Time, Not Treatment, Alters the Cell Cycle Position of A549 and PC9 Cells 
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To assess whether observed changes in miRNA expression correlate with cell 
cycle position, as a measure of time, A549 and PC9 cells were assessed for percentage 
of cells in each cell cycle position at each of the time points. Cells were treated and 
harvested as described for cell cycle analysis using propidium iodide staining and flow 
cytometry. For each sample, 10,000 events were counted to ensure percentages were not 
skewed by the differing number of cells present in each sample at the end of treatment. 
Overall proliferation following respective treatment times is shown in Figures 2.12 and 
2.13 as cell counts. 
 
Irrespective of treatment, the percentage of A549 cells in the G0-G1 phase of the 
cell cycle increased over time of treatment. PC9 cells behaved similarly (Figure 2.5). 
However, PC9 cells treated with TGFβ failed to continue to proliferate after 72 hours while 
the percentage of cells in G0-G1 changed. To understand the impact of time and treatment 
on percentage of cells in the G0-G1 phase of the cell cycle, a 2-way ANOVA was performed 
within each individual cell line to capture the most impactful factor influencing the trends. 
The ANOVA confirmed that the most important factor governing the increasing number of 
cells in of G0-G1 phase was cumulative time of treatment. In A549 cells, time of treatment 
significantly explained cells in the G0-G1 phase of the cell cycle (p<0.0001). In PC9, both 
treatment conditions (p<0.0001), time of treatment (p = 0.0002), and the interaction of the 
two variables (p = 0.0168) had a significant impact on the percentage of cells in the G0-G1 
phase of the cell cycle. Because cell cycle position interacted with time of treatment, we 
wondered whether a specific non-canonical signal transduction cascade downstream of 
TGFβ was activated that might impact cell cycle progression. 
 
TGFβ Activation of Non-Canonical Effectors ERK1/2 and AKT Differs Between A549 
and PC9 
 
Since miRNA endogenous expression changes appeared to correlate with 
changes in the cell cycle rather than TGFβ treatment, we endeavored to understand the 
impact of TGFβ treatment on non-canonical effectors known to drive growth and 
proliferation, Ras/MAPK and PI3K/AKT pathways. The same protein lysates profiled for 
the R-Smad effectors and EMT marker proteins in Figure 2.2 were assessed for both 
pERK1/2 and pAKT expression. Corresponding total protein expression of each across 
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the same treatments and time points described above were measured by western blot 
(Figure 2.6). In A549, pERK1/2 levels increase with TGFβ treatment across the time points 
while total protein levels remained constant. pAKT levels in A549 increased at the 24-hour 
time point, but then diminish across time points while total levels of the protein were 
constant. In PC9, pERK1/2 and pAKT levels were elevated at the 24-hour time point, but 
both diminish over time without a decrease in total protein levels in the cells treated with 
SB-431542 with and without co-treatment with TGFβ. Densitometry performed on these 
blots can be seen in Figure 2.14. These data suggest that the relationship between TGFβ 
and non-canonical growth and proliferation pathways and may explain why the changes 
in endogenous miRNA expression correlated with an increasing percentage of cells in the 
G0-G1 phase of the cell cycle. 
 
 
D. DISCUSSION 
 
In early stages of tumor development, TGFβ acts as a tumor suppressor 
preventing the proliferation, differentiation, and overall survival of the impacted cells. In 
later stages of tumor development, TGFβ shifts from tumor suppressive functions to 
promotion of tumorigenesis by driving the transcription of pro-EMT genes, which stimulate 
tumor cells to invade and metastasize (354, 355). The role of TGFβ signaling in EMT is of 
particular interest to our group because the 13-gene miRNA signature not only stratified 
NSCLC into erlotinib-sensitive and erlotinib-resistant groups, but was also able to 
discriminate between primary and metastatic tumors (327), and multiple members of the 
miRNA signature have been shown to play either a promoting or repressing role in EMT 
in NSCLC (332, 356, 357). For this reason, we endeavored to understand the role of TGFβ 
signaling on the expression of microRNA genes dysregulated in erlotinib-sensitive 
compared with erlotinib–resistant cell lines. 
 
TGFβ drives EMT by using the canonical signaling pathway, mediated by the R-
Smads, which upregulate transcription responsible for the repression of epithelial 
characteristics (190). Analysis of the TGFβ-driven R-Smad family members, showed a 
differential response to TGFβ treatment between the erlotinib-resistant, A549 cells, and 
erlotinib-sensitive, PC9 cells. Activated Smad 2 and Smad 3 expression was observed in 
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both cell lines at similar levels at early time points of treatment. At the 168-hour time point, 
activated Smad 2 levels return in A549 cells treated with TGFβ, compared to unchanging 
total Smad 2, Smad 3 and Smad 4 levels across treatments. In PC9 cells after 168 hours 
of TGFβ treatment, the total expression of all TGFβ effectors tested was reduced 
suggesting the impact of some negative feedback mechanism. TGFβ is known for 
promoting EMT in late stages of tumor development, but in the early stages, it functions 
in an anti-EMT capacity (355). We believe this cyclical pattern of TGFβ activation and R-
Smad molecule repression to be indicative of TGFβ acting in an anti-EMT capacity in these 
cells. 
 
To delve further into whether TGFβ treatment acted by different mechanisms 
between the two lines tested, we explored TGFβ-driven morphological changes and EMT 
marker protein expression changes. It is known that TGFβ treatment induces a very long, 
fibroblast-like phenotype in A549 cells (Figure 2.8) and western blot analysis of the EMT 
markers E-cad, vimentin, N-cad, and Zeb1 shows that TGFβ treatment induced a protein 
expression phenotype consistent with EMT (Figure 2.2B) (358). However, this study is the 
first to demonstrate biological differences in “epithelial” NSCLC cell lines, like PC9 cells, 
treated with TGFβ. In PC9 cells, the morphology after TGFβ treatment is unchanged. 
Interestingly, PC9 cells treated with the TGFβ inhibitor, SB-431542, with and without co-
stimulation with TGFβ develop a morphology consistent with an EMT-intermediate 
phenotype known as “metastable” suggesting that the inhibition of TGFβ in PC9 cells may 
play a role in the induction of EMT (Figure 2.8) (353, 359). This observation, as well as 
that of the change in expression of the R-Smads in these cells, is consistent with the 
TGFβ-paradox theory and also correlates with the signature’s ability to stratify primary and 
metastatic lesions. To test whether TGFβ inhibition induced EMT initiation in PC9 cells, 
we profiled EMT protein markers to determine if the morphological change was indeed 
indicative of an EMT intermediate. While PC9 cells treated with the TGFβ inhibitor, SB-
431542, undergo a morphological change consistent with EMT initiation, the western blot 
and immunofluorescence analyses revealed that the cadherin switch, that is essential for 
full-EMT, did not occur in response to treatment (360). Taken together, these data suggest 
that while TGFβ may act as a pro-tumorigenic, pro-EMT fashion in A549 cells, it may play 
an anti-EMT and protective role in PC9 cells because the inhibition of TGFβ did not induce 
a complete EMT transition in these cells. 
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Since A549 and PC9 cells appeared to represent either side of the TGFβ paradox, 
we sought to elucidate whether TGFβ directly regulated the expression of the candidate 
signature miRNA genes to understand whether the differing impact of TGFβ observed by 
R-Smad and EMT marker expression was also differentially regulating the expression of 
some of the signature miRNA genes. We expected TGFβ to directly regulate the 
expression of the signature miRNA and from there we expected to be able to triangulate 
a relationship between erlotinib- sensitivity, TGFβ signaling, and the 13-miRNA gene 
signature to determine therapeutically-relevant, secondary targets for overcoming 
inherent or acquired erlotinib-resistance. To test if TGFβ was directly influencing the 
expression of miR-200c and miR-141, we performed a ChIP assay to determine whether 
TGFβ induced the binding of Smad 4 to an SBE site in the shared promoter of mir-
200c/mir-141. These two miRNA genes have very different baseline expression profiles 
between the mesenchymal, A549, and epithelial, PC9, cell lines. We showed that TGFβ 
treatment induced Smad 4 interaction with the shared mir-141/mir-200c promoter only in 
PC9 cells. However, in PC9 cells endogenous miR-141 and miR-200c expression at 24 
hours after treatment showed no impact of any treatment condition, suggesting that TGFβ 
signaling may not be important in this context. Importantly, Smad 4 must be bound to 
activated Smad 2 or Smad 3 to carry out transcriptional control, and we did not test 
whether pSmad 2/3 was present with Smad 4. 
 
While we did not observe a change in endogenous expression of any of the three 
miRNA in response to treatment, we did observe that the change in expression of miR-
200c and miR-141 in response to changes in the time of treatment, and we believe that 
time is reflective of cell cycle position. Importantly, miR-200c and miR-141 are thought to 
be under coordinated transcriptional regulation because of an overlapping promoter 
region (361). Our data suggests that, at least in these treatment conditions and cell lines 
tested, miR-141 and miR-200c are not commonly regulated as is expected of genes that 
share a promoter region. We also observed that the trends in expression changes did not 
segregate the two erlotinib-resistant lines, A549 and H460 cells, from the two erlotinib-
sensitive lines, PC9 and H1650 cells, suggesting that changes in the expression of these 
miRNA did not correlate with erlotinib-resistance or EMT status (Figure 2.4 and Figure 
2.11). 
 
Using a 5-way ANOVA, we discovered that that the most important factor 
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governing the changes in endogenous miRNA expression was the time of treatment. Thus, 
we investigated whether cell cycle stage could impact the expression of these genes. In 
Figure 2.15, we interrogated the putative transcription factor binding sites of one cell cycle 
regulated effector, ELK1, using the ChipMAPPER algorithm (347, 348). The analysis 
revealed putative ELK1 sites in the promoters of 12 out of 13 of the miRNA genes profiled, 
supporting our hypothesis that cell cycle progression may control the expression of the 
candidate miRNA genes. Analysis of the cell cycle position of A549 and PC9 cells across 
the same treatments and time points revealed that as time of treatment increased, the 
percentage of cells in the G1-G0 phase of the cell cycle increased, except in TGFβ treated 
cells at the final time point (Figure 2.5). Importantly, the impact of treatment alone on cell 
cycle stage was only significant in PC9 cells (Figure 2.5). Figures 2.12 and 2.13 illustrate 
cell counts, reflective of doublings, in both 1% and 10% serum across treatment 
conditions. PC9 cells failed to continue to grow in the presence of TGFβ and 1% serum 
which may explain the reduction of cells in G1-G0 phase of the cell cycle at 168 hours. 
Further experimentation will be necessary to understand this modest but significant 
decline. 
 
Finally, because of the observation that cell cycle position may be important in 
expression of the miRNA examined in this study, we interrogated the activation of TGFβ 
non-canonical growth and proliferation pathways, Ras/MAPK and PI3K/AKT, to determine 
if they may play a role in the relationship of cell cycle position and endogenous miRNA 
expression. pERK activation increased across the time points in A549 cells, and its 
activation may influence the re-emergence of pSmad 2 levels at 168 hours  because pERK 
is  known to phosphorylate the linker region of Smad 2 to stabilize the signal (190). pERK 
signaling is also required for TGFβ- driven EMT, consistent with the increase in pERK 
signal in A549 cells undergoing TGFβ-induced EMT (353). PC9 cells harbor an EGFR-
activating mutation resulting in the constant expression of pERK and pAKT. Perhaps most 
interestingly, treatment with the TGFβ receptor inhibitor, SB-431542, resulted in the 
reduction of both signals regardless of co-treatment with TGFβ ligand. SB-431542 is a 
competitive ATP binding site kinase inhibitor and has been shown to disallow ERK, JNK, 
or p38 pathway activation from other signals or their response to serum (362). These data 
suggest that, at least in PC9 cells, the perpetual activation of ERK and AKT signals from 
active EGFR signaling may rely on basal activation from TGFβRII in order to persist. We 
anticipate testing this using a TGFβ-receptor knock-down to observe whether the same 
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impact on ERK and AKT signals is observed. 
 
Our future experiments will attempt to fill the gaps noted from this work. We will 
determine whether the remaining erlotinib-sensitive cell lines used to generate gene 
expression data have a similar response to long term TGFβ treatment even though we 
know that erlotinib-sensitive tumors also have metastatic capability. We will also determine 
if erlotinib response is altered by time in treatment as miRNA expression and cell cycle 
position were. We will test whether the expression of ELK1 in cells is important for cell 
cycle progression in this context because the shared promoter of mir-141 and mir-200c 
contains an ELK1 binding site. We might also determine if E2F sites are present and active 
because TGFβ-driven, DNA-binding Smad complexes have been shown to interact with 
cell cycle regulating elements (363, 364). Therefore, it is possible that Smad 4 binding to 
the SBE in PC9 cells does requires coordinate cell cycle regulation, through ELK1, to 
regulate the expression of miR-141. The presence of known cell cycle responsive 
elements in the promoters of most of the 13-signature miRNA suggests that the cell cycle 
may play a role in governing the expression levels of these miRNA genes. Understanding 
the mechanism of regulation of the signature miRNA genes might help us further 
understand whether TGFβ signaling is a driver of EMT and metastasis or a passenger 
alongside cell cycle-dependent regulation of these genes. 
 
E. CONCLUSIONS 
 
Our original hypothesis that TGFβ directly regulated the expression of the 
microRNA gene signature and that it modulated gene expression differently in erlotinib-
resistant versus erlotinib-sensitive cells was founded on a bioinformatics analysis of these 
genes with little regard for cellular context. We found that TGFβ is likely not directly 
responsible for control of the expression of the microRNA genes we tested. However, we 
still find it an attractive therapeutic target if we can understand the cellular or tumoral 
context wherein targeting this cytokine impacts NSCLC patient survival. 
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Figure 2.1: Signature microRNA genes contain SBE elements. Promoter analysis was 
conducted using the ChipMAPPER algorithm (347, 348). microRNA genes -140, -141, 
and -200 contain putative SBE elements as represented by the triangle with conservative 
E-values less than or equal to 25 and a score greater than 3.0. 
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Figure 2.2: Total Smad expression, Smad activation and EMT program marker 
expression varies with TGFβ or inhibitor treatment. Erlotinib-resistant, A549 cells, 
and erlotinib-sensitive, PC9 cells were plated, treated and harvested as described. 
Proteins were visualized by western blotting. All blots from the same samples; α-tubulin 
levels are representative controls for each sample. (A) Profiling of Smad family 
member expression and activation across time demonstrates changes in TGFβ 
canonical signaling. (B) EMT protein markers demonstrate program initiation and 
progression among treatment conditions. (C) A549 cells treated for 24 hours for E-
cadherin and vimentin expression by immunofluorescence (D) A549 cells treated for 7 
days for E-cadherin and vimentin expression by immunofluorescence (E) PC9 cells 
treated for 24 hours for E-cadherin and vimentin expression by immunofluorescence 
(F) PC9 cells treated for 7 days for E-cadherin and vimentin expression by 
immunofluorescence. 
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Figure 2.3: TGFβ induces Smad 4 binding to SBEs in the promoter of mir-200/141 
in PC9 cells. Chromatin immunoprecipitation was performed to identify whether a 
physical interaction between Smad 4 and a predicted SBE locus in the shared promoter 
of mir-200c/-141 resulted from TGFβ treatment. Normal rabbit IgG served as the 
antibody negative control and α-Satellite primers as the negative PCR control. ID1 locus 
immunoprecipitation was the positive control for Smad 4 binding. (A) In A549, positive 
Smad 4-ID1 association is observed with TGFβ treatment, but an Smad 4-SBE 
interaction is not. (B) In PC9, both Smad 4-ID1 and Smad 4-SBE interaction is 
observed. Significance was calculated using an unpaired t-test comparing TGFβ-
treated cells and -untreated samples with the same primer set. (n=3) 
 
A 
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Figure 2.3 (continued): TGFβ induces Smad 4 binding to SBEs in the promoter of 
mir-200/141 in PC9 cells. 
 
 
B 
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Figure 2.4: Time of TGFβ treatment reflects changes in endogenous miRNA gene 
expression. Changes in endogenous gene expression were analyzed using a five-
way ANOVA considering the variables: TGFβ treatment, SB-431542 treatment, time 
point, expression as internally normalized Ct values, and cell line, along with all 
interaction terms. (A) Data presented here is aggregated by averaging over treatments 
in order to capture overarching trends in miRNA and cell line patterns at multiple time 
points. Fine-scale trends were broken down by individual treatments as presented in 
Figure 2.10. (B) Comparison of the significance of endogenous expression changes 
between time point’s samples and by individual miRNA genes in each cell line. 
 
A 
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Figure 2.4 (Continued): Time of TGFβ treatment reflects changes in endogenous 
miRNA gene expression. 
 
B 
 Cell Line miRNA 24 vs 72 hours 24 vs 168 hours 
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A549 
miR-140 <0.0001**** 0.0002*** 
miR-141 <0.0001**** <0.0001**** 
miR-200c 0.0471* 0.0675 
 
H460 
miR-140 0.5221 0.0656 
miR-141 0.2548 0.0605 
miR-200c 0.9663 0.1077 
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PC9 
miR-140 0.1875 0.5760 
miR-141 <0.0001**** <0.0001**** 
miR-200c 0.0561 0.0500* 
 
H1650 
miR-140 0.7751 <0.0001**** 
miR-141 0.4358 <0.0001**** 
miR-200c 0.7586 0.0051*** 
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Figure 2.5: A549 and PC9 cells exit the cell cycle regardless of treatment with 
TGFβ or SB-431542. The graph reflects the percentage of A) A549 or B) PC9 cell 
populations in G0-G1 phase of the cell cycle at 24, 72, and 168 hours following 
treatment. Significance was determined using an unpaired t-test comparing the 72- and 
168-hour time points individually to the 24-hour time point of the same treatment. (C) 
A two-way ANOVA was utilized to determine the significance of treatment and/or time 
point reflective of the percentage of cells in the G0-G1 phase of the cell cycle. 
 
A 
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Figure 2.5 (Continued): A549 and PC9 cells exit the cell cycle regardless of 
treatment with TGFor SB-431542. 
B 
C 
 
 
 
 
 
 
 
 
  
Source of 
Variation 
A549 PC9 
Interaction 0.0583 0.0168* 
Time <0.0001**** <0.0001**** 
Treatment 0.1042 0.0002*** 
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Figure 2.6: TGFβ modulation differentially impacts ERK and AKT activation 
between A549 and PC9. A549 and PC9 cells were plated, treated, and harvested as 
described in the methods. α-tubulin levels are representative of an individual lysate pool. 
Lysates profiled here are the same as in figure 2.2. ERK-MAPK and PI3K-AKT signaling 
are non-canonical signaling effectors of the TGFβ signaling pathway. All blots from the 
same samples; α-tubulin levels are representative of each sample. 
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Figure 2.7: Signature microRNA genes contain SBE elements. Promoter analysis was 
conducted using the ChipMAPPER algorithm (347, 348). Twelve out of thirteen of the 
signature microRNA genes contain putative SBE elements as represented by the triangle 
with conservative E-values less than or equal to 25 and a score greater than 3.0 (181, 
184).  
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Figure 2.8: TGFβ induces a mesenchymal phenotype in A549, but inhibition 
generates an EMT-intermediate phenotype in erlotinib-sensitive, PC9 cells. A549 
and PC9 cells were treated as described in the methods. Bright field images of cell 
morphology were acquired using the microscope and software described in the methods. 
(A) Shows full-sized bright-field images taken at 5X magnification, and (B) shows a closer 
representation of the morphology changes. Time is in hours. 
 
 
 A 
 
 
B 
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Figure 2.9: E-cad expression in response to treatment. (A) E-cad mRNA levels 
quantified by qRT-PCR  in A549 (n=1). (B) E-cad mRNA levels quantified by qRT-PCR 
in PC9 (n=1). mRNA levels are demonstrated as fold change relative to respective 
untreated samples which are standardized to a fold change of 1. 
 
 
A 
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Figure 2.9 (continued): E-cad expression in response to treatment. (A) E-cad 
mRNA levels quantified by qRT-PCR  in A549 (n=1). (B) E-cad mRNA levels quantified 
by qRT-PCR in PC9 (n=1). mRNA levels are demonstrated as fold change relative to 
respective untreated samples which are standardized to a fold change of 1. 
 
 
B 
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Figure 2.10: Normalized Ct values demonstrate that time change, not individual 
treatment, affects endogenous miRNA expression changes in A549 and PC9 cells. 
(A-F) Raw miRNA expression levels using qRT-PCR experiments as described in Figure 
4 and Supplemental Figure 5. 
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Figure 2.11: Time of treatment has the most significant influence on miRNA 
expression changes. Changes in endogenous gene expression were analyzed using a 
five-way ANOVA considering the variables: TGFβ treatment, SB-431542 treatment, time 
point, expression as internally normalized Ct values, and cell line, along with all interaction 
terms.   
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Figure 2.12: A549 cell counts following corresponding treatments and time points 
comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml TGFβ (C) 
+3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 x 104 
cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted at 
the appropriate harvest time using a hemocytometer. (n=2) 
 
 
A 
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Figure 2.12 (continued): A549 cell counts following corresponding treatments and 
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml 
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted 
at the appropriate harvest time using a hemocytometer. (n=2) 
 
 
B 
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Figure 2.12 (continued): A549 cell counts following corresponding treatments and 
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml 
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted 
at the appropriate harvest time using a hemocytometer. (n=2) 
 
 
C 
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Figure 2.12 (continued): A549 cell counts following corresponding treatments and 
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml 
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted 
at the appropriate harvest time using a hemocytometer. (n=2) 
 
 
D 
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Figure 2.13: PC9 cell counts following corresponding treatments and time points 
comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml TGFβ (C) 
+3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 x 104 
cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted at 
the appropriate harvest time using a hemocytometer. (n=2) 
 
 
A 
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Figure 2.13 (continued): PC9 cell counts following corresponding treatments and 
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml 
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted 
at the appropriate harvest time using a hemocytometer. (n=2) 
 
 
B 
  
 
 
CHAPTER 2  
 
89 
 
Figure 2.13 (continued): PC9 cell counts following corresponding treatments and 
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml 
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted 
at the appropriate harvest time using a hemocytometer. (n=2) 
 
 
C 
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Figure 2.13 (continued): PC9 cell counts following corresponding treatments and 
time points comparing growth in 1% and 10% serum media. (A) Untreated (B) +5ng/ml 
TGFβ (C) +3µM SB-431542 (D) +5ng/ml TGFβ +3µM SB-431542. Cells were plated at 1 
x 104 cells/well in a 6-well dish 48 hours prior to 0 hour treatment introduction and counted 
at the appropriate harvest time using a hemocytometer. (n=2) 
 
 
D 
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Figure 2.14: Densitometry of Figure 2.6 western blots. (A) pERK and tERK in A549 
(B) pERK and tERK in PC9 (C) pAKT and AKT in A549 (D) pAKT and AKT in PC9. Blots 
were quantified using ImageJ and quantification was calculated using the area under the 
curve measurements for each band using the same sized box sample for each to ensure 
consistency (n=1). 
 
 
A 
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Figure 2.14 (continued): Densitometry of Figure 2.6 western blots. (A) pERK and 
tERK in A549 (B) pERK and tERK in PC9 (C) pAKT and AKT in A549 (D) pAKT and AKT 
in PC9. Blots were quantified using ImageJ and quantification was calculated using the 
area under the curve measurements for each band using the same sized box sample for 
each to ensure consistency (n=1). 
 
 
B 
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Figure 2.14 (continued): Densitometry of Figure 2.6 western blots. (A) pERK and 
tERK in A549 (B) pERK and tERK in PC9 (C) pAKT and AKT in A549 (D) pAKT and AKT 
in PC9. Blots were quantified using ImageJ and quantification was calculated using the 
area under the curve measurements for each band using the same sized box sample for 
each to ensure consistency (n=1). 
 
 
C 
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Figure 2.14 (continued): Densitometry of Figure 2.6 western blots. (A) pERK and 
tERK in A549 (B) pERK and tERK in PC9 (C) pAKT and AKT in A549 (D) pAKT and AKT 
in PC9. Blots were quantified using ImageJ and quantification was calculated using the 
area under the curve measurements for each band using the same sized box sample for 
each to ensure consistency (n=1). 
 
 
D 
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Figure 2.15: Signature microRNA genes contain both putative SBE elements and 
putative ELK1 binding sites. Promoter analysis was conducted using the ChipMAPPER 
algorithm (348). Twelve out of 13 of the signature microRNA genes contain putative SBE 
elements as represented by the grey triangle with conservative E-values less than or equal 
to 25 and a score greater than 3.0. Twelve out of the thirteen signature miRNA also contain 
putative ELK1 binding sites meting the same inclusion criteria as represented by the blue 
triangles. 
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CHAPTER 3 
 
A. OVERVIEW 
 
Erlotinib is a small molecule Epidermal Growth Factor Receptor (EGFR) inhibitor 
that has been FDA approved for clinical use since 2004 (144). In October 2016, it was 
specifically redesignated by the FDA for the treatment of locally advanced or metastatic 
Non-Small Cell Lung Cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 
L858R substitution mutations (143). However, utilizing EGFR mutation statuses as the 
sole determinant of erlotinib treatment remains limiting because EGFR somatic mutations 
alone may not encompass all NSCLC that would respond to erlotinib. Further, the majority 
of responders do eventually develop resistance to erlotinib therapy (365).  
 
To encompass responders not captured by these EGFR mutations, prior work in 
the Black laboratory showed that estimating response to EGFRI can likely be improved by 
using multivariate gene expression patterns demonstrated in NSCLC cells and in a 
retrospective analysis of tumors (327, 328). From this work, a 13-gene miRNA signature 
predictive of response to the EGFRI, erlotinib, was identified (327). Bioinformatic analysis 
of the 13-gene miRNA signature revealed a functional convergence on the TGFβ signaling 
pathway, suggesting a relationship between the TGFβ and EGFR signaling pathways 
(327). The 13-gene miRNA signature of response was able to stratify cells and tumor 
samples into erlotinib-sensitive and -resistant groups and it discriminated primary tumors 
from metastatic lesions (327). Others have shown that NSCLC patient tumors that have 
undergone the Epithelial to Mesenchymal Transition (EMT) are largely erlotinib-resistant 
when compared with the epithelial-phenotype tumors (366). TGFβ is an inducer of EMT 
and it has also been shown to have paradoxical functions in tumorigenesis, as a tumor 
suppressor in early stages of the disease and as an oncogenic, pro-metastatic player in 
later stages (349, 350).  
 
In a previous study comparing the effects of TGFβ treatment between 
representative erlotinib-resistant and –sensitive NSCLC cell lines, I showed that erlotinib-
resistant, A549, and erlotinib-sensitive, PC9, cells show different activation and 
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expression profiles of the canonical TGFβ effectors, Smads 2, 3, and 4, as well as 
differential activation of non-canonical TGFβ signaling pathways (ERK-MAPK and PI3K-
AKT) after TGFβ treatment (367). As expected, TGFβ treatment induced a mesenchymal 
phenotype in A549 cells as evidenced by morphological changes and expression of EMT 
marker proteins (368). In PC9 cells, which maintain a baseline epithelial phenotype, 
inhibiting TGFβ with the TGFβ inhibitor, SB-431542, induced an EMT-intermediate 
morphological change even though EMT marker protein expression did not change (367). 
These results suggest that there are relationships between the induction of EMT by TGFβ, 
EMT and erlotinib resistance, and the expression of the 13 miRNA genes comprising the 
signature. 
 
For these reasons, we hypothesize that TGFβ induces EMT in erlotinib-resistant 
NSCLC and that inhibiting TGFβ signaling may sensitize these NSCLC to erlotinib 
treatment. 
 
 
B. METHODS 
 
Cell Culture 
 
NSCLC cell lines are from ATCC (A549) or gifted from the Haura laboratory (Moffitt 
Cancer Center, FL). All cells were cultured in RPMI 1640 (Life Technologies) 
supplemented with 10% Fetal Bovine Serum (FBS/serum) (USA Scientific), HEPES, 
glucose and pyruvate and maintained in a humidified incubator at 37 °C at 5% CO2 unless 
otherwise specified. Cells were seeded in-6 well plates and were allowed to grow in 10% 
serum-containing RPMI 1640 media conditions for 48 hours prior to treatments. Dishes 
were seeded with 1 x 104 cells and were treated with SB-431542 (3 µM) (Selleck Chem), 
LY-2109761 (3 µM) (Cayman Chem), and/or TGFβ (5 ng/ml) (Cell Signalling 
Technologies) under minimal serum (1% FBS) conditions for time frames specified. 
Treatment media was replenished at the 72-hour time point in 168-hour culture 
experiments.  
 
Transwell Migration Assay 
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Cells were pre-treated for 7 days as described above prior to plating for the viability 
assay. After pretreatment, cells were trypsinized and resuspended in serum-free RPMI 
1640 media. The top of the 96-well HTS Transwell permeable plate (Corning) membranes 
was coated with 600 µl of a collagen coating solution (750 µl 10X PBS, 14 µl culture-grade 
collagen, 3.2 µl 0.1 M NaOH, 6.73 ml dH2O) and incubated for 1 hour in the culture 
incubator at 37 °C. The collagen was aspirated, and the inserts were washed once with 
1X PBS. Next, the bottoms of each Transwell were blocked with 600 µl of a serum-free 
RPMI 1640 containing 0.1% BSA, and 100 µl of the blocking media was placed into each 
Transwell insert. Blocking continued in the culture incubator at 37 °C for at least 1 hour up 
to overnight. Following blocking, blocking medium is aspirated from the top and the bottom 
wells. Cells (1 x 103) were seeded on top of each Transwell in serum free media and 
allowed to migrate towards a bottom chamber containing RPMI 1640 and 1% serum for 
16 hours. At this time, membranes were fixed in 100% methanol and stained with 0.5% 
crystal violet in 100% methanol.  
 
Wound Healing Assay 
 
Cells were plated in 12-well plates at 5 x 105 cells/well to ensure confluence at time of 
wounding. Cells were incubated in maintenance media (RPMI 1640 containing 10% 
serum) for 24 hours following plating. After the initial 24-hour incubation, media was 
changed to RPMI 1640 and 1% serum with respective treatments for 24 additional hours. 
After 24 hours in treatments, cell monolayers were wounded using a 200 µl pipette tip and 
media was changed to fresh RPMI 1640 and 1% serum with corresponding treatment. 
Plates were marked to ensure the same point in the wound was analyzed each day. 
Wound healing was measured over 72 hours and imaged using the Zeiss AxioObserver 
Microscope and processed using the AxioVision software. Wounds were imaged at 24 
hour intervals for 72 hours total. Wound healing measurements are averaged from 3 
independent linear measurements across the field imaged per sample, per recording time.  
 
Cell Viability Assay  
 
Cells underwent pretreatment in 1% serum-containing RPMI 1640 with drug and/or 
cytokine for 7 days as described above to ensure that all EMT-like events occurring in 
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response to TGFβ treatment were fully realized prior to assessment of erlotinib response. 
After treatment, cells were trypsinized, counted, and plated at 3x103 cells/well in a 96-well 
plate in fresh treatments matching those from the 7-day period. After 36 hours adherence 
time, erlotinib was added in indicated concentrations. Drug treatment persisted for 72 
hours. After 72 hours, resazurin was added (100 µM final concentration) to each well, the 
plates were gently rocked for 1 minute and then incubated for 3 hours prior to reading. 
The plate was read for fluorescence at excitation, 560 nm, and emission, 590 nm, 
wavelengths using a Spectramax M5 and corresponding Spectramax X5 software 
(Spectramax).  
 
Data Processing and Statistics 
 
All graphical representations of data were made and analyzed using Prism Version 
7.00 (GraphPad). Significance points in viability assay data compare the points specified 
in each figure legend and in the results section. Significance was determined using 
unpaired t-tests. Values measured between biological replicates from all viability assays 
and wound healing assays were subjected to a Dixon’s Q test to eliminate outlier values.  
For the Transwell migration assay, ‘cells migrated’ values are the number of cells 
counted in five non-overlapping views per well, averaged from triplicate technical 
replicates per individual experiment by three separate viewers. Values determined by 
each individual were subjected to a Dixon’s Q-test outlier analysis prior to acceptance. 
 For the wound healing assay, ‘percent wound remaining’ was determined relative 
to respective 0 hour wound width. Four independent biological replicates were performed, 
and the four replicates were assessed for outliers using a Dixon’s Q-test. 
 For the viability assay, response to each treatment is normalized to cells from each 
corresponding treatment that were not subjected to erlotinib. Readings were also 
normalized to empty wells on each plate containing only media and resazurin. Data is the 
result of four biological replicate experiments (n=4). 
 
 
 
C. RESULTS 
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TGFβ Treatment Has Opposing Effects on Migration in Erlotinib-Sensitive versus 
Erlotinib-Resistant NSCLC Cells 
 
We first wanted to understand the long-term functional changes in erlotinib-
resistant, A549 cells, and erlotinib-sensitive, PC9 cells, subjected to long-term TGFβ 
treatment, and we assessed their migration ability using a Transwell Assay. TGFβ pre-
treatment induced a significant increase in A549 cells that migrated compared to untreated 
cells (Figure 3.1).  PC9 cells, pre-treated with TGFβ, demonstrated reduced migratory 
ability, but this effect was not found to be significant (Figure 3.1). Since TGFβ treatment 
induced migration in A549 cells, we next asked how TGFβ influenced wound healing ability 
of cells. 
 
TGFβ Inhibition Significantly Impairs Wound Healing Ability in PC9 Cells  
 
Another measurable characteristic of migratory ability is wound healing and we 
used this assay to determine the cellular response of A549 and PC9 cells to short-term 
TGFβ treatment. For this experiment, we also used the TGFβ receptor inhibitor, LY-
2109761, that targets both type I and II TGFβ receptors, unlike SB-431542, to determine 
whether differences observed could be attributed to partial TGFβ receptor inhibition. TGFβ 
treatment did not significantly change the wound healing ability of either cell line. 
Treatment with LY-2109761 significantly impaired the ability of A549 cells to migrate at 
the 48-hour time point (Figure 3.2A). PC9 cells treated with LY-2109761, with and without 
co-treatment with TGFβ, were significantly impaired in wound healing at the 48- and 72-
hour time points (Figure 3.2B).  
 
 
TGFβ Influences Erlotinib Resistance Differently between A549 and PC9 Cells 
 
We found that TGFβ induced an EMT-phenotype and increased chemotactic ability 
in A549 cells, but not in PC9 cells. Next, we aimed to determine if TGFβ treatment had an 
impact on erlotinib-sensitivity in each cell line. A549 cells pre-treated with TGFβ showed 
significantly increased erlotinib resistance at lower erlotinib concentrations, but at 10 µM 
and 30 µM erlotinib levels, TGFβ pre-treated A549 cells were significantly more sensitive 
to erlotinib than untreated A549 cells (Figure 3.3A). No significant impact was observed in 
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any combination of either TGFβ inhibitor with or without TGFβ ligand in A549 cells when 
compared to untreated A549 cells (Figure 3.3A). Most notably, PC9 cells that had 
undergone pre-treatment with TGFβ showed significant increased sensitivity to erlotinib 
(Figure 3.3B). Moreover, pre-treatment with either TGFβ inhibitor with or without TGFβ 
ligand significantly reversed the phenotype in PC9 cells (Figure 3.3B).  
 
 
D. DISCUSSION 
 
Bioinformatic analysis of a previously published 13-gene miRNA signature led us 
to explore the contribution of TGFβ with respect to EMT-progression and its relationship 
to erlotinib-sensitivity (327). Our previous work showed that TGFβ likely has opposing 
roles in relation to EMT-induction and erlotinib-resistance between erlotinib-resistant and 
-sensitive NSCLC cells. We observed that TGFβ treatment induced mesenchymal 
morphologies between 5-6 days of treatment (367), so we chose to pre-treat cells for 7 
days prior to the Transwell assay. We found that TGFβ pre-treatment in A549 cells 
significantly increased cell migration by Transwell assay. TGFβ pre-treatment in PC9 cells 
modestly decreased mobility, but this effect was not found to be significant. Changes in 
PC9 cell migration after SB-431542 pre-treatment were not observed (Figure 3.1). We 
also examined treatment with the TGFβ receptor type 1/2 inhibitor, LY-2109761, as a 
comparison to SB-431542 by wound healing (369). We found that LY-2109761 pre-
treatment also induces a morphological change in PC9 cells consistent with the EMT-
intermediate phenotype known as metastable (353) (Data not shown). However, we 
observed that LY-2109761 treatment, both alone and in conjunction with TGFβ, resulted 
in a significantly suppressed wound healing capability in PC9 cells which is inconsistent 
with an induction of EMT in PC9.   
 
It has been noted by many groups that NSCLC cells sensitive to erlotinib usually 
to have an epithelial phenotype and NSCLC cells resistant to erlotinib often have a 
mesenchymal phenotype (366). We have shown that TGFβ treatment induces EMT-
progression in erlotinib-resistant A549 cells and does not in erlotinib-sensitive PC9 cells 
(367). For this reason, we endeavored to understand whether modulating TGFβ activity 
contributed to changes in erlotinib sensitivity in the two cell lines. Most interestingly, PC9 
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cells pre-treated with SB-431542 or LY-2109761, with and without TGFβ treatment, 
showed significantly decreased erlotinib sensitivity. While these cells did not undergo an 
EMT-reprogramming as defined by EMT marker-protein expression, increased wound 
healing and increased migratory capabilities, our observation that the metastable 
morphology corresponds with significantly decreased erlotinib-sensitivity in PC9 cells is 
consistent with the observation that stable EMT intermediate phenotypes tend to be more 
drug resistant (353, 370). Importantly, we did not examine whether the phenotypes 
induced by TGFβ inhibitors correlated with changes in expression of EGFR or the rate of 
EGFR receptor turnover. We have demonstrated that extended treatment did result in a 
decrease of constitutively active ERK1/2 and AKT signaling (Figure 3.6). However, 
Supplementary Figure I-7 (Appendix I) demonstrates that the decreases in ERK and AKT 
signals in PC9 cells do not correlate with a cytostatic response by PC9 cells to TGFβ-
inhibition.      
 
Here, I have shown that TGFβ treatment influences erlotinib resistance in A549 
cells but TGFβ inhibitors in combination with erlotinib do not sensitize A549 cells to 
treatment. The novel observation of this work is that TGFβ-inhibition significantly 
decreased erlotinib-sensitivity in PC9 cells, whereas TGFβ ligand induced more cell death 
in conjunction with erlotinib than erlotinib did alone in PC9 cells. This indicates that TGFβ 
likely plays a role in the maintenance of erlotinib-sensitivity in PC9 cells. Importantly, this 
mirrors the observations of unsuccessful TGFβ inhibitor drug trials that cite side effects 
that are likely due to pro- and anti-tumorigenic activities of TGFβ signaling (179, 219). 
Accurately pinpointing which half of the TGFβ paradox is occurring and where is an 
ongoing effort that has not been well established at this point in time (352, 371). This work 
should be expanded into other NSCLC cell lines across the erlotinib-sensitivity spectrum 
to reveal if these observations are specific to erlotinib-sensitivity status or linked to other 
factors (e.g., KRAS mutation status).  
 
 
E. CONCLUSIONS 
 
While the relationship between the TGFβ and EGFR signaling networks suggests 
that TGFβ represents a logical secondary target for the prevention of EMT and subsequent 
CHAPTER 3 
 
103 
 
EMT-driven EGFRI resistance, the limitation of targeting TGFβ in unselected tumor 
populations is evidenced by the PC9 cell model. Until a diagnostic test capable of 
dissecting the TGFβ paradox exists, targeting TGFβ will remain an enigmatic and 
implausible target in NSCLC and other tumor types. Further study to dissect the 
mechanism of how TGFβ-inhibition significantly increases erlotinib resistance in PC9 cells 
could have important implications for elucidating and diagnosing the arms of the TGFβ 
paradox as well as the future of targeting TGFβ in lung cancers.  
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Figure 3.1: TGFβ treatment influences the migratory ability of A549 and PC9 cells. 
Cells were plated as described in cell culture methods with the treatments specified over 
a course of 7 days. Values graphed are the total number of migrated cells counted 
between five independent views of each well by three independent readers. Outliers 
between biological replicates, technical replicates, and individual readers were identified 
and excluded using a Dixon’s Q-test. Significance was determined by an unpaired t-test 
comparing each experimental treatment to its respective untreated values (n = 3). * 
indicates p-value is 0.05 ≥ p.   
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Figure 3.2: LY-2109761 alters wound healing capabilities of A549 and PC9 cells. (A) 
A549 and (B) PC9 cells were plated and treated as described in the methods. Percent 
wound remaining is calculated for each biological replicate compared to the respective 0 
hour wound size. Biological replicates were assessed for outliers using a Dixon’s Q-test 
(n=4). * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is ≤ 0.0001. 
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Figure 3.2 (continued): LY-2109761 alters wound healing capabilities of A549 and 
PC9 cells. (A) A549 and (B) PC9 cells were plated and treated as described in the 
methods. Percent wound remaining is calculated for each biological replicate compared 
to the respective 0 hour wound size. Biological replicates were assessed for outliers using 
a Dixon’s Q-test (n=4). * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is 
≤ 0.0001. 
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Figure 3.3: TGFβ treatment alters erlotinib response in A549 and PC9 cells. (A) A549 
and (B) PC9 cells were treated for 7 days prior to initiation of the proliferation assay and 
treated as described. * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is 
≤ 0.0001. (n=3) 
 
 
 
A 
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Figure 3.3 (Continued): TGFβ treatment alters erlotinib response in A549 and PC9 
cells. (A) A549 and (B) PC9 cells were treated for 7 days prior to initiation of the 
proliferation assay and treated as described. * indicates p-value is 0.05 ≥ p > 0.0001, ǂ 
indicates that p-value is ≤ 0.0001. (n=3) 
 
 
 
B 
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A. OVERVIEW 
Inhibitors of the epidermal growth factor receptor (EGFR) were introduced as a 
targeted therapy because some non-small cell lung cancers (NSCLC) are dependent on 
the EGFR oncogene for growth and proliferation (3). Further, it was observed that cells 
and tumors with KRAS activating mutations were inherently resistant to treatment with 
these inhibitors (EGFRI) (67). KRAS activation mutations are the most common mutation 
in lung adenocarcinomas and are observed in 25-40% of cases (19, 22). Methods for 
targeting KRAS that have been investigated include farnesyl transferase inhibitors that 
target the necessary association of KRAS with the cell membrane, but resistance 
mechanisms involving other transferases occur (372, 373). Antisense oligonucleotides, 
including engineered miRNA, have also been explored as a method for targeting mutant 
KRAS without disrupting the expression of non-mutant KRAS and some have been 
successful in pre-clinical testing (374, 375). The high prevalence of patients with this 
inherent EGFRI resistance mechanism has made targeting mutant KRAS a priority, but so 
far, significant clinical benefits have not been observed (375). To overcome the limitation 
of our inability to successfully target mutant KRAS directly at this time is to target the 
multiple pathways that KRAS influences downstream (376). 
In early EGFRI research on gefitinib and erlotinib, several groups found that many 
patients who were initially sensitive to first-generation EGFRI became resistant because 
tumor cells emerge after therapy with secondary mutations in the EGFR gene (e.g., 
T790M) and mutations in other molecules (e.g., MET) from compensating signaling 
cascades (377). Regardless, inherent and acquired resistance leaves many patients 
without treatment options (23). Second- and third-generation EGFRI have been developed 
to subvert some resistance mechanisms that can provide new therapeutic options for 
some patients, but next generation inhibitors have already been met with new resistance 
mechanisms (147). We believe that bioinformatics interrogation of existing gene 
expression data may reveal alternative therapeutic strategies to overcome both inherent 
(e.g., KRAS) and acquired EGFRI resistance (e.g., EGFR T790M) (378). 
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This laboratory previously developed two gene expression signatures of response 
to the EGFRI, erlotinib, with the hypothesis that patients without EGFR activating 
mutations may also respond to EGFRI, and those patients might be identified by particular 
gene expression phenotypes (327). Genes from the second EGFRI response signature, 
comprised of miRNA genes, not only predicted response to erlotinib but also intersected 
the TGFβ signaling cascade (327). These data suggested that response to EGFRI may 
be influenced by activation of TGFβ receptors, and inhibition of this signaling pathway 
could sensitize EGFRI-resistant tumor cells to erlotinib (327). However, other groups have 
tested this hypothesis in clinical practice and have been largely unsuccessful in targeting 
TGFβ, likely due to the competing pro- and anti- tumorigenic activities of the TGFβ axis 
(179, 219). Despite these shortcomings, efforts to target aberrant TGFβ signaling are 
ongoing (379).  
 
Further inspection of the interactions between the mRNA and miRNA signatures 
of erlotinib response revealed enzymatic activities that integrated both the EGFR and 
TGFβ signaling cascades. Casein kinase 2 (CK2) emerged as a potential target. CK2 is a 
multi-subunit kinase that can contribute to tumorigenesis when subunit expression is 
altered. CK2 exists mainly as a tetrameric holoenzyme consisting of any combination of 
two α or α’ subunits and two β subunits, but it has been suggested that the α and α’ 
subunits have monomeric kinase activity as well (243, 244). Interestingly, no oncogenic 
mutations have been found in CK2 kinase subunits, but deregulation of subunit expression 
levels might contribute to the oncogenic process (252). Moreover, it has been shown to 
be an upstream regulator of AKT/PI3K/mTOR, NFκβ, and JAK/STAT signaling cascades 
irrespective of the receptor tyrosine kinases shown to activate them (380). As stated 
earlier, EGFRI resistance is known to be caused by alterations in parallel signaling 
pathways, including the PI3K/AKT/mTOR and JAK/STAT (145). Therefore, we postulated 
that inhibition of CK2 might represent an alternative target for the treatment of NSCLC that 
are resistant to EGFRI. This strategy may provide some NSCLC patients an additional 
opportunity for therapeutic intervention. 
 
 
B. METHODS 
 
Cell Culture and Western Blotting 
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A549, H460, and H1650 (NSCLC) cell lines were purchased from ATCC. PC9 cells 
were a gift from the Haura lab (Moffitt Cancer Center, FL) Cells were cultured in RPMI 
1640 (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (USA 
Scientific), HEPES, glucose and pyruvate and maintained in a humidified incubator at 
37°C at 5% CO2 unless otherwise specified. For western experiments, 1 x 104 cells were 
plated into a 12-well dish and allowed to adhere in RPMI 1640 containing 10% FBS for 48 
hours. Following the adherence period, cells were treated with the drug concentrations of 
CX-4945 (Cayman Chem) or AZD6244 (Astra Zeneca) in RPMI 1640 containing 1% FBS 
for the treatment durations indicated. Both adherent and non-adherent cells from each 
sample were harvested for total protein. Equal volumes of cell total cell extracts were 
loaded. Cleaved PARP and α-tubulin antibodies were purchased from Cell Signaling 
Technologies. 
 
Generation of miRNA and mRNA Expression Datasets  
 
mRNA and miRNA expression levels were measured in growing non-small cell 
lung cancer (NSCLC) cell lines using Affymetrix U133 2.0 microarrays (GSE31625) and 
Taqman cards from Applied Biosystems (ABI) (previously published data) (327, 328). We 
evaluated interactions among the 1495 mRNA genes and 23 miRNA that are significantly 
deregulated in erlotinib-sensitive compared with erlotinib-resistant NSCLC cells (327, 
328). 
 
Feasible Solutions (FS) Statistical Methodology with Work Flow and Protein-Protein 
Interaction Network Analysis 
 
The following analysis was performed by Dr. Arnold Stromberg and Josh Lambert 
(Department of Statistics, University of Kentucky): 
 
 Feasible Solutions (FS) was used to identify mathematical interactions in the 
expression data. We included mRNA that demonstrated higher expression (~800 
probeIDs) in the erlotinib-resistant cell lines, and we enumerated the possible solutions, 
or interacting miRNA, that resulted, regardless of direction of expression relative to the 
mRNA. The algorithm works as follows: 
CHAPTER 4 
 
112 
 
 
Consider fixing p+ explanatory variables in a preliminary model. Denote these 
variables Xp+. Let m(Y;Xp+) be an objective function that can be a measure of model 
quality i.e., R2; AIC; BIC; etc. We wish to find the k additional variables denoted Xk to add 
to the model that optimizes the objective function m(Y;Xp+;Xk). The FS algorithm attempts 
to solve this problem in the following way: 
 
1. Choose Xk randomly and compute the objective function m. 
2. Consider exchanging one of the k selected variables from the current model. 
3. Make the exchange that improves the objective function m the most. 
4. Keep making exchanges until the objective function does not improve. These 
variables Xp+;Xk are called a feasible solution. 
5. Return to (1) to find another feasible solution.  
 
We chose the 100 probeIDs with the lowest Prob>F (Supplementary Table II-1, 
Appendix II) for further biological evaluation by STRING analysis that was performed by 
Dr. Robert Flight (Markey Cancer Center, University of Kentucky). 
 
Using the miRNA:mRNA interactions described by FS modeling, the Affymetrix 
probesets were converted to Ensembl IDs.  STRING database v 10.0 (FS) (381) files 
specific for human proteins were downloaded for further processing. The Bioconductor 
v3.0 package (382) for Affymetrix(R) HGU133-plus2 chips (hgu133plus2.db v3.0.0) was 
used to translate Affymetrix (R) probeset identifiers to gene identifiers (symbols, gene 
names, Entrez IDs and ENSEMBL Proteins) in R  v3.3.2 (2016). From ENSEMBL protein 
IDs, the species ID 9606 was added to provide STRING protein IDs. The full set of 
STRING protein-protein interactions (PPI) were filtered to those with a combined score 
greater than 400, as well as individual scores greater than 400 in any one of the 
"experimental", "database", and "co-expression" evidences. From this subset of PPIs, the 
interactions with the original set of genes and their interactors (those genes within one 
edge or interaction) were extracted from the PPI database (Full list of initial genes 
extracted in Supplementary Table II-2, Appendix II). We were interested in interactions 
G1-X-G2, where G1 and G2 are from our list of proteins, X can be any protein that 
connects G1 to G2 (Full list of genes comprising the expanded network in Supplementary 
Table II-3, Appendix II). For each PPI, only a record that there was an interaction between 
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the two proteins was kept with no information on the number of evidences or the score of 
the interaction. STRING protein IDs were translated to gene IDs using the human 
database (org.Hs.eg.db v3.0.0) with Ensembl Protein (ENSEMBLPROT) as the query key 
(STRING protein identifiers are a combination of species ID and Ensembl protein ID). 
Cytoscape (383) and BioFabric (384) networks were constructed from these data. 
 
Within the induced network, communities of genes with shared and related 
functions (Supplementary Table II-7, Appendix II) were identified using the 
cluster_walktrap function in igraph 1.0.1 (385, 386). 
 
Cell Viability Assay 
 
Cells were plated at 3x103 cells/well in a 96-well plate in fresh treatments and 
allowed to adhere in RPMI 1640 containing 10% FBS for 36 hours. After 36 hours, CX-
4945 (Apex Bio) and AZD6244 (Astra Zeneca) was added in the final concentrations 
indicated in RPMI 1640 containing 1% FBS. Drug treatment persisted for 72 hours. After 
72 hours, resazurin was added (100 µM final concentration) to each well, the plates were 
gently rocked for 1 minute and then incubated for 3 hours prior to reading. Each plate was 
read for fluorescence at excitation, 560 nm, and emission, 590 nm, wavelengths using a 
Spectramax M5 and corresponding Spectramax X5 software (Spectramax). Response to 
each treatment is normalized to untreated cells from each corresponding treatment and 
normalized to empty wells on each plate containing only media and resazurin. Three 
biological replicates were performed and were assessed for outliers using a Dixon’s Q-
test. Data were analyzed using Prism Version 7.00 (GraphPad).  
 
Availability of Data 
 
All code for network generation and enrichment analysis and Supplemental files are 
available for download from figshare at: https://figshare.com/s/7e50e9ab2a66b5041451.  
 
 
C. RESULTS 
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CK2 Connects the miRNA and mRNA Signatures of EGFRI Sensitivity  
 
We hypothesized that mRNA and microRNA gene expression data from NSCLC 
cell lines could be used to identify novel targets for therapy in lung cancer patients resistant 
to EGFRI. The Black laboratory previously identified two independent gene expression 
signatures of response to EGFRI using a panel of NSCLC cell lines demonstrating 
differential response to EGFR inhibition as measured by a cell death assay (327). The 
signatures were culled from a larger set of differentially-expressed mRNA and miRNA. 
Using the larger lists of genes (1495 mRNA and 23 miRNA), we sought to identify new 
protein targets for therapy using statistically significant interacting pairs of mRNA and 
miRNA discovered by the feasible solutions algorithm (FS) (Supplementary Table II-1, 
Appendix II). FS modeling first evaluates expression levels of a random combination of 
mRNA and miRNA pairs then considers swap-pairings of other miRNA to improve model 
fit and arrive at significant pairings. Each pairing then becomes a feasible solution. In this 
case, the model sought mRNA-miRNA pairs that have the property of high mRNA 
expression in the erlotinib-resistant cell lines (~800 probe IDs) in order to find targets that 
may have therapeutic value in erlotinib-resistant tumors. Given this outcome, we 
hypothesized that identifying new druggable targets for erlotinib-resistant NSCLC may 
depend on interactions with the EGFR signaling network. To investigate this hypothesis, 
we chose to use our FS gene list to find other proteins that physically interact with the 
candidate(s) and EGFR.  
 
 The 100 probes with the lowest probability (low Prob>F, Supplementary Table II-
1, Appendix II) were identified by FS. These 100 probes translated into 85 Ensembl IDs 
that had matches in the STRING v10 network (387). We also included EGFR as a node 
to triangulate the network specifically around EGFRI resistance. We carried out the 
network expansion analysis considering the scenario G1-X-G2 wherein G1 and G2 were 
proteins from the original list of 85 Ensembl IDs while X could be anything. Only 81 of the 
85 proteins remained in this “induced network” (Supplementary Table II-3, Appendix II). 
However, another 304 nodes were found (for a total of 385 proteins in the network) that fit 
in the G1-X-G2 network (Supplementary Table II-3, Appendix II).  
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From these induced nodes, CK2 was chosen for further study for three reasons: 
1) It has been shown to regulate many of the signaling pathways represented in the 
network, 2) it has been shown to be within 2 edges of 366 out of 385 of the identified nodes 
in the network (Supplementary Table II-5, Appendix II), and 3) it has enzymatic activity 
with an available pharmacological inhibitor (Table 4.1). The aim of this study was to 
understand whether CK2 inhibition reduced cell viability in EGFRI resistant NSCLC cells. 
We chose to examine the impact of CK2 inhibition on EGFRI resistant NSCLC cells with 
a variety of driver mutations (Figure 4.2B). 
 
 
CK2 Inhibition Induces Greatest Cell Death in KRAS Active NSCLC  
 
To determine if CK2 activity is a novel target in EGFRI-resistant NSCLC with 
KRAS-activation mutations, we performed a viability assay to determine whether 
treatment with the CK2 small molecule inhibitor, CX-4945, decreased viability of KRAS-
active NSCLC cells. In A549 and H460 cells, we observed a ~50% decrease in cell viability 
in CX-4945 treated cells compared to untreated cells (Figure 4.2). Considering CK2 
inhibition alone was not sufficient to decrease cell viability completely, we next aimed to 
identify and test a secondary target within or related to the expanded network.   
 
 
CK2 and the Members of the EGFR-MAPK-ERK Signaling Cascade Appear to 
Function Exclusively of one Another 
 
 Of the 366 members of the induced network shown to be within two edges of CK2α 
and CK2α‘ (CSNK2A1/CSNK2A2), we isolated the network members that are within one 
edge of CK2α/CK2α’ (Supplementary Table II-4, Appendix II). Unexpectedly, 
Supplementary Table II-4 (Appendix II) specifically demonstrates that CK2α and CK2α’ do 
not directly interact with any of the members of the EGFR-RAS-RAF-MEK-ERK signaling 
cascade. All of the members of that signaling cascade identified by FS (HRAS, KRAS, 
NRAS, MAPK1, RAF1) were found to be at least two edges away from CK2α/CK2α’ 
(Supplementary Table II-5, Appendix II). Because CK2 inhibition alone did not reduce cell 
viability completely in any cell line, we next explored whether downstream members of the 
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MAPK-ERK pathway could be logically co-targeted with CK2 in EGFRI resistant NSCLC 
cells. 
 
 
Combinatorial Targeting of CK2 and MEK Induces Apoptosis in KRAS Active 
NSCLC Cells  
 
We focused our selection of a secondary target on the goal of inhibiting the EGFR-
MAPK-ERK pathway without targeting the EGFR receptor. CX-4945 resistance has been 
demonstrated in head and neck cancers and was shown to be overcome by MEK inhibition 
(388). Importantly, MEK was not a member of the induced network and none of the other 
EGFR-MAPK-ERK pathway members identified exist within one edge of CK2α/CK2α’ 
(Supplementary Tables II-3 and II-4, Appendix II). Moreover, CK2α/CK2α’ were 
determined to be members of community #19 whereas EGFR was identified in community 
#4 and other ERBB receptor family members and KRAS were identified in community #2 
(Supplementary Table II-7, Appendix II). This suggests that while connected in the overall 
network, the MAPK-ERK cascade and CK2 likely function independently of one another.  
 
 To examine the impact of CK2 inhibition (CX-4945) in combination with MEK 
inhibition (AZD6244), we observed the induction of apoptosis in NSCLC cells by western 
blot (Figure 4.3). Both of the KRAS active cell lines examined demonstrated elevated 
levels of cleaved PARP at the higher concentrations of CX-4945. Levels of cleaved PARP 
also appear to increase between the 24- and 48-hour time points in both cell lines. 
 
 We screened A549 and H460 cells to determine if the responses to the 
combination of CX-4945 and AZD6244 represented a synergistic, additive, or antagonistic 
using a resazurin-based viability assay as was used for the single agent CX-4945 viability 
assays (Figure 4.4). The strongest synergism between the CX-4945 inhibitor and the 
AZD6244 inhibitor occurred when AZD6244 was present at 10μM and 3μM and 
concentrations of CX-4945 were between 0.1-30μM in both KRAS active cell lines (Figure 
4.4).     
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D. DISCUSSION 
 
There is an urgent need to develop strategies for treating lung tumors harboring 
KRAS activation or other EGFRI-resistance mutations. Not only are inherent EGFRI-
resistance mutations common, but secondary mutations that cause EGFRI-resistance to 
develop are also prevalent and novel drug targets and treatment strategies are paramount 
for all lung cancer patients. Our goal was to use a combination of statistical and 
computational methods that integrated existing gene expression signatures linked by 
disease and drug response phenotypes. From this, we aimed to use interacting pairs of 
mRNA:miRNA to identify a network of relevant protein-protein interactions (389). In 
collaboration with Dr. Flight and the Stromberg group, we used the FS algorithm to identify 
interacting pairs of mRNA and miRNA because of prior work that indicated that pairing 
these RNA species may lead to an improved understanding of the disease (390). To return 
pharmacologically actionable targets, we focused on evaluating the protein-coding genes 
as drug targets, rather than the microRNA partner of the pair. The FS data was empirically 
reduced to the top 100 statistically-significant pairs of which the mRNA partner had highest 
expression in erlotinib-resistant cell lines (Supplementary Table II-1, Appendix II). Using 
KEGG GENES and Gene Ontology databases, each mRNA gene was paired with a 
molecular function, and STRING was utilized to determine protein-protein interactions 
(PPI). Each of these filters was intended to be an in silico screen to identify candidate 
protein-coding genes that are involved in or linked to EGFR signaling in EGFRI-resistant 
NSCLC. Because of our efforts to focus the network identification around EGFR and 
EGFRI resistance, the nodes identified thereby represent putative drug targets for the 
treatment of EGFRI-resistant NSCLC. 
 
The limitation of our initial method of identifying alternative drug targets is that not 
all pharmacologically actionable proteins influencing EGFRI resistance are captured when 
considering only those deregulated genes directly connected to EGFR. For this reason, 
we chose to expand the network of deregulation in search of plausible nodes controlling 
EGFRI resistance. We specifically chose to look for a node linking at least two oncogenic 
signaling pathways (391).  
 
To identify actionable nodes linking the members of our list of significantly 
deregulated proteins, we chose to expand our network by only identifying and adding 
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proteins known to link two members of the original list. We did this by identifying proteins 
that met the criteria: G1-X-G2, where G1 and G2 are members of the original list of 
deregulated genes including EGFR while X is any protein linking the two. What we 
determined is that by adding this additional level of selection, we identified nearly every 
EGFRI resistance mechanism described in NSCLC thus far (Communities #2 and #4, 
Supplementary Table II-7, Appendix II) among a number of novel putative targets 
(Supplementary Table II-7, Appendix II). Of the expanded network, we selected CSNK2A1 
and CSNK2A2, which encode the kinase subunits of CK2. We determined that they are 
within two edges of 366 out of 385 members of the expanded network indicating their 
value as a well-connected target (Supplementary Table II-3, Appendix II). Not only was 
CK2 predicted by our in silico model to interact with many sources of EGFRI resistance, 
but it has been also described as influencing many other members of the network of 
deregulated genes between EGFRI resistant and sensitive NSCLC, notably including NFκ-
β and PI3K/AKT (392). The network specifically includes nearly every source of inherent 
or acquired EGFRI resistance described to date (19, 145) and they were largely contained 
to two communities of common action, neither of which included CK2 (Supplementary 
Table II-7). Considering the global potential influence of CK2 in the network of 
dysregulation of EGFRI resistance, and that a kinase inhibitor of CK2 has been tested in 
Phase II trials (323), we next aimed to determine if CK2 inhibition was impactful against 
NSCLC cells that are resistant to EGFRI. 
 
EGFRI-resistant, KRAS active NSCLC cells were found to be sensitive to CK2 
inhibition, but the maximal response observed was only around 50% cell viability 
compared to untreated cells (Figure 4.2A). We compared the effect of CX-4945 in KRAS 
active NSCLC to other cell lines harboring EGFR mutations. We found that PC9 cells, that 
harbor only an EGFR exon 19 deletion mutation, were resistant to CX-4945. However, 
H1650 cells that harbor both an exon 19 deletion as well as a PTEN null mutation 
demonstrated a response curve similar to KRAS active A549 and H460 (Figure 4.2A). 
Specifically, H1650 cells only have intermediate sensitivity to EGFRI despite the EGFR 
activation mutation because loss of the PTEN tumor suppressor allowing these cells to 
compensate for EGFRI action through deregulated PI3K/AKT signaling. Importantly, CK2 
was identified as a possible target for overcoming PTEN null mutations via a 
chemogenomic study in 2015 (393). It is also interesting to note that both PC9 and H1650 
harbor a p53 mutation, and from these data, it would appear that mutant p53 likely does 
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not influence CX-4945 efficacy. Interestingly, H460 cells have a PIK3CA E545K mutation 
resulting in less efficient activation of the p110α isoform of the PI3K catalytic domain but 
were still sensitive to upstream CK2 inhibition. We have previously demonstrated that 
PI3K p110 isoforms are capable of compensation. H460 express high levels of the p110β 
isoform as well as high levels of PTEN protein expression suggesting that the regulation 
of this pathway by CK2 is still possible despite the PIK3CA mutation (331). To examine 
whether these observations were related to expression of CK2 subunits, we profiled each 
of the NSCLC cell lines tested above for CSNK2A1, CSNK2A2 and CSNK2B mRNA 
expression (Supplementary Figure II-1, Appendix II). Of the NSCLC cell lines we profiled, 
KRAS active cells demonstrated the lowest expression of CSNK2B compared to normal 
cells. This suggests that constitutively active KRAS signaling may play a role in repressing 
CK2β expression.  
 
We next aimed to identify a second expanded network member or member of a 
network pathway as a plausible secondary target to be paired with CK2 inhibition because 
none of the cell lines tested were exquisitely sensitive to CK2 inhibition. Importantly, the 
KRAS active NSCLC tested were the most sensitive to CK2 inhibition. The KRAS 
activation mutation drives MAPK-ERK signaling regardless of EGFR activation or 
inhibition, and we observed in the expanded network that not all of the MAPK-ERK 
signaling cascade were represented and none were directly connected to CK2. For this 
reason, we hypothesized that CK2 and MEK inhibition would be sufficient to overcome 
compensatory signaling by the induced network identified in KRAS active NSCLC. This 
hypothesis was also founded with the knowledge that MEK inhibition has been used to 
overcome CX-4945 resistance in head and neck cancers (388). Our lab and others have 
similarly demonstrated that inhibition of MEK concurrently with EGFRI sensitizes NSCLC 
with EGFR T790M mutations to treatment (329, 394). Initial exploration of AZD6244 and 
CX-4945 co-treatment on NSCLC cells revealed that the apoptotic marker, cleaved PARP, 
was expressed in KRAS active NSCLC cells. Moreover, increased cleaved PARP relative 
to α-tubulin were observed at 48 hours when compared with 24 hours. We screened KRAS 
active A549 and H460 for synergistic drug interactions between CX-4945 and AZD6244 
and found that the strongest synergism between the two drugs occurred when AZD6244 
was present at 10μM and 3μM and concentrations of CX-4945 were between 0.1-30μM in 
both KRAS active cell lines (Figure 4.4). These data demonstrate that this combination of 
CK2 and MEK inhibition may represent a novel approach for the treatment of EGFRI-
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resistant, KRAS-active NSCLC. We plan to expand on this observation by performing a 
battery of viability assays against a range of NSCLC cells to determine if these 
observations reign true for other cell lines with varying responses to EGFRI therapies.  
 
A combination of MEK and CK2 inhibition encompasses many of the signaling 
pathways by which non-EGFR-receptor EGFRI resistance develops and should continue 
to be explored as an avenue for the treatment of inherently resistant NSCLC (e.g., KRAS). 
It should also be explored as an avenue for overcoming acquired EGFRI-resistance (e.g., 
EGFR T790M) as well. This strategy of bypassing EGFR and KRAS as therapeutic targets 
may represent a novel therapeutic approach for treating a variety of NSCLC tumors. 
 
 
E. CONCLUSIONS 
 
Many cancers are quickly becoming chronic diseases and will require new therapies 
for patient care and management of emerging resistant diseases. We have demonstrated 
that gene expression signatures descriptive of a specific tumor phenotype can be used to 
identify potential targets for new therapeutics or co-therapeutic methodologies. Using the 
FS algorithm and STRING, we unveiled a network of proteins found to be deregulated 
between EGFRI resistant and sensitive NSCLC. From this network, we identified and 
tested CK2α/CK2α’ as a therapeutic target for the treatment of EGFRI resistant NSCLC, 
but CK2 inhibition alone did not substantially decrease cell viability. The expanded network 
suggests that EGFR-MAPK-ERK signaling and CK2 activity exist somewhat exclusively 
which prompted us to examine the impact of combinatorial CK2 and MEK inhibition. Initial 
CK2+MEK inhibition experiments revealed that the combination of the two drugs is lethal 
in KRAS active NSCLC cells and was synergistic when AZD6244 was present at 10μM 
and 3μM with all concentrations of CX-4945 in both KRAS active cell lines. We believe 
that the combination of MEK and CK2 inhibition has important implications for the 
treatment of KRAS active NSCLC and has potential as an alternative to those who acquire 
EGFRI-resistance during treatment. We also seek to improve this novel pipeline for drug 
discovery by automating a process that utilizes gene expression signature as inputs and 
objectively leverages bioinformatics filtering of prospective targets to minimize wet lab 
validation. We must also consider multiple computational and statistical methods to 
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identify gene-gene interactions and associated validation schemes that appropriately 
manage high-density data from comparatively few biological observations. 
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Figure 4.1: The G1-X-G2 expanded network links nearly every EGFRI resistance 
described to date. The network of protein protein interactions was simplified to a 
collection of “communities” with collective activities using the cluster_walktrap function in 
igraph. Putative community activities were determined by manual data mining and 
literature search. (A) Complete network of communities. (B) Magnification of central 
communities with putative actions and known EGFRI resistance mechanisms highlighted. 
 
A 
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Figure 4.1 (continued): The G1-X-G2 expanded network links nearly every EGFRI 
resistance described to date. The network of protein protein interactions was simplified 
to a collection of “communities” with collective activities using the cluster_walktrap function 
in igraph. Putative community activities were determined by manual data mining and 
literature search. (A) Complete network of communities. (B) Magnification of central 
communities with putative actions and known EGFRI resistance mechanisms highlighted. 
 
B 
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Table 4.1: G1-X-G2 Analysis-Induced EGFRI Resistance Network Members that 
interact with CK2α or CK2α’ within one edge and are pharmacologically actionable. 
Table members are from the complete network of 385 proteins that interact with CK2α or 
CK2α’ within one edge (Supplementary Table II-4, Appendix II). Abridged table members 
below represent those for which both pharmacological inhibitors exist and have at least 
entered Phase I clinical trials. 
 
SYMBOL GENE NAME TYPE 
AKT1 v-akt murine thymoma viral oncogene homolog 1 Induced 
CDK1 cyclin-dependent kinase 1 Induced 
CSNK2A1 casein kinase 2, alpha 1 polypeptide Induced 
CSNK2A2 casein kinase 2, alpha prime polypeptide Induced 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa Induced 
HDAC1 histone deacetylase 1 Induced 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 Induced 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B member 1 Induced 
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 Induced 
PSMA3 proteasome subunit alpha 3 Induced 
PSMA4 proteasome subunit alpha 4 Induced 
PTEN phosphatase and tensin homolog Input 
SIRT1 sirtuin 1 Induced 
SRC SRC proto-oncogene, non-receptor tyrosine kinase Induced 
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Figure 4.2: NSCLC cells resistant to EGFRI are most sensitive to CK2 inhibition. (A) 
Viability assays were performed on KRAS active, EGFRI resistant NSCLC (A549 and 
H460 cells) treated with CX-4945. Shown in comparison with intermediate-EGFRI 
sensitivity, H1650 cells (EGFR exon 19 deletion and PTEN null), and EGFRI-sensitive, 
PC9 cells (EGFR exon 19 deletion). Values are log-transformed. (n=3) (B) A table 
demonstrating the EGFRI resistance, mutational statuses, and response to 10μM CX-
4945 for each of the NSCLC analyzed.  
 
 
A 
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Figure 4.2 (continued): NSCLC cells resistant to EGFRI are most sensitive to CK2 
inhibition. (A) Viability assays were performed on KRAS active, EGFRI resistant NSCLC 
(A549 and H460 cells) treated with CX-4945. Shown in comparison with intermediate-
EGFRI sensitivity, H1650 cells (EGFR exon 19 deletion and PTEN null), and EGFRI-
sensitive, PC9 cells (EGFR exon 19 deletion). Values are log-transformed. (n=3) (B) A 
table demonstrating the EGFRI resistance, mutational statuses, and response to 10μM 
CX-4945 for each of the NSCLC analyzed. 
 
 
B 
 
 
CELL 
LINE 
EGFRI 
Resistance 
Status 
EGFR 
Mutation 
Status 
KRAS 
Mutation 
Status 
PI3K/AKT 
Mutations 
Status 
Percent 
Viability at 
10μM CX-
4945 
A549 Resistant WT 
G12S 
(Active) 
WT 53.2405 
H460 Resistant WT 
Q61H 
(Active) 
PIK3CA 
E545K (Null) 
57.2708 
H1650 Intermediate 
Exon 19 
Deletion 
(Activating) 
WT 
PTEN Null 
(Activating) 
53.4981 
PC9 Sensitive 
Exon 19 
Deletion 
(Activating) 
WT WT 74.7392 
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Figure 4.3: Co-treatment with CX-4945 and MEK inhibitor, AZD6244, induces cell 
death in KRAS active NSCLC. Cells handled and treated as described in the methods. 
Both adherent and non-adherent components of each well were harvested for total protein. 
Each well represents 1/3 of the total volume of protein harvested from each sample 
assessed for cleaved PARP and α-tubulin. Response to drug combinations were observed 
by western blot using the apoptotic marker, cleaved PARP at 24 and 48 hours. (A) A549 
cells (B) H460 cells. 
 
 
A 
 
 
 
 
 
B 
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Figure 4.4: Screening for synergistic interactions between the CK2 inhibitor, CX-
4945, and the MEK inhibitor, AZD6244. Cells were assessed by resazurin viability assay 
to identify possible synergistic, additive or antagonistic responses of CX-4945 in 
combination with AZD6244 using combination index (CI) values. CI values were then used 
to generate the heat map for each cell line. (A) A549 cells (B) H460 cells. 
 
CI Values 
≤0.5  Synergism 
0.51-0.99  Slight Synergism 
1-1.49  Additive 
1.5-1.99  Slight Antagonism 
≥2.0  Antagonism 
 
A 
 
 
AZD6244 (μM) 
30 10 3 1 0.3 0.1 
C
X
-4
9
4
5
 (
μ
M
) 
30 1.02049 0.71992 0.59235 0.55049 0.61981 0.73616 
10 0.95206 0.55608 0.5078 0.98279 0.98735 0.73973 
3 0.79595 0.42711 0.72412 1.63317 6.43996 3.39567 
1 1.14371 0.67159 0.89036 2.10645 15.3454 1.78956 
0.3 1.258 0.71075 0.65023 1.00434 12.1634 0.36242 
0.1 1.51505 0.85743 0.72815 0.59457 115.893 0.29457 
 
B 
 AZD6244 (μM) 
30 10 3 1 0.3 0.1 
C
X
-4
9
4
5
 (
μ
M
) 30 0.23853 0.15484 0.24985 0.35815 0.1522 0.23068 
10 0.6804 0.78631 0.59991 2.73233 0.7952 0.74581 
3 1.79495 0.59703 0.41602 1.09675 4.1732 0.44567 
1 5.32872 0.68241 0.52064 1.04351 0.78227 0.97133 
0.3 10.7842 0.57414 0.45335 10.8271 7.33228 0.40307 
0.1 0.67055 0.56424 0.26205 25.8473 37.7681 0.13553 
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CHAPTER 5 
 
A. OVERVIEW 
 
EGFR is not the only driver mutations found in NSCLC which is why not all tumors 
are responsive to EGFRI treatments (19).  Moreover, many patients that receive EGFRI 
therapies eventually develop resistance which underscores the need for alternative 
therapeutic options to overcome these limitations of EGFRI. Our 13-gene miRNA 
signature of EGFRI response initially indicated that the TGFβ signaling cascade may be 
a putative secondary target for the treatment of drug-resistant NSCLC (327). In Chapter 
3, we demonstrated that TGFβ inhibitors had value in impeding cell mobility as well as 
increased erlotinib resistance in A549 cells. However, we also determined that the 
inhibition of TGFβ induced a significant increase in erlotinib resistance in PC9 cells that 
are otherwise exquisitely sensitive to erlotinib treatment. Our work examining the value of 
TGFβ as a target confirmed observations that targeting TGFβ may be detrimental in 
unselected tumor populations (Chapter 3) (179, 213). 
 
Further analysis of our gene expression data using Feasible Solutions 
mathematical model to find putative mRNA-miRNA gene interactions (Chapter 4) identified 
CK2 as an alternative target for the treatment of EGFRI-resistant NSCLC. Initial 
examination of CK2 as a therapeutic target demonstrated that it may have value as a 
treatment option for NSCLC harboring KRAS activation mutations or PTEN null mutations 
(Chapter 4). Maximal cell viability decreases  were only observed at approximately 50% 
cell viability suggesting that CK2 inhibition would likely be most successful as part of a 
combination therapy. Interestingly, the inhibition of CK2 has been shown to impede the 
induction of EMT by TGFβ (239). CK2 inhibition showed promise in treating A549 cells, 
but had no effect in PC9 cells (Chapter 4). Given these results combined with the observed 
relationship between the induction of EMT by TGFβ and CK2, we hypothesize that 
inhibition of CK2 can block TGFβ-induction of EMT and reduce erlotinib resistance in A549 
cells. In this context, CK2 inhibition could augment EGFRI by blocking the induction of 
EMT and EGFRI-resistance thereby eliminating the need for TGFβ inhibition all together. 
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B. METHODS 
 
Cell Culture 
 
The NSCLC cell lines used were A549, purchased from ATCC, and PC9, gifted 
from the Haura lab (Moffitt Cancer Center, FL). All cells were cultured in RPMI 1640 (Life 
Technologies) supplemented with 10% FBS (USA Scientific), HEPES, glucose and 
pyruvate and maintained in a humidified incubator at 37 °C at 5% CO2 unless otherwise 
specified. Cells were seeded in 6-well plates and were allowed to grow under RPMI 1640 
containing 10% serum media conditions for 48 hours prior to treatments. Cells were plated 
at 1 x 104 cells and were treated with SB-431542 (3 µM) (Selleck Chem), LY-2109761 (3 
µM) (Cayman Chem), CX-4945 (1 µM) (Apex Bio) and/or TGFβ (5 ng/ml) (Cell Signalling) 
under minimal serum (1%) conditions for time frames specified. Treatment media was 
replenished at the 72-hour time point in 168-hour culture experiments.  
 
Cell Viability Assay 
 
Cells underwent pretreatment in 1% serum-containing RPMI 1640 with drug and/or 
cytokine for 7 days following the plating and treatment conditions described above. After 
treatment, cells were trypsinized, counted, and plated at 3x103 cells/well in a 96-well plate 
in fresh treatments matching those from the 7-day period. After 36 hours adherence time, 
erlotinib was added in indicated concentrations. Drug treatment persisted for 72 hours. 
After 72 hours, resazurin was added (100 µM final concentration) to each well, the plates 
were gently rocked for 1 minute and then incubated for 3 hours prior to reading. The plate 
was read for fluorescence at excitation, 560 nm, and emission, 590 nm, wavelengths using 
a Spectramax M5 and corresponding Spectramax X5 software (Spectramax).  
Data Processing and Statistics 
 
Values measured between biological replicates from all viability assays and wound 
healing assays were subjected to a Dixon’s Q test to eliminate outlier values. For viability 
assays, response to each treatment is normalized to cells from each corresponding 
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treatment that were not subjected to erlotinib. Readings were also normalized to empty 
wells on each plate containing only media and resazurin. Individual experiments were 
done in triplicate and were assessed for outliers using a Dixon’s Q-test (n=4). All graphical 
representations of data were made and analyzed using Prism Version 7.00 (GraphPad). 
Significance points in viability assay data compare the points specified in each figure 
legend and in the results section. Significance was determined using unpaired t-tests.  
 
 
 
C. RESULTS 
 
CX-4945 increases erlotinib-sensitivity in PC9 but not in A549 cells  
 
In Chapter 3, we demonstrated that while TGFβ ligand treatment increases 
erlotinib sensitivity in PC9 cells, it significantly decreased A549 erlotinib-sensitivity in a 
dose-dependent manner (Figure 3.3). Also, TGFβ receptor inhibition (with SB-431542 or 
LY-2109761) reversed the erlotinib phenotype in TGFβ ligand-treated A549 cells, and the 
presence of either TGFβ receptor inhibitor significantly decreased erlotinib sensitivity in 
PC9 cells (Figure 3.3). For this reason, we endeavored to determine whether co-inhibition 
of another linked target, CK2, could sensitize erlotinib-resistant A549 cells to treatment. 
CK2 and TGFβ activate common growth, proliferation and survival pathways. For these 
reasons, we sought to elucidate whether CK2 inhibition could prevent the changes on 
erlotinib-sensitivity in A549 and PC9 cells induced by TGFβ ligand or TGFβ inhibitors 
respectively.   
 
 Pre-treatment of A549 cells with a combination of CX-4945 and TGFβ ligand 
(Figure 5.1A) prevented the increased erlotinib-resistance phenotype observed in A549 
cells that had been pre-treated with TGFβ ligand  alone (Chapter 3, Figure 3.3A). 
Conversely, SB-431542 pre-treatment in combination with CX-4945 decreased erlotinib-
resistance in A549 cells at lower erlotinib concentrations (0.1-3 µM) compared with cells 
pre-treated with CX-4945 alone (Figure 5.1A).  
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 In PC9 cells, pre-treatment with CX-4945 alone and in combination with TGFβ 
ligand increased erlotinib sensitivity when compared to the matched CX-4945 naïve cells 
in Chapter 3, Figure 3.3B (Figure 5.1B). Importantly, this experiment showed that the pre-
treatment of PC9 cells with CX-4945 did not eliminate the decrease in erlotinib-sensitivity 
resulting from exposure to either of the TGFβ inhibitors (SB-431542 or LY-2109761) with 
or without TGFβ ligand (Figure 5.1B). 
 
 
D. DISCUSSION 
 
In Chapter 3, we showed that TGFβ ligand can contribute to erlotinib resistance in 
A549 cells because TGFβ inhibitors reversed this phenotype. Conversely, TGFβ-inhibition 
significantly reduced erlotinib sensitivity in PC9 cells, whereas TGFβ ligand induced more 
cell death in conjunction with erlotinib than erlotinib did alone (Figure 3.3B, Chapter 3). 
Identifying which arm of the TGFβ paradox signaling is active remains elusive, but CK2 
inhibition has been shown to reverse TGFβ-driven EMT offering a possible alternative 
(239). For this reason, we endeavored to determine if CK2 inhibition using CX-4945 
(Silmitasertib) could similarly prevent the increase in erlotinib resistance.  
 
We found that CX-4945 impedes the increase in erlotinib resistance induced by 
TGFβ ligand in A549 cells (Figure 3.3A), but it does not sensitize A549 cells to erlotinib. 
This suggests that the combination of EGFRI and CK2 inhibition is not a sufficient 
treatment option for KRAS active NSCLC like A549. Importantly, the significant decrease 
in erlotinib-sensitivity induced by TGFβ-inhibition in PC9 cells was not blocked by co-
inhibition with CX-4945. CX-4945 treatment did increase erlotinib sensitivity significantly 
in PC9 cells both treated and untreated with TGFβ ligand when compared to matched PC9 
(Supplemental Figure III-1, Appendix III).  
 
 
E. CONCLUSIONS 
 
EGFRI and CX-4945 efficacy appear to be linked by a co-dependent relationship 
between PI3K/AKT and MAPK-ERK signaling (238, 395, 396). The decrease in erlotinib 
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sensitivity in PC9 cells induced by TGFβ inhibitors was not prevented by co-incubation 
with the CK2 inhibitor, CX-4945. This reinforces that TGFβ-inhibitors continue to have 
limited to no value in this context since the off-target effects of TGFβ-inhibition are still 
evident in PC9 cells. While the interactions among signaling networks certainly impacts 
the influence of TGFβ on EGFRI resistance, the limitation of targeting TGFβ in unselected 
tumor populations is not mitigated by the inclusion of CK2 inhibitors.  
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Figure 5.1: TGFβ treatment in combination with CX-4945 alters erlotinib response 
in A549 and PC9 cells. (A) A549 and (B) PC9 cells. Cells were treated with TGFβ in 
combination with CX-4945 with or without SB-431542 or LY-2109761 at the same time as 
the samples used in figure 3.3. Values are normalized to corresponding cells untreated by 
erlotinib. * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is ≤ 0.0001. (n 
= 3) 
 
 
 
A 
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Figure 5.1 (Continued): TGFβ treatment in combination with CX-4945 alters erlotinib 
response in A549 and PC9 cells. (A) A549 and (B) PC9 cells. Cells were treated with 
TGFβ in combination with CX-4945 with or without SB-431542 or LY-2109761 at the same 
time as the samples used in figure 3.3. Values are normalized to corresponding cells 
untreated by erlotinib. * indicates p-value is 0.05 ≥ p > 0.0001, ǂ indicates that p-value is 
≤ 0.0001. (n = 3) 
 
 
B 
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CHAPTER 6 
 
A. SUMMARY OF RESULTS 
 
My goal for this body of work was to utilize genomic data to identify and test 
putative targets for the treatment of drug-resistant lung cancers. Using the previous data 
generated by the lab to produce two gene signatures of EGFRI response, I hypothesized 
that: 
 
1) The 13 miRNA genes comprising the second expression signature of response 
to EGFRI are transcriptionally regulated by TGFβ signaling. 
2) TGFβ drives EMT and enforces EGFRI resistance in EGFRI-resistant NSCLC. 
3) The cell line RNA expression data used to generate the miRNA and mRNA 
signatures can be analyzed using novel mathematical and computational 
models to uncover interactions among these RNA. These nodes of cellular 
regulation, captured by utilizing both lists of deregulated genes, may identify 
novel targets to combat EGFRI-resistance in NSCLC.  
 
In Chapter 2, I explored my first hypothesis that the miRNA comprising the 
signature of response were being transcriptionally regulated by canonical TGFβ 
signaling via the Smads. It has been demonstrated that TGFβ has the ability to promote 
or repress the expression of genes in a contextually-specific manner (351, 352). More 
importantly, twelve out of the thirteen miRNA genes contained putative Smad binding 
elements (SBEs) in their promoter regions (Figure 2.7) (347, 348). Considering that 
miRNA frequently act upon the pathways that regulate their expression, I aimed to 
determine if the differences in signature miRNA expression between EGFRI-resistant and 
EGFRI-sensitive NSCLC cells were regulated by TGFβ (327, 397). I demonstrated that 
over a 7-day course of TGFβ treatment, activation of the canonical TGFβ signaling 
pathway via the R-smads, Smad 2, Smad 3 and Smad 4, occurs differently between the 
model EGFRI-resistant and EGFRI-sensitive cell lines. Moreover, extended TGFβ 
treatment induced downregulation of total Smad 2, Smad 3, and Smad 4 by long-term 
TGFβ treatment in the EGFRI-sensitive cell line. TGFβ induced morphological and protein 
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expression changes in the EGFRI-resistance model consistent with EMT, but this effect 
was not observed in the EGFRI-sensitive model. In the EGFRI-sensitivity model, the 
inhibition of TGFβ induced a morphology consistent with an EMT intermediate phenotype 
known as metastable (353). These data confirm that TGFβ possesses differential activity 
that may be responsible for the expression of the miRNA differentiating EGFRI-resistant 
from EGFRI-sensitive cells. Because of this, I next explored the direct contribution of TGFβ 
on the expression of three candidate miRNA from opposing sides of the response 
signature, miR-140, miR-141, and miR-200c. 
 
Using chromatin immunoprecipitation, I determined that Smad 4 bound to the 
shared promoter of miR-141 and miR-200c in EGFRI-sensitive cell lines in response to 
TGFβ stimulation. Because there was no binding to the promoter of miR-140, I suspected 
that differential regulation was occurring in line with the initial hypothesis. Because of this, 
I next aimed to observe if TGFβ induced differential endogenous expression changes of 
the three candidate miRNA. Using a 5-way ANOVA and two models of EGFRI-resistant 
cells and two EGFRI-sensitive cell lines, I aimed to elucidate the source of the endogenous 
expression changes considering five factors: 1) miRNA expression, 2) time of treatment, 
3) TGFβ treatment, 4) SB-431542 treatment, 5) cell line. I considered the additional H460 
and H1650 cell lines as a metric of determining if the changes observed correlated with 
EGFRI-sensitivity status of cells or if miRNA expression changes were a cell line specific 
phenomena. I determined that the most impactful variable governing the expression of the 
signature miRNA levels was the time of treatment. I interpreted this to be a response to 
the loss of cell cycle progression and aimed to elucidate whether the percentage of cells 
in the G0G1 phase of the cell cycle correlated with the changes in miRNA endogenous 
expression levels. I determined that regardless of treatment conditions, all cell lines 
accumulated in the G0G1 phase of the cell cycle as a function of time in culture.  
 
Analysis of the qRT-PCR data and the cell cycle experiment led us to explore 
whether the signature miRNA promoters contained putative cell-cycle responsive 
elements. I determined that twelve of thirteen signature miRNA contained promoter 
elements that may be cell-cycle responsive (Supplementary Figure I-9, Appendix I). I then 
asked whether TGFβ stimulation activated growth and proliferation pathways, MAPK-ERK 
and PI3K/AKT, and correlated with endogenous miRNA expression level changes. I 
determined that TGFβ activation of these pathways was different between the cell models 
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but did not correlate with the endogenous miRNA expression changes observed. I 
concluded that the signature miRNA are likely responsive to elements associated with cell 
cycle progression. I also concluded that while the activity of TGFβ in the EGFRI-resistance 
model is consistent with the ability of TGFβ to drive EMT, an opposing phenotype was 
found in the EGFRI-sensitive cell line.  
 
Future directions of this work will explore the influence of the cell cycle on the 
expression of the signature miRNA. To start, we will use the ChIP method for determining 
transcription factor association with a promoter to determine if ELK1 is bound to the sites 
in each of the promoters. We will triangulate this back to the changes in miRNA expression 
at each time point as well as the percentage of cells exiting the cell cycle at this time point. 
If ELK1 is not found to be bound to the promoters of the signature miRNA, other cell cycle 
responsive transcription factors will also be examined by western blot at each time point 
in order to isolate another cell cycle responsive candidate to interrogate. 
 
In Chapter 3, I tested my second hypothesis that TGFβ signaling enforces 
EGFRI-resistance correlating with its ability to activate EMT. I explored the 
contribution of the differential TGFβ activity observed to cellular migration, wound healing 
and response to a candidate EGFRI, erlotinib. I determined that TGFβ induced migration 
in the EGFRI-resistance model and the phenotype was reversed with the TGFβ inhibitor. 
I also determined by wound healing assay that TGFβ inhibition prevented wound healing 
in both the EGFRI-resistance and EGFRI-sensitive models. This demonstrated that the 
TGFβ-induced, EMT phenotype in the EGFRI-resistant cells was prevented by TGFβ-
inhibition. It also demonstrated that the EMT-like intermediate observed in the EGFRI-
sensitive model did not correlate with the induction of other EMT-characteristics such as 
migratory ability. Finally, to determine if TGFβ represented a clinically-relevant secondary 
target in relation to resistance to EGFRI, I determined whether extended TGFβ treatments 
altered sensitivity to EGFRI. In the EGFRI-resistance cell model, I determined that long-
term TGFβ treatment significantly increased cell viability in response to erlotinib. This 
increase in erlotinib resistance by TGFβ in EGFRI-resistant cells was not observed in cells 
co-treated with a TGFβ inhibitor. This suggests that while TGFβ inhibitors may reduce 
TGFβ-driven EMT events and erlotinib resistance, it is not a secondary target that will 
sensitize EGFRI-resistant cells to EGFRI treatment. 
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I also examined the role of TGFβ signaling on EGFRI-sensitivity in known EGFRI-
sensitive cell line model. Interestingly, extended TGFβ pre-treatment in the EGFRI-
sensitive model cell significantly decreased erlotinib sensitivity in these cells. This effect 
may be due to the ability of TGFβ to impair cell proliferation in this cell line model (179, 
371). Because these were cells treated with TGFβ in minimal serum (1% FBS) media 
conditions, the reduced proliferation may be due to a cross talk between TGFβ and EGFR 
signaling in response to nutrient availability. These observations are consistent with the 
anti-tumorigenic-arm of the “TGFβ paradox” theory (371). Most importantly, all instances 
of TGFβ-inhibition in the EGFRI-sensitive cell model resulted in a significant increase in 
erlotinib resistance. However, I confirmed by measuring the migration and wound healing 
capabilities indicative of EMT induction that TGFβ-inhibition was not inducing EMT in the 
EGFRI-sensitive cell line. Remarkably, the change in erlotinib-sensitivity aligns with the 
observations from Figure 2.6 where TGFβ inhibition resulted in a reduction of pERK1/2 
and pAKT signaling in these cells. I did not examine whether the phenotype was related 
to an increase in internalization and ubiquitination of active EGFR or the result of 
downstream signal ablation (e.g., RAS downregulation). From the data herein, I cannot 
confirm a mechanism for how TGFβ inhibition reduces erlotinib sensitivity in cells that are 
otherwise exquisitely sensitive to EGFRI treatment. To determine a mechanism, I would 
propose measuring the impact of TGFβ modulation on the expression of EGFR mRNA 
and protein levels. A study on the internalization and degradation rates of EGFR would 
also be informative in determining the source of the decreasing pERK1/2 and pAKT levels 
in response to TGFβ inhibition. Nevertheless, this observation reinforces that anti-TGFβ 
therapies will likely continue to be unsuccessful clinically in unselected patient populations, 
as has been observed (179, 219).   
 
Future directions of this work will be to identify alternative targets besides TGFβ 
for the treatment of drug-resistant NSCLC. To identify targets for the treatment of drug-
resistant NSCLC, I employed mathematical and protein-protein interaction modeling 
algorithms. This effort to identify alternative targets for EGFRI-resistant NSCLC is 
described in Chapter 4.  
 
In Chapter 4, I tested my hypothesis that combining the mRNA and miRNA 
data would identify nodes of cellular deregulation captured by both lists of 
deregulated genes. This may identify alternative targets for combatting EGFRI 
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resistance in NSCLC. I sought to identify other, pharmacologically actionable signaling 
nodes that may be targeted to overcome EGFRI resistance in NSCLC. We used the 
Feasible Solutions (FS) algorithm to systematically test for possible direct interactions 
between the 1495 mRNA and 23 miRNA found to be deregulated in EGFRI resistant 
NSCLC cells. We took the mRNA member of each of the 100 most statistically-significant 
interacting mRNA:miRNA pairs as determined by FS and annotated them to 85 separate 
Ensembl IDs that had protein matches in STRING v10 (387). The 85 proteins were 
inducted in the STRING network to search for interactions with EGFR. We found that 81 
proteins were within two edges of EGFR in the initial STRING network. Of the 81 proteins, 
many have been studied and/or implicated in EGFRI resistance. We chose to expand the 
network of genes considering the scenario “G1-X-G2” where G1 and G2 are any member 
of the original 85 Ensembl IDs imported into STRING and X is any induced node that 
connects them. From this, the network grew to 304 induced nodes, for a total of 385 nodes 
in the expanded deregulated network.  
 
The resulting network identified nearly every EGFRI resistance or compensatory 
signaling mechanism currently known, including: AKT/PI3K/mTOR (398), ataxia 
telangiectasia mutated (ATM) kinase (399), Aurora kinase (400), other ErbB family 
receptors (Her2, ErbB3 and ErbB4)(401), all three RAS isoforms (HRAS, KRAS and 
NRAS) (402), insulin-like growth factor receptor (IGFR) (403), MET receptor tyrosine 
kinase (39), and members of NFκβ, Notch, and TNFα signaling (109, 404, 405). The list 
also includes a number of cellular functions related to EGFR signaling regulation 
mechanisms including internalization (e.g., calmodulin1/2), ubiquitination (e.g., E3 protein 
ligases), and proteosomal degradation (e.g., proteasome subunits). Moreover, when 
divided into “communities” of node cellular functionality (Supplementary Table II-5, 
Appendix II), nearly every of the hallmarks of cancer were represented in the deregulated 
network suggesting that this network encompasses many of the mechanisms employed 
by EGFRI resistant NSCLC cells to maintain proliferation. 
  
 Of the list of proteins comprising the network of deregulation we, I selected 
CK2α/CK2α’ (the catalytic subunits of CK2 encoded by genes CSNK2A1 and CSNK2A2) 
to further pursue for three reasons: 1) the complete holoenzyme has been shown to 
interact with/regulate many of the members and pathways represented in the network, 2) 
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it was shown to be within two edges of most of the induced nodes in the network, and 3) 
it possesses enzymatic activity that can be inhibited by a pharmacological agent.  
 
I assessed pharmacological inhibition of CK2 using the CK2 inhibitor, CX-4945, on 
NSCLC cells that are resistant to EGFRI. I determined that NSCLC harboring KRAS 
activation and PTEN null mutations, both inherently resistant to EGFRI, were most 
sensitive to CK2 inhibition. However, the maximal response observed in these cells was 
approximately 50% cell viability, suggesting that CX-4945 may be most successful as a 
combination therapy. Further, cells harboring EGFR activation mutations were resistant to 
CX-4945 treatment suggesting that a coupling of EGFRI and CX-4945 would likely have 
no added therapeutic value.  
 
My goal was to identify an alternate target or a combination of targets to overcome 
EGFRI resistance in NSCLC. Considering that the majority of EGFRI resistance occurs as 
either mutations to EGFR (e.g., EGFR T790M) or downstream (e.g., KRAS), I aimed to 
identify a secondary drug target downstream of these resistance mechanisms. When we 
reduced the network to include only proteins within one edge of CK2α/CK2α’, no member 
of the EGFR-RAS-RAF-MEK-ERK signaling cascade was represented. This suggests that 
while EGFR-MAPK-ERK and CK2 signaling may interact, they do not do so directly (Table 
4.2). Because of this, I chose to evaluate the value of coupling CK2 and MEK inhibition. 
Initial experiments examining the impact of co-treatment of CX-4945 and the MEK 
inhibitor, AZD6244, revealed that the drug combination resulted in increasing levels of the 
apoptotic marker, cleaved PARP, across increasing drug concentrations and across time 
points (Figure 4.3). Future experiments will determine if this effect is also observed in cell 
viability assays, and if so, whether the effect is additive or synergistic. 
 
Finally, I explored whether CK2 inhibition could act as a surrogate for inhibition of 
TGFβ in KRAS active NSCLC. I previously demonstrated that TGFβ inhibition prevented 
increased EGFRI resistance in A549 cells and TGFβ inhibition induced EGFRI resistance 
in PC9 cells. This illustrates that in unselected populations, TGFβ inhibition is not clinically 
meaningful. I found that the combination of treatments did not increase cell death overall 
in A549 cells. I observed that CK2 inhibition can act as a surrogate for TGFβ inhibition 
blocking the increased erlotinib resistance brought on by TGFβ. Unfortunately, CK2 
inhibition did not prevent the induction of EGFRI resistance by TGFβ inhibitors in PC9. 
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These results suggest that TGFβ inhibition will still be a clinically-irrelevant treatment 
option until we have a methodology for selecting patients considering the status of TGFβ 
with regards to the “TGFβ paradox”.  
 
Intriguingly, I observed that the combination of CX-4945 and EGFRI decreased 
cell viability in PC9 cells at low doses of EGFRI although this effect was not found to be 
significant. These data suggest that the combination of therapies may be ideal in EGFRI-
sensitive tumors to prevent acquired mutations. CX-4945 treatment has already been 
shown specifically to prevent the development of EGFR T790M acquired-EGFRI-
resistance mutations in PC9 (238).  
 
 
B. EXPERIMENTAL LIMITATIONS 
 
The work described herein is the result of a combination of pharmacogenomic, 
systems biology, and pharmacologic methods to identify treatment alternatives for drug-
resistant NSCLC using gene expression data. This combinatorial analysis allows us to test 
broad inferences about the biology that underpins the phenotype of EGFRI resistance in 
NSCLC. From the data analyzed, I formed hypotheses regarding the role of the 
deregulated proteins identified in EGFRI sensitivity and/or resistance. Finally, I tested my 
hypotheses using cell line models of NSCLC with pharmacological agents that interrupt 
the pathways of interest. While this method allows us to gain a valuable understanding of 
the biology of EGFRI resistance and streamline the putative target discovery pipeline, it 
does have a number of limitations.  
 
Genomic Modeling of the Deregulation of EGFRI-Resistant NSCLC 
 
The strength in this methodology is that the in silico models can identify large 
networks of deregulated genes and proteins. Bioinformatic tools can also identify the 
nodes that connect them. The difficulty in developing and employing these methodologies 
is that many data points are generated and must be annotated in order to find meaningful 
putative targets. In revisiting Supplementary Table II-2 (Appendix II), one will find that 
there are many known oncogenic kinases and deregulated signaling pathways known to 
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drive tumorigenesis. There are also many network members that are less characterized 
that must be sorted through. The expanded network of 385 proteins also includes 
members known to be pharmacologically non-targetable to date (e.g., KRAS).  
 
Another limitation to the specific genomic analyses that we performed is that we 
specifically used expression data derived from NSCLC cells with known EGFRI sensitivity 
and known mutational statuses influencing EGFRI sensitivity in each of the lines. For the 
first of these profiling endeavors (the deregulated mRNA), the favorable alternative would 
have been to use human tumors with known EGFRI clinical outcomes. Unfortunately, 
samples with known EGFRI outcomes were not available at the time of the mRNA 
signature development (328). By the time we profiled the miRNA genes in the same cells, 
clinical samples were growing increasingly available. However, the ideal choice was to 
profile for miRNA expression in the same cell lines profiled for mRNA deregulation so the 
data sets could be compared. Specifically, this also allowed us to revisit the miRNA data 
and mRNA together with the goal of identifying nodes of deregulation shared between the 
two probesets as we’ve done here. This allowed us to identify a network of putative drug 
targets with more evidence than the original two analyses because it encompasses two 
“omic” levels of deregulation between EGFRI-resistant and –sensitive NSCLC.   
 
Biological and Pharmacological Testing of the Hypotheses Identified in silico 
 
 A prominent limitation of the work herein is the use of only cell line models for 
examining in silico generated hypotheses for the sake of determining novel avenues for 
the clinical treatment of lung tumors. The value of cell culture models lies in their ability to 
be a method for testing hypotheses in a well-controlled environment, but this is also the 
downside of the model. Cell line testing is an important stage in the development of an in 
silico hypothesis to a clinical treatment model because it allows us to rapidly test the value 
of novel targets both alone and in combinatorial analyses in a model that is significantly 
less expensive than in vivo models. 
  
 
C. CONTRIBUTION TO THE FIELD 
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Bioinformatic analysis of the 13-miRNA gene signature that predicts erlotinib 
sensitivity in NSCLC cells and tumor samples identified TGFβ signaling as a pathway of 
convergence of the miRNA genes. For this reason, I asked whether TGFβ played a role 
in the expression regulation of three of the candidate miRNA. We determined that TGFβ 
did not directly impact the expression of the miRNA, but cell cycle position may be 
important. Further study to characterize the remaining miRNA and to directly test the 
promoter elements for the transcriptional regulation of the signature miRNA is necessary 
to validate this hypothesis. However, a deeper understanding of if and how the cell cycle 
contributes to the expression of the signature miRNA could be useful for retraining the 13-
miRNA gene signature to not only indicate putative erlotinib response, but to indicate 
reliance on rapid cell cycle passage for viability. This additional piece of information could 
have value in determining which tumors are likely to respond to cell cycle targeting agents.  
 
This study was the first to characterize that TGFβ inhibition in PC9 cells leads to a 
significant loss of erlotinib sensitivity. TGFβ also decreased proliferation in these cells in 
low serum conditions indicating that it may play a role in attenuating mutant EGFR 
signaling. TGFβ inhibitors have entered clinical trials numerous times and are chronically 
unsuccessful due to side effects on TGFβ signaling in normal cells (179, 219).  
 
This is a combinatorial analysis of two “omic”-level studies of deregulated mRNA 
and miRNA species adds value to the targets identified as they are represented in both 
the mRNA and miRNA transcriptomes. This methodology for identifying networks of 
deregulation between phenotypes is valuable for dissecting the differences between many 
cellular phenotypes. We believe this paired analysis of functionally-related “omic”-level 
data (such as miRNA that act on mRNA) is ideal for identifying the network of genes most 
pertinent to a chosed phenotype (e.g., EGFRI-resistance). This study is also proof-of-
concept that mining existing gene expression data has merit for identifying and addressing 
new hypotheses surrounding specific phenotypes (e.g., EGFRI-resistance versus -
sensitivity). 
 
This study is the first to specifically identify the network of deregulated signaling 
surrounding CK2 as it relates to EGFRI-resistance. CK2 is both a member of this network 
and is connected to most of its members. A relationship between EGFR and CK2 signaling 
activity has been described in the sense of co-targetability and common influence.  
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Figure 6.1: The Impact of Co-Targeting MEK and CK2 on Cancer Signaling 
Pathways.  
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However, our analysis is the first to model that they likely act independently of one another 
with common downstream signaling nodes in pathways other than MAPK-ERK. I showed 
that EGFRI resistant cells harboring a KRAS activation mutation were most sensitive to 
CK2 inhibition suggesting that it could be a viable option for KRAS active lung tumors that 
comprise approximately 20% of the lung cancer population (168). I demonstrated that CK2 
inhibition in conjunction with EGFRI was not sufficient to sensitize KRAS active cells to 
EGFRI. This indicates that inhibition downstream of active KRAS is likely necessary to 
attenuate signaling. My initial examination of the CK2 and MEK co-inhibition is the first 
study to demonstrate that this combination likely has value in treating EGFRI resistant 
NSCLC harboring a KRAS activation mutation.  
 
 
D. CONCLUSIONS 
 
I conclude that an analysis considering multiple gene expression species that 
physically interact and regulate one another (e.g., mRNA and miRNA) are ideal for 
identifying a concise network of proteins that define a phenotype of choice. The network 
identified using this methodology performed best for us using the G1-X-G2 scheme to 
capture other the contributing members of a network. This novel approach for identifying 
possible therapeutic targets requires further validation in cell culture as well as in another 
data set to determine the sensitivity and specificity of the approach. I identified CK2 as a 
putative target due to its expansive relationships with the other network members, 
specifically those known to contribute mechanistically to the generation of EGFRI-
resistance. Examination of its activity suggests that CK2 inhibition shows promise for 
treating EGFRI-resistant NSCLC, specifically those harboring KRAS active mutations. We 
also conclude that inhibition of CK2 concurrently with MEK inhibition has the potential to 
maximize targeted therapy benefit for the treatment of KRAS active, EGFRI-resistant 
NSCLC tumors. 
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APPENDIX I: SUPPLEMENTARY FIGURES FOR CHAPTER 2 
 
Supplementary Table I-1: Output of 5-way ANOVA analysis. (Data pairs with 
Supplementary figures I-4 and I-5) (A) Variable names used in analysis. (B)  Five-way 
ANOVA Overall F-test of the endogenous miRNA data. (C) Tests of the effects within the 
five-way ANOVA.  
 
A 
 Class Level Information 
Class Levels Values 
Time 3 168 Hour 24 Hour 72 
Hour 
Expr 3 miR-140 miR-141 miR200 
status 4 A549 H1650 H460 PC9 
TGF 2 N Y 
SB 2 N Y 
 
B 
Source DF 
Sum of 
Squares Mean Square F Value Pr > F 
Model 143 8088.984432 56.566325 57.40 <.0001 
Error 288 283.797472 0.985408   
Corrected Total 431 8372.781904    
  
APPENDIX I 
148 
 
Supplementary Table I-1 (Continued): Output of 5-way ANOVA analysis. (Data pairs 
with Supplementary figures I-4 and I-5) 
 
C 
 
Source DF Type III SS Mean Square F Value Pr > F 
Time 2 79.952136 39.976068 40.57 <.0001 
Expr 2 1885.221769 942.610885 956.57 <.0001 
Time*expr 4 54.519027 13.629757 13.83 <.0001 
TGF 1 10.424204 10.424204 10.58 0.0013 
Time*TGF 2 1.076126 0.538063 0.55 0.5798 
expr*TGF 2 1.079149 0.539574 0.55 0.5790 
Time*expr*TGF 4 0.646410 0.161602 0.16 0.9565 
SB 1 1.546384 1.546384 1.57 0.2113 
Time*SB 2 0.471393 0.235697 0.24 0.7874 
expr*SB 2 1.520563 0.760281 0.77 0.4633 
Time*expr*SB 4 0.324106 0.081027 0.08 0.9878 
TGF*SB 1 0.134397 0.134397 0.14 0.7122 
Time*TGF*SB 2 0.541967 0.270983 0.27 0.7598 
expr*TGF*SB 2 1.295853 0.647926 0.66 0.5189 
Time*expr*TGF*SB 4 0.965323 0.241331 0.24 0.9126 
Status 3 3240.479541 1080.159847 1096.16 <.0001 
Time*status 6 364.036762 60.672794 61.57 <.0001 
expr*status 6 2266.034942 377.672490 383.27 <.0001 
Time*expr*status 12 127.856402 10.654700 10.81 <.0001 
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Supplementary Table I-1 (Continued): Output of 5-way ANOVA analysis. (Data pairs 
with Supplementary figures I-4 and I-5) 
 
Source DF Type III SS Mean Square F Value Pr > F 
status*TGF 3 2.810260 0.936753 0.95 0.4165 
Time*status*TGF 6 4.252351 0.708725 0.72 0.6344 
expr*status*TGF 6 2.875868 0.479311 0.49 0.8183 
Time*expr*status*TGF 12 2.785062 0.232089 0.24 0.9964 
status*SB 3 12.852156 4.284052 4.35 0.0051 
Time*status*SB 6 0.954675 0.159113 0.16 0.9866 
expr*status*SB 6 6.327867 1.054644 1.07 0.3804 
Time*expr*status*SB 12 3.120940 0.260078 0.26 0.9939 
status*TGF*SB 3 6.390615 2.130205 2.16 0.0927 
Time*status*TGF*SB 6 2.107473 0.351246 0.36 0.9058 
expr*status*TGF*SB 6 4.105405 0.684234 0.69 0.6544 
Tim*expr*stat*TGF*SB 12 2.275306 0.189609 0.19 0.9987 
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Supplementary File I-1: Experimental Ct Averages. (A)A549, (B) H460, (C) H1650, 
(D) PC9. 
(A) A549 
 
 Untreated +TGFβ 
m
iR
-1
4
0
 
24 
Hour 12.33757 11.43739 11.60239 12.39578 12.97549 12.15190 
72 
Hour 9.787602 10.08148 10.61999 9.900755 10.42333 11.50879 
168 
Hour 9.758026 10.54176 11.49169 10.53289 11.00631 11.92199 
m
iR
-1
4
1
 
24 
Hour 17.06016 15.32151 19.90596 17.07662 17.98000 20.07600 
72 
Hour 15.54128 13.97606 14.51325 15.44358 15.80907 16.95060 
168 
Hour 14.27188 12.21063 11.12456 15.88630 13.84227 15.35418 
m
iR
-2
0
0
c
 24 
Hour 14.10283 14.30923 14.84075 14.54479 14.74094 15.67361 
72 
Hour 13.32989 12.92316 14.99424 13.60149 13.89697 15.47936 
168 
Hour 12.67405 13.07983 14.84481 13.63927 14.52270 16.56609 
 
 +SB-431542 +TGFβ + SB-431542 
m
iR
-1
4
0
 
24 
Hour 11.89172 12.01508 11.48558 12.45281 11.61382 12.25275 
72 
Hour 9.535458 10.08252 10.83031 9.738522 10.67040 11.51334 
168 
Hour 8.811357 9.751716 10.45633 10.03573 10.56819 11.34701 
m
iR
-1
4
1
 
24 
Hour 12.00429 16.11283 19.87011 14.06351 15.08848 19.66269 
72 
Hour 14.33568 16.13022 13.74338 14.67358 11.94453 12.31492 
168 
Hour 13.87545 11.08248 12.75059 14.71158 10.58473 13.92210 
m
iR
-2
0
0
c
 24 
Hour 14.04283 14.31766 14.49006 14.54913 14.46255 15.62704 
72 
Hour 13.09006 12.68363 15.03674 12.67218 12.74576 15.55015 
168 
Hour 12.99181 13.09153 14.56104 12.99181 12.78577 15.02792 
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Supplementary File I-1 (Continued): Experimental Ct Averages. (A)A549, (B) H460, 
(C) H1650, (D) PC9. 
(B) H460 
 
 Untreated +TGFβ 
m
iR
-1
4
0
 
24 
Hour 
17.14272 17.91426 18.13599 17.05264 17.90481 17.99017 
72 
Hour 
17.21708 17.84024 17.46496 17.12854 16.66626 18.02826 
168 
Hour 
16.66319 17.54043 16.98263 16.64818 17.56977 17.08109 
m
iR
-1
4
1
 
24 
Hour 
17.08539 17.28380 17.33617 17.18618 17.62590 17.00420 
72 
Hour 
16.61845 17.04087 15.97914 17.28608 16.24639 16.81126 
168 
Hour 
16.26302 16.34669 15.99137 16.66824 17.00029 16.70879 
m
iR
-2
0
0
c
 24 
Hour 
10.67178 11.04102 11.36006 10.62387 11.23187 11.26765 
72 
Hour 
10.96402 11.11371 10.36812 11.05747 10.45827 11.33282 
168 
Hour 
10.77904 13.99327 10.41068 11.04071 11.77847 11.16143 
 
 +SB-431542 +TGFβ + SB-431542 
m
iR
-1
4
0
 
24 
Hour 
17.39966 18.23286 18.15083 17.61480 18.01347 18.38200 
72 
Hour 
16.91612 18.07499 17.15804 17.68611 18.51481 18.12220 
168 
Hour 
16.93595 17.08220 16.81208 16.85756 17.29420 17.47745 
m
iR
-1
4
1
 
24 
Hour 
17.10256 17.40165 17.29394 17.65773 17.38723 16.82007 
72 
Hour 
16.67177 17.03223 16.15025 17.48135 17.73611 16.58182 
168 
Hour 
16.83432 16.60688 16.06160 16.52186 16.67512 16.34198 
m
iR
-2
0
0
c
 24 
Hour 
10.75649 11.10807 11.17131 10.87258 11.09417 11.12668 
72 
Hour 
10.32638 11.28246 10.31851 11.51607 12.77857 11.01471 
168 
Hour 
13.58082 10.98377 10.31083 11.05021 11.20028 13.88309 
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Supplementary File I-1 (Continued): Experimental Ct Averages. (A)A549, (B) H460, 
(C) H1650, (D) PC9. 
(C) H1650 
 
 Untreated +TGFβ 
m
iR
-1
4
0
 
24 
Hour 
12.24568 12.01147 12.93231 12.28511 12.96206 12.49449 
72 
Hour 
12.17126 12.94157 12.64218 12.49287 13.47596 13.12842 
168 
Hour 
17.22546 17.23288 17.92211 17.46275 17.47145 17.98014 
m
iR
-1
4
1
 
24 
Hour 
7.839454 7.535492 7.558471 8.04034 7.626134 6.945391 
72 
Hour 
7.115704 6.608805 7.225541 7.719368 7.437265 7.523124 
168 
Hour 
11.69064 11.75101 11.83241 11.88982 11.90958 11.97695 
m
iR
-2
0
0
c
 24 
Hour 
4.654358 4.169437 5.087824 4.834063 5.230578 4.853105 
72 
Hour 
4.231399 4.793982 4.516056 4.626641 5.374649 5.112733 
168 
Hour 
5.979657 6.024038 6.170614 5.993081 6.253736 6.156914 
 
 +SB-431542 +TGFβ + SB-431542 
m
iR
-1
4
0
 
24 
Hour 
12.02541 13.26263 12.93686 12.56955 13.30433 12.94468 
72 
Hour 
12.13073 13.18402 12.97675 12.74410 13.90631 11.57144 
168 
Hour 
17.24517 17.57818 17.67087 17.44893 17.80485 17.78832 
m
iR
-1
4
1
 
24 
Hour 
7.658577 8.035284 7.288847 7.757186 8.216744 6.859854 
72 
Hour 
7.295649 7.448415 7.114004 7.415254 8.310852 6.352814 
168 
Hour 
11.48486 11.61927 11.82947 11.41379 11.91031 11.76493 
m
iR
-2
0
0
c
 24 
Hour 
4.553339 5.694854 5.120974 5.110865 5.906208 4.517555 
72 
Hour 
4.311621 4.661685 4.998656 4.919242 7.163925 3.526715 
168 
Hour 
5.897517 6.226531 6.095646 6.014628 6.505982 6.126934 
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Supplementary File I-1 (Continued): Experimental Ct Averages. (A)A549, (B) H460, 
(C) H1650, (D) PC9. 
(D) PC9 
 
 Untreated +TGFβ 
m
iR
-1
4
0
 
24 
Hour 
14.94061 13.26866 14.54584 14.57736 11.73476 13.76189 
72 
Hour 
12.83986 13.43117 13.88492 12.71534 13.55068 14.44901 
168 
Hour 
13.50625 13.77642 14.75037 13.84855 14.09694 14.88830 
m
iR
-1
4
1
 
24 
Hour 
7.121312 10.00169 9.931498 7.876611 8.188897 10.06823 
72 
Hour 
6.306454 3.402984 3.121106 6.319069 4.80151 5.335824 
168 
Hour 
5.817623 3.519702 5.124096 5.819985 4.690588 5.166902 
m
iR
-2
0
0
c
 24 
Hour 
5.756327 6.305108 6.344949 5.612942 5.945666 6.384396 
72 
Hour 
4.948423 4.166431 6.540284 4.255959 3.853093 7.538871 
168 
Hour 
4.483598 4.663599 6.590467 4.483084 4.430461 6.680311 
 
 +SB-431542 +TGFβ + SB-431542 
m
iR
-1
4
0
 
24 
Hour 
14.78079 13.46474 13.18096 14.64627 13.47323 13.75304 
72 
Hour 
12.70899 13.05903 13.79732 12.37238 13.11935 13.77495 
168 
Hour 
13.05962 14.00124 14.74730 13.65988 13.76325 14.75263 
m
iR
-1
4
1
 
24 
Hour 
8.433583 10.00693 8.825805 8.76599 10.44693 10.97337 
72 
Hour 
6.583571 3.124386 2.23386 6.249595 4.266571 6.207948 
168 
Hour 
6.500151 1.581450 5.662973 6.34292 3.582123 6.186862 
m
iR
-2
0
0
c
 24 
Hour 
6.06497 5.257848 5.868316 5.77605 6.038063 5.926589 
72 
Hour 
4.760397 3.741873 6.390911 4.907626 4.191823 6.659156 
168 
Hour 
4.517351 4.478639 6.310415 4.340795 4.377823 6.354835 
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APPENDIX II: SUPPLEMENTARY FIGURES FOR CHAPTER 4 
 
Supplementary Table II-1: Interacting mRNA:miRNA genes (100) from the Feasible 
Solutions (FS) analysis. The 100 probe IDs with the lowest probability (low Prob>F) as 
determined by the FS analysis. To identify targets that may have value in EGFRI resistant 
tumors, the model sought mRNA with high expression in EGFRI-resistant NSCLC cells.   
Probe ID 
Interacting 
miRNA  Prob > F 
213302_at hsa.miR.135b hsa.miR.616.4395525 2.14712E-05 
204497_at hsa.miR.210 hsa.miR.616.4395525 2.49071E-05 
201002_s_at hsa.miR.135b hsa.miR.616.4395525 3.56988E-05 
210139_s_at hsa.miR.197. hsa.miR.616.4395525 5.82491E-05 
214830_at hsa.miR.410 hsa.miR.616.4395525 8.11249E-05 
208241_at hsa.miR.135b hsa.miR.616.4395525 8.31544E-05 
218467_at hsa.miR.200b hsa.miR.628.5p.4395544 0.000132681 
218970_s_at hsa.miR.200b hsa.miR.616.4395525 0.000168687 
211505_s_at hsa.miR.200b hsa.miR.628.5p.4395544 0.000169371 
203482_at hsa.miR.200b hsa.miR.616.4395525 0.000169684 
212764_at hsa.miR.518b hsa.miR.125a.3p.4395310 0.000211397 
58780_s_at hsa.miR.873 hsa.miR.628.5p.4395544 0.000233999 
208919_s_at hsa.miR.30c hsa.miR.616.4395525 0.000251931 
201379_s_at hsa.miR.141 hsa.miR.616.4395525 0.000320846 
213262_at hsa.miR.873 hsa.miR.636.4395199 0.000364971 
210910_s_at hsa.miR.205 hsa.miR.873.4395467 0.000398141 
201778_s_at hsa.miR.873 hsa.miR.616.4395525 0.000410072 
37117_at hsa.miR.197 hsa.miR.518f.4395499 0.000434778 
219002_at 
hsa.miR.873.43
95467 hsa.miR.636.4395199 0.000449861 
219020_at 
hsa.miR.758.43
95180 hsa.miR.616.4395525 0.000511882 
204115_at 
hsa.miR.873.43
95467 hsa.miR.636.4395199 0.000574862 
213058_at 
hsa.miR.873.43
95467 hsa.miR.30c.4373060 0.000638761 
219395_at 
hsa.miR.125a.5
p.4395309 hsa.miR.616.4395525 0.000662677 
213798_s_at 
hsa.miR.636.43
95199 hsa.miR.628.5p.4395544 0.000670364 
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Supplementary Table II-1 (continued): Interacting mRNA:miRNA genes (100) from 
the Feasible Solutions (FS) analysis.  
 
Probe ID 
Interacting 
miRNA  Prob > F 
219388_at 
hsa.miR.200c.4
395411 hsa.miR.363.4378090 0.000675789 
201565_s_at 
hsa.miR.200c.4
395411 hsa.miR.363.4378090 0.000684861 
209222_s_at 
hsa.miR.200c.4
395411 hsa.miR.363.4378090 0.000752997 
204243_at 
hsa.miR.200b.4
395362 hsa.miR.410.4378093 0.000754944 
219785_s_at 
hsa.miR.135b.4
395372 hsa.miR.616.4395525 0.000762204 
217744_s_at 
hsa.miR.125a.5
p.4395309 hsa.miR.616.4395525 0.000856678 
209225_x_at 
hsa.miR.363.43
78090 hsa.miR.628.5p.4395544 0.000926545 
219547_at 
hsa.miR.200b.4
395362 hsa.miR.224.4395210 0.000932786 
221704_s_at 
hsa.miR.135b.4
395372 hsa.miR.873.4395467 0.001141837 
205807_s_at 
hsa.miR.224.43
95210 hsa.miR.628.5p.4395544 0.001186811 
203551_s_at 
hsa.miR.135b.4
395372 hsa.miR.616.4395525 0.001191469 
201380_at 
hsa.miR.873.43
95467 hsa.miR.616.4395525 0.001287701 
218264_at 
hsa.miR.628.5p
.4395544 hsa.miR.616.4395525 0.001328277 
207320_x_at 
hsa.miR.410.43
78093 hsa.miR.628.5p.4395544 0.001400914 
218720_x_at 
hsa.miR.200b.4
395362 hsa.miR.197.4373102 0.001477025 
207000_s_at 
hsa.miR.200b.4
395362 hsa.miR.616.4395525 0.001484342 
201608_s_at 
hsa.miR.873.43
95467 hsa.miR.628.5p.4395544 0.001502097 
201566_x_at 
hsa.miR.200b.4
395362 hsa.miR.616.4395525 0.001534329 
201589_at 
hsa.miR.125a.5
p.4395309 hsa.miR.363.4378090 0.001595775 
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Supplementary Table II-1 (continued): Interacting mRNA:miRNA genes (100) from 
the Feasible Solutions (FS) analysis.  
 
Probe ID 
Interacting 
miRNA  Prob > F 
55065_at 
hsa.miR.518f.4
395499 hsa.miR.616.4395525 0.001647671 
200929_at 
hsa.miR.636.43
95199 hsa.miR.628.5p.4395544 0.001668389 
218365_s_at 
hsa.miR.197.43
73102 hsa.miR.518b.4373246 0.001691602 
213434_at 
hsa.miR.628.5p
.4395544 hsa.miR.758.4395180 0.001763671 
210662_at 
hsa.miR.873.43
95467 hsa.miR.616.4395525 0.001784274 
201594_s_at 
hsa.miR.205.43
73093 hsa.miR.363.4378090 0.001825064 
208747_s_at 
hsa.miR.210.43
73089 hsa.miR.363.4378090 0.001914552 
211240_x_at 
hsa.miR.363.43
78090 hsa.miR.616.4395525 0.002018453 
203650_at 
hsa.miR.873.43
95467 hsa.miR.636.4395199 0.002040117 
210114_at 
hsa.miR.873.43
95467 hsa.miR.616.4395525 0.0020832 
205847_at 
hsa.miR.125a.5
p.4395309 hsa.miR.616.4395525 0.002085028 
215146_s_at 
hsa.miR.873.43
95467 hsa.miR.636.4395199 0.002090153 
219121_s_at 
hsa.miR.363.43
78090 hsa.miR.616.4395525 0.002093259 
216095_x_at 
hsa.miR.30c.43
73060 hsa.miR.628.5p.4395544 0.002122563 
219733_s_at 
hsa.miR.221.43
73077 hsa.miR.616.4395525 0.002188182 
200640_at 
hsa.miR.205.43
73093 hsa.miR.628.5p.4395544 0.002204398 
203884_s_at 
hsa.miR.200b.4
395362 hsa.miR.636.4395199 0.002214892 
201426_s_at 
hsa.miR.125a.5
p.4395309 hsa.miR.616.4395525 0.00231613 
218451_at 
hsa.miR.141.43
73137 hsa.miR.139.5p.4395400 0.00236974 
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Supplementary Table II-1 (continued): Interacting mRNA:miRNA genes (100) from 
the Feasible Solutions (FS) analysis.  
 
Probe ID 
Interacting 
miRNA  Prob > F 
205980_s_at 
hsa.miR.197.43
73102 hsa.miR.410.4378093 0.002425474 
201839_s_at 
hsa.miR.200b.4
395362 hsa.miR.628.5p.4395544 0.002481076 
203287_at 
hsa.miR.205.43
73093 hsa.miR.758.4395180 0.002584299 
216641_s_at 
hsa.miR.200c.4
395411 hsa.miR.363.4378090 0.002615599 
213220_at 
hsa.miR.200c.4
395411 hsa.miR.200b.4395362 0.002645648 
217388_s_at 
hsa.miR.200c.4
395411 hsa.miR.628.5p.4395544 0.002692429 
208862_s_at 
hsa.miR.873.43
95467 hsa.miR.616.4395525 0.002761436 
208634_s_at 
hsa.miR.200c.4
395411 hsa.miR.363.4378090 0.002775792 
221646_s_at 
hsa.miR.197.43
73102 hsa.miR.616.4395525 0.002913831 
218526_s_at 
hsa.miR.224.43
95210 hsa.miR.616.4395525 0.0029388 
214136_at 
hsa.miR.873.43
95467 hsa.miR.636.4395199 0.002991045 
206343_s_at 
hsa.miR.200b.4
395362 hsa.miR.197.4373102 0.002996291 
202286_s_at 
hsa.miR.224.43
95210 hsa.miR.628.5p.4395544 0.003004819 
208319_s_at 
hsa.miR.873.43
95467 hsa.miR.636.4395199 0.003172694 
205667_at 
hsa.miR.873.43
95467 hsa.miR.616.4395525 0.003211669 
203883_s_at 
hsa.miR.200b.4
395362 hsa.miR.30c.4373060 0.003239375 
206907_at 
hsa.miR.200c.4
395411 hsa.miR.616.4395525 0.003303832 
207011_s_at 
hsa.miR.200b.4
395362 hsa.miR.628.5p.4395544 0.003310737 
214876_s_at 
hsa.miR.200c.4
395411 hsa.miR.616.4395525 0.003649619 
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Supplementary Table II-1 (continued): Interacting mRNA:miRNA genes (100) from 
the Feasible Solutions (FS) analysis.  
Probe ID 
Interacting 
miRNA  Prob > F 
209110_s_at 
hsa.miR.873.43
95467 hsa.miR.616.4395525 0.003676755 
208009_s_at 
hsa.miR.139.5p
.4395400 hsa.miR.758.4395180 0.003697195 
200982_s_at 
hsa.miR.873.43
95467 hsa.miR.636.4395199 0.003710188 
202087_s_at 
hsa.miR.200b.4
395362 hsa.miR.758.4395180 0.003774459 
204416_x_at 
hsa.miR.410.43
78093 hsa.miR.628.5p.4395544 0.003811245 
221825_at 
hsa.miR.135b.4
395372 hsa.miR.139.5p.4395400 0.003949163 
206015_s_at 
hsa.miR.200c.4
395411 hsa.miR.363.4378090 0.00401435 
209666_s_at 
hsa.miR.197.43
73102 hsa.miR.518b.4373246 0.004126397 
55872_at 
hsa.miR.135b.4
395372 hsa.miR.628.5p.4395544 0.004136091 
217717_s_at 
hsa.miR.205.43
73093 hsa.miR.224.4395210 0.004187272 
219157_at 
hsa.miR.363.43
78090 hsa.miR.616.4395525 0.004209738 
218823_s_at 
hsa.miR.200b.4
395362 hsa.miR.410.4378093 0.004274431 
205263_at 
hsa.miR.200b.4
395362 hsa.miR.335.4373045 0.004329786 
209188_x_at 
hsa.miR.210.43
73089 hsa.miR.363.4378090 0.004396567 
219338_s_at 
hsa.miR.141.43
73137 hsa.miR.224.4395210 0.004645033 
201131_s_at 
hsa.miR.221.43
73077 hsa.miR.616.4395525 0.004743977 
214724_at 
hsa.miR.125a.3
p.4395310 hsa.miR.518f.4395499 0.004792734 
203011_at 
hsa.miR.125a.3
p.4395310 hsa.miR.518f.4395499 0.004849912 
204148_s_at 
hsa.miR.197.43
73102 hsa.miR.616.4395525 0.004863654 
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Supplementary Table II-2: Initial FS candidates that interact with EGFR. Table 
members represent the 85 independent Ensembl IDs identified by the FS analysis.  
 
SOURCE GENE NAME 
ARHGEF9 Cdc42 guanine nucleotide exchange factor (406) 9 
DHRS4:DH
RS4L2:DHR
S4L1 
dehydrogenase/reductase (SDR family) member 4, 
dehydrogenase/reductase (SDR family) member 4 like 2, 
dehydrogenase/reductase (SDR family) member 4 like 1 
FANCF Fanconi anemia, complementation group F 
FBXO31 F-box protein 31 
GNG11 guanine nucleotide binding protein (G protein), gamma 11 
NRG1 neuregulin 1 
NUBP2 nucleotide binding protein 2 
PMP22 peripheral myelin protein 22 
RAB11FIP2 RAB11 family interacting protein 2 (class I) 
RNMTL1 RNA methyltransferase like 1 
S100A3 S100 calcium binding protein A3 
TFE3 transcription factor binding to IGHM enhancer 3 
TNFSF9 tumor necrosis factor (ligand) superfamily, member 9 
ACTA2 actin, alpha 2, smooth muscle, aorta 
ADCY9 adenylate cyclase 9 
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 
ANGEL2 angel homolog 2 (Drosophila) 
ANXA6 annexin A6 
ARHGEF40 Rho guanine nucleotide exchange factor (406) 40 
ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9) 
BCCIP BRCA2 and CDKN1A interacting protein 
BRCC3 BRCA1/BRCA2-containing complex, subunit 3 
C1QBP complement component 1, q subcomponent binding protein 
CAMK1 calcium/calmodulin-dependent protein kinase I 
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Supplementary Table II-2 (continued): Initial FS candidates that interact with EGFR. 
Table members represent the 85 independent Ensembl IDs identified by the FS analysis.  
 
SOURCE GENE NAME 
COX15 cytochrome c oxidase assembly homolog 15 (yeast) 
CRTAP cartilage associated protein 
CTSL cathepsin L 
CUTC cutC copper transporter 
DARS2 aspartyl-tRNA synthetase 2, mitochondrial 
DIP2C disco-interacting protein 2 homolog C 
DIXDC1 DIX domain containing 1 
DOCK10 dedicator of cytokinesis 10 
DPYSL3 dihydropyrimidinase-like 3 
EGFR epidermal growth factor receptor 
EIF3A eukaryotic translation initiation factor 3, subunit A 
FASTKD1 FAST kinase domains 1 
FBXL15 F-box and leucine-rich repeat protein 15 
GLRX glutaredoxin (thioltransferase) 
HS1BP3 HCLS1 binding protein 3 
HSPA12A heat shock 70kDa protein 12A 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
IMPA1 inositol(myo)-1(or 4)-monophosphatase 1 
INVS Inversin 
KCTD9 potassium channel tetramerization domain containing 9 
KYNU Kynureninase 
LIG3 ligase III, DNA, ATP-dependent 
MID1IP1 MID1 interacting protein 1 
MTMR9 myotubularin related protein 9 
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Supplementary Table II-2 (continued): Initial FS candidates that interact with EGFR. 
Table members represent the 85 independent Ensembl IDs identified by the FS analysis.  
 
SOURCE GENE NAME 
PFAS phosphoribosylformylglycinamidine synthase 
POMZP3 POM121 and ZP3 fusion 
PPP3CC protein phosphatase 3, catalytic subunit, gamma isozyme 
PROCR protein C receptor, endothelial 
PWP1 PWP1 homolog, endonuclein 
RANGRF RAN guanine nucleotide release factor 
RBM3 RNA binding motif (RNP1, RRM) protein 3 
SACS sacsin molecular chaperone 
SMC1A structural maintenance of chromosomes 1A 
STX2 syntaxin 2 
TNPO1 transportin 1 
TTC28 tetratricopeptide repeat domain 28 
TUBGCP2 tubulin, gamma complex associated protein 2 
UIMC1 ubiquitin interaction motif containing 1 
USP9X ubiquitin specific peptidase 9, X-linked 
VIM Vimentin 
VPS33B vacuolar protein sorting 33 homolog B (yeast) 
WRN Werner syndrome, RecQ helicase-like 
ZC3H14 zinc finger CCCH-type containing 14 
ZEB1 zinc finger E-box binding homeobox 1 
CHUK conserved helix-loop-helix ubiquitous kinase 
PBK PDZ binding kinase 
PTEN phosphatase and tensin homolog 
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Supplementary Table II-3: G1-X-G2 Analysis-Induced EGFRI Resistance Network 
Members. Table members were generated using the 85 independent Ensembl IDs 
identified by the FS analysis. Table members generated by the STRING analysis 
considering the scenario G1-X-G2 where G1 and G2 are from the original list of 85 
Ensembl IDs of mRNA found to be upregulated in EGFRI resistant NSCLC cells and X is 
any other node that connects them.   
 
SYMBOL GENE NAME TYPE 
ACACB acetyl-CoA carboxylase beta Induced 
ACTA1 actin, alpha 1, skeletal muscle Induced 
ACTA2 actin, alpha 2, smooth muscle, aorta Input 
ADCY9 adenylate cyclase 9 Input 
ADSS adenylosuccinate synthase Induced 
AKT1 v-akt murine thymoma viral oncogene homolog 1 Induced 
AKT2 v-akt murine thymoma viral oncogene homolog 2 Induced 
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 Input 
ANGEL2 angel homolog 2 (Drosophila) Input 
ANXA6 annexin A6 Input 
AP2A1 adaptor-related protein complex 2, alpha 1 subunit Induced 
APC adenomatous polyposis coli Induced 
AR androgen receptor Induced 
ARHGEF
40 Rho guanine nucleotide exchange factor (406) 40 Input 
ARHGEF
9 Cdc42 guanine nucleotide exchange factor (406) 9 Input 
ARRB2 arrestin, beta 2 Induced 
ATM ATM serine/threonine kinase Induced 
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 Induced 
ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9) Input 
AURKA aurora kinase A Induced 
BABAM1 BRISC and BRCA1 A complex member 1 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
BARD1 BRCA1 associated RING domain 1 Induced 
BCCIP BRCA2 and CDKN1A interacting protein Input 
BCL2 B-cell CLL/lymphoma 2 Induced 
BIRC2 baculoviral IAP repeat containing 2 Induced 
BIRC3 baculoviral IAP repeat containing 3 Induced 
BLM Bloom syndrome, RecQ helicase-like Induced 
BRCA1 breast cancer 1, early onset Induced 
BRCC3 BRCA1/BRCA2-containing complex, subunit 3 Input 
BRE brain and reproductive organ-expressed (TNFRSF1A modulator) Induced 
BTRC beta-transducin repeat containing E3 ubiquitin protein ligase Induced 
C1QBP complement component 1, q subcomponent binding protein Input 
CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase Induced 
CALM1 
CALM2 
calmodulin 1 (phosphorylase kinase, delta), calmodulin 2 
(phosphorylase kinase, delta) Induced 
CALM2 calmodulin 2 (phosphorylase kinase, delta) Induced 
CAMK1 calcium/calmodulin-dependent protein kinase I Input 
CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 Induced 
CAPZB capping protein (actin filament) muscle Z-line, beta Induced 
CASP8 caspase 8, apoptosis-related cysteine peptidase Induced 
CAV1 caveolin 1, caveolae protein, 22kDa Induced 
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase Induced 
CCND1 cyclin D1 Induced 
CCT4 chaperonin containing TCP1, subunit 4 (delta) Induced 
CD2AP CD2-associated protein Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
CDC37 cell division cycle 37 Induced 
CDH1 cadherin 1, type 1 Induced 
CDK1 cyclin-dependent kinase 1 Induced 
CDK2 cyclin-dependent kinase 2 Induced 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) Induced 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) Induced 
CFL1 cofilin 1 (non-muscle) Induced 
CHAF1A chromatin assembly factor 1, subunit A (p150) Induced 
CHORDC
1 
cysteine and histidine-rich domain (CHORD) 
containing 1 Induced 
CHUK conserved helix-loop-helix ubiquitous kinase Input 
CKAP5 cytoskeleton associated protein 5 Induced 
CNOT4 CCR4-NOT transcription complex, subunit 4 Induced 
COPS5 COP9 signalosome subunit 5 Induced 
COX15 cytochrome c oxidase assembly homolog 15 (yeast) Input 
CREBBP CREB binding protein Induced 
CRTAP cartilage associated protein Input 
CSE1L CSE1 chromosome segregation 1-like (yeast) Induced 
CSNK2A1 casein kinase 2, alpha 1 polypeptide Induced 
CSNK2A2 casein kinase 2, alpha prime polypeptide Induced 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa Induced 
CTSL cathepsin L Input 
CUL1 cullin 1 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
CUTC cutC copper transporter Input 
DARS2 aspartyl-tRNA synthetase 2, mitochondrial Input 
DAZAP1 DAZ associated protein 1 Induced 
DCP2 decapping mRNA 2 Induced 
DHRS4 
DHRS4L2 
DHRS4L1 
dehydrogenase/reductase (SDR family) member 4, 
dehydrogenase/reductase (SDR family) member 4 like 
2, dehydrogenase/reductase (SDR family) member 4 
like 1 
Input 
DIP2C disco-interacting protein 2 homolog C Input 
DIXDC1 DIX domain containing 1 Input 
DKC1 dyskeratosis congenita 1, dyskerin Induced 
DLG1 discs, large homolog 1 (Drosophila) Induced 
DOCK10 dedicator of cytokinesis 10 Input 
DPYSL3 dihydropyrimidinase-like 3 Input 
DVL2 dishevelled segment polarity protein 2 Induced 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 Induced 
EGF epidermal growth factor Induced 
EGFR epidermal growth factor receptor Input 
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Induced 
EIF3A eukaryotic translation initiation factor 3, subunit A Input 
EIF4A3 eukaryotic translation initiation factor 4A3 Induced 
ELAVL1 ELAV like RNA binding protein 1 Induced 
EP300 E1A binding protein p300 Induced 
EPN1 epsin 1 Induced 
EPS15 epidermal growth factor receptor pathway substrate 15 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
ERBB2 erb-b2 receptor tyrosine kinase 2 Induced 
ERBB3 erb-b2 receptor tyrosine kinase 3 Induced 
ERBB4 erb-b2 receptor tyrosine kinase 4 Induced 
ERP44 endoplasmic reticulum protein 44 Induced 
ESR1 estrogen receptor 1 Induced 
EXOSC10 exosome component 10 Induced 
FAM175A family with sequence similarity 175, member A Induced 
FAM175B family with sequence similarity 175, member B Induced 
FANCA Fanconi anemia, complementation group A Induced 
FANCF Fanconi anemia, complementation group F Input 
FANCG Fanconi anemia, complementation group G Induced 
FANCM Fanconi anemia, complementation group M Induced 
FASTKD1 FAST kinase domains 1 Input 
FBXL15 F-box and leucine-rich repeat protein 15 Input 
FBXO31 F-box protein 31 Input 
FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase Induced 
GAB1 GRB2-associated binding protein 1 Induced 
GAPDH glyceraldehyde-3-phosphate dehydrogenase Induced 
GDA guanine deaminase Induced 
GLRX glutaredoxin (thioltransferase) Input 
GNG11 guanine nucleotide binding protein (G protein), gamma 11 Input 
GNS glucosamine (N-acetyl)-6-sulfatase Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.   
 
SYMBOL GENE NAME TYPE 
GPHN Gephyrin Induced 
GRSF1 G-rich RNA sequence binding factor 1 Induced 
H2AFV H2A histone family, member V Induced 
H2AFX H2A histone family, member X Induced 
HDAC1 histone deacetylase 1 Induced 
HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 Induced 
HES1 hes family bHLH transcription factor 1 Induced 
HGS hepatocyte growth factor-regulated tyrosine kinase substrate Induced 
HIST3H3 histone cluster 3, H3 Induced 
HNRNPA
1 heterogeneous nuclear ribonucleoprotein A1 Induced 
HNRNPF heterogeneous nuclear ribonucleoprotein F Induced 
HRAS Harvey rat sarcoma viral oncogene homolog Induced 
HS1BP3 HCLS1 binding protein 3 Input 
HSP90A
A1 
heat shock protein 90kDa alpha (cytosolic), class A 
member 1 Induced 
HSP90A
B1 
heat shock protein 90kDa alpha (cytosolic), class B 
member 1 Induced 
HSP90B
1 heat shock protein 90kDa beta (Grp94), member 1 Induced 
HSPA12
A heat shock 70kDa protein 12A Input 
HSPA4 heat shock 70kDa protein 4 Induced 
HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) Induced 
HSPA9 heat shock 70kDa protein 9 (mortalin) Induced 
HSPB1 heat shock 27kDa protein 1 Induced 
HTT Huntingtin Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
HUWE1 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase Induced 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein Input 
IGBP1 immunoglobulin (CD79A) binding protein 1 Induced 
IGF1R insulin-like growth factor 1 receptor Induced 
IGFBP3 insulin-like growth factor binding protein 3 Induced 
IKBKAP inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein Induced 
IMPA1 inositol(myo)-1(or 4)-monophosphatase 1 Input 
INVS Inversin Input 
IQGAP1 IQ motif containing GTPase activating protein 1 Induced 
IRS1 insulin receptor substrate 1 Induced 
IRS2 insulin receptor substrate 2 Induced 
IRS4 insulin receptor substrate 4 Induced 
ITCH itchy E3 ubiquitin protein ligase Induced 
KCTD9 potassium channel tetramerization domain containing 9 Input 
KEAP1 kelch-like ECH-associated protein 1 Induced 
KNG1 kininogen 1 Induced 
KRAS Kirsten rat sarcoma viral oncogene homolog Induced 
KYNU Kynureninase Input 
LAMTOR
3 
late endosomal/lysosomal adaptor, MAPK and MTOR 
activator 3 Induced 
LDHA lactate dehydrogenase A Induced 
LDHAL6
B lactate dehydrogenase A-like 6B Induced 
LIG3 ligase III, DNA, ATP-dependent Input 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
LIN7C lin-7 homolog C (C. elegans) Induced 
LRRK2 leucine-rich repeat kinase 2 Induced 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) Induced 
MAGOH mago homolog, exon junction complex core component Induced 
MAP1LC3
A microtubule-associated protein 1 light chain 3 alpha Induced 
MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase Induced 
MAP3K3 mitogen-activated protein kinase kinase kinase 3 Induced 
MAP3K5 mitogen-activated protein kinase kinase kinase 5 Induced 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 
4 
Induced 
MAPK1 mitogen-activated protein kinase 1 Induced 
MAPT microtubule-associated protein tau Induced 
MARK2 MAP/microtubule affinity-regulating kinase 2 Induced 
MAVS mitochondrial antiviral signaling protein Induced 
MDC1 mediator of DNA-damage checkpoint 1 Induced 
MET MET proto-oncogene, receptor tyrosine kinase Induced 
MID1IP1 MID1 interacting protein 1 Input 
MINOS1 mitochondrial inner membrane organizing system 1 Induced 
MLH3 mutL homolog 3 Induced 
MRPS7 mitochondrial ribosomal protein S7 Induced 
MSH2 mutS homolog 2 Induced 
MSI1 musashi RNA-binding protein 1 Induced 
MSI2 musashi RNA-binding protein 2 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
MTMR9 myotubularin related protein 9 Input 
MTOR mechanistic target of rapamycin (serine/threonine kinase) Induced 
MVP major vault protein Induced 
MYH11 myosin, heavy chain 11, smooth muscle Induced 
MYH9 myosin, heavy chain 9, non-muscle Induced 
NAGK N-acetylglucosamine kinase Induced 
NCOA3 nuclear receptor coactivator 3 Induced 
NDFIP1 Nedd4 family interacting protein 1 Induced 
NDFIP2 Nedd4 family interacting protein 2 Induced 
NEDD4 neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase Induced 
NEDD8 neural precursor cell expressed, developmentally down-regulated 8 Induced 
NMI N-myc (and STAT) interactor Induced 
NOTCH1 notch 1 Induced 
NOTCH2 notch 2 Induced 
NOTCH3 notch 3 Induced 
NR3C1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) Induced 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog Induced 
NRG1 neuregulin 1 Input 
NSF N-ethylmaleimide-sensitive factor Induced 
NSMCE2 NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase Induced 
NUBP2 nucleotide binding protein 2 Input 
NUDT21 nudix (nucleoside diphosphate linked moiety X)-type motif 21 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.   
 
SYMBOL GENE NAME TYPE 
NUP153 nucleoporin 153kDa Induced 
NXF1 nuclear RNA export factor 1 Induced 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Induced 
PABPC4 poly(A) binding protein, cytoplasmic 4 (inducible form) Induced 
PARP1 poly (ADP-ribose) polymerase 1 Induced 
PBK PDZ binding kinase Input 
PCNA proliferating cell nuclear antigen Induced 
PDGFRB platelet-derived growth factor receptor, beta polypeptide Induced 
PEX19 peroxisomal biogenesis factor 19 Induced 
PEX5 peroxisomal biogenesis factor 5 Induced 
PFAS phosphoribosylformylglycinamidine synthase Input 
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha Induced 
PIP5K1A phosphatidylinositol-4-phosphate 5-kinase, type I, alpha Induced 
PLK1 polo-like kinase 1 Induced 
PLK2 polo-like kinase 2 Induced 
PLK3 polo-like kinase 3 Induced 
PLK4 polo-like kinase 4 Induced 
PLK5 polo-like kinase 5 Induced 
PML promyelocytic leukemia Induced 
PMP22 peripheral myelin protein 22 Input 
POLB polymerase (DNA directed), beta Induced 
POLR1C polymerase (RNA) I polypeptide C, 30kDa Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.   
 
SYMBOL GENE NAME TYPE 
POMZP3 POM121 and ZP3 fusion Input 
PPP2CA protein phosphatase 2, catalytic subunit, alpha isozyme Induced 
PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme Induced 
PPP3CC protein phosphatase 3, catalytic subunit, gamma isozyme Input 
PRDX1 peroxiredoxin 1 Induced 
PRKACA protein kinase, cAMP-dependent, catalytic, alpha Induced 
PRKCA protein kinase C, alpha Induced 
PRKCB protein kinase C, beta Induced 
PRKCD protein kinase C, delta Induced 
PRKCZ protein kinase C, zeta Induced 
PRKD1 protein kinase D1 Induced 
PRKDC protein kinase, DNA-activated, catalytic polypeptide Induced 
PROCR protein C receptor, endothelial Input 
PSMA2 proteasome subunit alpha 2 Induced 
PSMA3 proteasome subunit alpha 3 Induced 
PSMA4 proteasome subunit alpha 4 Induced 
PSMA7 proteasome subunit alpha 7 Induced 
PSMA8 proteasome subunit alpha 8 Induced 
PSMB1 proteasome subunit beta 1 Induced 
PSMB2 proteasome subunit beta 2 Induced 
PSMB4 proteasome subunit beta 4 Induced 
PSMD4 proteasome 26S subunit, non-ATPase 4 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
PSMD6 proteasome 26S subunit, non-ATPase 6 Induced 
PTEN phosphatase and tensin homolog Input 
PTK2 protein tyrosine kinase 2 Induced 
PTMA prothymosin, alpha, prothymosin alpha-like Induced 
PTPN1 protein tyrosine phosphatase, non-receptor type 1 Induced 
PTPN11 protein tyrosine phosphatase, non-receptor type 11 Induced 
PWP1 PWP1 homolog, endonuclein Input 
RAB11A RAB11A, member RAS oncogene family Induced 
RAB11B RAB11B, member RAS oncogene family Induced 
RAB11FI
P2 RAB11 family interacting protein 2 (class I) Input 
RAB7A RAB7A, member RAS oncogene family Induced 
RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) Induced 
RAD23B RAD23 homolog B, nucleotide excision repair protein Induced 
RAD51 RAD51 recombinase Induced 
RAF1 Raf-1 proto-oncogene, serine/threonine kinase Induced 
RAN RAN, member RAS oncogene family Induced 
RANGRF RAN guanine nucleotide release factor Input 
RASA1 RAS p21 protein activator (GTPase activating protein) 1 Induced 
RBM3 RNA binding motif (RNP1, RRM) protein 3 Input 
RBX1 ring-box 1, E3 ubiquitin protein ligase Induced 
RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 Induced 
RNMTL1 RNA methyltransferase like 1 Input 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
RPL17 ribosomal protein L17 Induced 
RPL5 ribosomal protein L5 Induced 
RPS20 ribosomal protein S20 Induced 
RPS23 ribosomal protein S23 Induced 
RPS27A ribosomal protein S27a Induced 
RPS7 ribosomal protein S7 Induced 
RPTOR regulatory associated protein of MTOR, complex 1 Induced 
RQCD1 RCD1 required for cell differentiation1 homolog (S. pombe) Induced 
RUVBL1 RuvB-like AAA ATPase 1 Induced 
S100A1 S100 calcium binding protein A1 Induced 
S100A3 S100 calcium binding protein A3 Input 
S100B S100 calcium binding protein B Induced 
SACS sacsin molecular chaperone Input 
SEC23A Sec23 homolog A, COPII coat complex component Induced 
SGTA small glutamine-rich tetratricopeptide repeat (407)-containing, alpha Induced 
SHARPI
N SHANK-associated RH domain interactor Induced 
SIN3A SIN3 transcription regulator family member A Induced 
SIRT1 sirtuin 1 Induced 
SKP1 S-phase kinase-associated protein 1 Induced 
SLC25A3 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 Induced 
SLC9A3
R1 
solute carrier family 9, subfamily A (NHE3, cation 
proton antiporter 3), member 3 regulator 1 Induced 
SMAD1 SMAD family member 1 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
SMAD 2 SMAD family member 2 Induced 
SMAD 3 SMAD family member 3 Induced 
SMAD 4 SMAD family member 4 Induced 
SMC1A structural maintenance of chromosomes 1A Input 
SMS spermine synthase Induced 
SMURF1 SMAD specific E3 ubiquitin protein ligase 1 Induced 
SNCA synuclein, alpha (non A4 component of amyloid precursor) Induced 
SNRPA small nuclear ribonucleoprotein polypeptide A Induced 
SPTAN1 spectrin, alpha, non-erythrocytic 1 Induced 
SRC SRC proto-oncogene, non-receptor tyrosine kinase Induced 
SSU72 SSU72 homolog, RNA polymerase II CTD phosphatase Induced 
STAT5A signal transducer and activator of transcription 5A Induced 
STUB1 STIP1 homology and U-box containing protein 1, E3 ubiquitin protein ligase Induced 
STX2 syntaxin 2 Input 
SUMO1 small ubiquitin-like modifier 1 Induced 
SUMO2 small ubiquitin-like modifier 2 Induced 
SUMO3 small ubiquitin-like modifier 3 Induced 
TCP1 t-complex 1 Induced 
TERT telomerase reverse transcriptase Induced 
TFE3 transcription factor binding to IGHM enhancer 3 Input 
TJP1 tight junction protein 1 Induced 
TLR4 toll-like receptor 4 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A Induced 
TNFSF9 tumor necrosis factor (ligand) superfamily, member 9 Input 
TNPO1 transportin 1 Input 
TOM1L1 target of myb1 like 1 membrane trafficking protein Induced 
TOMM40 translocase of outer mitochondrial membrane 40 homolog (yeast) Induced 
TOP2A topoisomerase (DNA) II alpha Induced 
TOP2B topoisomerase (DNA) II beta Induced 
TOP3B topoisomerase (DNA) III beta Induced 
TP53 tumor protein p53 Induced 
TP53BP1 tumor protein p53 binding protein 1 Induced 
TPR translocated promoter region, nuclear basket protein Induced 
TRAF1 TNF receptor-associated factor 1 Induced 
TRAF2 TNF receptor-associated factor 2 Induced 
TTC28 tetratricopeptide repeat domain 28 Input 
TUBA1A tubulin, alpha 1a Induced 
TUBA4A tubulin, alpha 4a Induced 
TUBGCP2 tubulin, gamma complex associated protein 2 Input 
TUBGCP4 tubulin, gamma complex associated protein 4 Induced 
TXN Thioredoxin Induced 
UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 Induced 
UBB ubiquitin B Induced 
UBC ubiquitin C Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
UBE2D1 ubiquitin-conjugating enzyme E2D 1 Induced 
UBE2D2 ubiquitin-conjugating enzyme E2D 2 Induced 
UBE2I ubiquitin-conjugating enzyme E2I Induced 
UBE2L3 ubiquitin-conjugating enzyme E2L 3 Induced 
UBE2N ubiquitin-conjugating enzyme E2N Induced 
UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 Induced 
UBL4A ubiquitin-like 4A Induced 
UBQLN1 ubiquilin 1 Induced 
UBQLN2 ubiquilin 2 Induced 
UBQLN4 ubiquilin 4 Induced 
UBQLNL ubiquilin-like Induced 
UBR4 ubiquitin protein ligase E3 component n-recognin 4 Induced 
UBR7 ubiquitin protein ligase E3 component n-recognin 7 (putative) Induced 
UBXN7 UBX domain protein 7 Induced 
UCHL3 ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) Induced 
UIMC1 ubiquitin interaction motif containing 1 Input 
USP10 ubiquitin specific peptidase 10 Induced 
USP14 ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase) Induced 
USP34 ubiquitin specific peptidase 34 Induced 
USP39 ubiquitin specific peptidase 39 Induced 
USP7 ubiquitin specific peptidase 7 (herpes virus-associated) Induced 
USP8 ubiquitin specific peptidase 8 Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
USP9X ubiquitin specific peptidase 9, X-linked Input 
UVRAG UV radiation resistance associated Induced 
VIM Vimentin Input 
VPS16 vacuolar protein sorting 16 homolog (S. cerevisiae) Induced 
VPS33B vacuolar protein sorting 33 homolog B (yeast) Input 
WASL Wiskott-Aldrich syndrome-like Induced 
WDHD1 WD repeat and HMG-box DNA binding protein 1 Induced 
WDR48 WD repeat domain 48 Induced 
WRN Werner syndrome, RecQ helicase-like Input 
WWP1 WW domain containing E3 ubiquitin protein ligase 1 Induced 
WWP2 WW domain containing E3 ubiquitin protein ligase 2 Induced 
XIAP X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase Induced 
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining) Induced 
XRCC6 X-ray repair complementing defective repair in Chinese hamster cells 6 Induced 
YAP1 Yes-associated protein 1 Induced 
YBX1 Y box binding protein 1 Induced 
YEATS4 YEATS domain containing 4 Induced 
YKT6 YKT6 v-SNARE homolog (S. cerevisiae) Induced 
YWHAB tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta Induced 
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon Induced 
YWHAH tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta Induced 
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Supplementary Table II-3 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members.  
 
SYMBOL GENE NAME TYPE 
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta Induced 
ZC3H14 zinc finger CCCH-type containing 14 Input 
ZEB1 zinc finger E-box binding homeobox 1 Input 
ZYX Zyxin Induced 
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Supplementary Table II-4: G1-X-G2 Analysis-Induced EGFRI Resistance Network 
Members that interact with CK2α or CK2α’ within one edge. Table members were 
generated using the 85 independent Ensembl IDs identified by the FS analysis. Table 
members generated by the STRING analysis considering the scenario G1-X-G2 where 
G1 and G2 are from the original list of 85 Ensembl IDs of mRNA found to be upregulated 
in EGFRI resistant NSCLC cells and X is any other node that connects them. Table 
members are from the complete network of 385 proteins that interact with CK2α or CK2α’ 
within one edge. 
 
SYMBOL GENE NAME TYPE 
AKT1 v-akt murine thymoma viral oncogene homolog 1 Induced 
APC adenomatous polyposis coli Induced 
ARRB2 arrestin, beta 2 Induced 
BRCA1 breast cancer 1, early onset Induced 
CALM1:CALM2 calmodulin 1 (phosphorylase kinase, delta), calmodulin 2 (phosphorylase kinase, delta) Induced 
CAV1 caveolin 1, caveolae protein, 22kDa Induced 
CDC37 cell division cycle 37 Induced 
CDH1 cadherin 1, type 1 Induced 
CDK1 cyclin-dependent kinase 1 Induced 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) Induced 
CHUK conserved helix-loop-helix ubiquitous kinase Input 
CREBBP CREB binding protein Induced 
CSNK2A1 casein kinase 2, alpha 1 polypeptide Induced 
CSNK2A2 casein kinase 2, alpha prime polypeptide Induced 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa Induced 
DVL2 dishevelled segment polarity protein 2 Induced 
H2AFX H2A histone family, member X Induced 
HDAC1 histone deacetylase 1 Induced 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 Induced 
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Supplementary Table II-4 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one edge. Table members 
were generated using the 85 independent Ensembl IDs identified by the FS analysis. 
Table members generated by the STRING analysis considering the scenario G1-X-G2 
where G1 and G2 are from the original list of 85 Ensembl IDs of mRNA found to be 
upregulated in EGFRI resistant NSCLC cells and X is any other node that connects them. 
Table members are from the complete network of 385 proteins that interact with CK2α or 
CK2α’ within one edge. 
 
SYMBOL GENE NAME TYPE 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B member 1 Induced 
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 Induced 
HSPA4 heat shock 70kDa protein 4 Induced 
IGFBP3 insulin-like growth factor binding protein 3 Induced 
IRS1 insulin receptor substrate 1 Induced 
ITCH itchy E3 ubiquitin protein ligase Induced 
MAP1LC3A microtubule-associated protein 1 light chain 3 alpha Induced 
MAPT microtubule-associated protein tau Induced 
MYH9 myosin, heavy chain 9, non-muscle Induced 
PBK PDZ binding kinase Input 
PML promyelocytic leukemia Induced 
PRKDC protein kinase, DNA-activated, catalytic polypeptide Induced 
PSMA3 proteasome subunit alpha 3 Induced 
PSMA4 proteasome subunit alpha 4 Induced 
PTEN phosphatase and tensin homolog Input 
PTPN1 protein tyrosine phosphatase, non-receptor type 1 Induced 
RPL5 ribosomal protein L5 Induced 
SIN3A SIN3 transcription regulator family member A Induced 
SIRT1 sirtuin 1 Induced 
SNCA synuclein, alpha (non A4 component of amyloid precursor) Induced 
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Supplementary Table II-4 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one edge. Table members 
were generated using the 85 independent Ensembl IDs identified by the FS analysis. 
Table members generated by the STRING analysis considering the scenario G1-X-G2 
where G1 and G2 are from the original list of 85 Ensembl IDs of mRNA found to be 
upregulated in EGFRI resistant NSCLC cells and X is any other node that connects them. 
Table members are from the complete network of 385 proteins that interact with CK2α or 
CK2α’ within one edge. 
 
SYMBOL GENE NAME TYPE 
SRC SRC proto-oncogene, non-receptor tyrosine kinase Induced 
TOP2A topoisomerase (DNA) II alpha Induced 
TOP2B topoisomerase (DNA) II beta Induced 
TP53 tumor protein p53 Induced 
UBC ubiquitin C Induced 
WDR48 WD repeat domain 48 Induced 
XRCC5 
X-ray repair complementing defective repair in 
Chinese hamster cells 5 (double-strand-break 
rejoining) 
Induced 
XRCC6 X-ray repair complementing defective repair in Chinese hamster cells 6 Induced 
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Supplementary Table II-5: G1-X-G2 Analysis-Induced EGFRI Resistance Network 
Members that interact with CK2α or CK2α’ within one or two edges. Table members 
were generated using the 85 independent Ensembl IDs identified by the FS analysis. 
Table members generated by the STRING analysis considering the scenario G1-X-G2 
where G1 and G2 are from the original list of 85 Ensembl IDs of mRNA found to be 
upregulated in EGFRI resistant NSCLC cells and X is any other node that connects them. 
Table members are from the complete network of 385 proteins that interact with CK2α or 
CK2α’ within one or two edges. 
 
SYMBOL GENE NAME TYPE 
ACACB acetyl-CoA carboxylase beta Induced 
ACTA1 actin, alpha 1, skeletal muscle Induced 
ACTA2 actin, alpha 2, smooth muscle, aorta Input 
ADCY9 adenylate cyclase 9 Input 
ADSS adenylosuccinate synthase Induced 
AKT1 v-akt murine thymoma viral oncogene homolog 1 Induced 
AKT2 v-akt murine thymoma viral oncogene homolog 2 Induced 
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 Input 
ANGEL2 angel homolog 2 (Drosophila) Input 
ANXA6 annexin A6 Input 
AP2A1 adaptor-related protein complex 2, alpha 1 subunit Induced 
APC adenomatous polyposis coli Induced 
AR androgen receptor Induced 
ARHGEF40 Rho guanine nucleotide exchange factor (406) 40 Input 
ARRB2 arrestin, beta 2 Induced 
ATM ATM serine/threonine kinase Induced 
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 Induced 
ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9) Input 
AURKA aurora kinase A Induced 
BABAM1 BRISC and BRCA1 A complex member 1 Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
BARD1 BRCA1 associated RING domain 1 Induced 
BCCIP BRCA2 and CDKN1A interacting protein Input 
BCL2 B-cell CLL/lymphoma 2 Induced 
BIRC2 baculoviral IAP repeat containing 2 Induced 
BIRC3 baculoviral IAP repeat containing 3 Induced 
BLM Bloom syndrome, RecQ helicase-like Induced 
BRCA1 breast cancer 1, early onset Induced 
BRCC3 BRCA1/BRCA2-containing complex, subunit 3 Input 
BRE brain and reproductive organ-expressed (TNFRSF1A modulator) Induced 
BTRC beta-transducin repeat containing E3 ubiquitin protein ligase Induced 
C1QBP complement component 1, q subcomponent binding protein Input 
CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase Induced 
CALM1:C
ALM2 
calmodulin 1 (phosphorylase kinase, delta), calmodulin 
2 (phosphorylase kinase, delta) Induced 
CALM2 calmodulin 2 (phosphorylase kinase, delta) Induced 
CAMK1 calcium/calmodulin-dependent protein kinase I Input 
CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 Induced 
CAPZB capping protein (actin filament) muscle Z-line, beta Induced 
CASP8 caspase 8, apoptosis-related cysteine peptidase Induced 
CAV1 caveolin 1, caveolae protein, 22kDa Induced 
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase Induced 
CCND1 cyclin D1 Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
CCT4 chaperonin containing TCP1, subunit 4 (delta) Induced 
CD2AP CD2-associated protein Induced 
CDC37 cell division cycle 37 Induced 
CDH1 cadherin 1, type 1 Induced 
CDK1 cyclin-dependent kinase 1 Induced 
CDK2 cyclin-dependent kinase 2 Induced 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) Induced 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) Induced 
CFL1 cofilin 1 (non-muscle) Induced 
CHAF1A chromatin assembly factor 1, subunit A (p150) Induced 
CHORDC
1 
cysteine and histidine-rich domain (CHORD) 
containing 1 Induced 
CHUK conserved helix-loop-helix ubiquitous kinase Input 
CKAP5 cytoskeleton associated protein 5 Induced 
CNOT4 CCR4-NOT transcription complex, subunit 4 Induced 
COPS5 COP9 signalosome subunit 5 Induced 
COX15 cytochrome c oxidase assembly homolog 15 (yeast) Input 
CREBBP CREB binding protein Induced 
CRTAP cartilage associated protein Input 
CSE1L CSE1 chromosome segregation 1-like (yeast) Induced 
CSNK2A1 casein kinase 2, alpha 1 polypeptide Induced 
CSNK2A2 casein kinase 2, alpha prime polypeptide Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa Induced 
CTSL cathepsin L Input 
CUL1 cullin 1 Induced 
CUTC cutC copper transporter Input 
DARS2 aspartyl-tRNA synthetase 2, mitochondrial Input 
DAZAP1 DAZ associated protein 1 Induced 
DCP2 decapping mRNA 2 Induced 
DIP2C disco-interacting protein 2 homolog C Input 
DIXDC1 DIX domain containing 1 Input 
DKC1 dyskeratosis congenita 1, dyskerin Induced 
DLG1 discs, large homolog 1 (Drosophila) Induced 
DOCK10 dedicator of cytokinesis 10 Input 
DPYSL3 dihydropyrimidinase-like 3 Input 
DVL2 dishevelled segment polarity protein 2 Induced 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 Induced 
EGFR epidermal growth factor receptor Input 
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Induced 
EIF3A eukaryotic translation initiation factor 3, subunit A Input 
EIF4A3 eukaryotic translation initiation factor 4A3 Induced 
ELAVL1 ELAV like RNA binding protein 1 Induced 
EP300 E1A binding protein p300 Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
EPN1 epsin 1 Induced 
EPS15 epidermal growth factor receptor pathway substrate 15 Induced 
ERBB2 erb-b2 receptor tyrosine kinase 2 Induced 
ERBB3 erb-b2 receptor tyrosine kinase 3 Induced 
ERBB4 erb-b2 receptor tyrosine kinase 4 Induced 
ERP44 endoplasmic reticulum protein 44 Induced 
ESR1 estrogen receptor 1 Induced 
EXOSC1
0 exosome component 10 Induced 
FAM175
A family with sequence similarity 175, member A Induced 
FAM175
B family with sequence similarity 175, member B Induced 
FANCA Fanconi anemia, complementation group A Induced 
FANCG Fanconi anemia, complementation group G Induced 
FANCM Fanconi anemia, complementation group M Induced 
FASTKD
1 FAST kinase domains 1 Input 
FBXL15 F-box and leucine-rich repeat protein 15 Input 
FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase Induced 
GAPDH glyceraldehyde-3-phosphate dehydrogenase Induced 
GDA guanine deaminase Induced 
GLRX glutaredoxin (thioltransferase) Input 
GNS glucosamine (N-acetyl)-6-sulfatase Induced 
GPHN Gephyrin Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
GRSF1 G-rich RNA sequence binding factor 1 Induced 
H2AFV H2A histone family, member V Induced 
H2AFX H2A histone family, member X Induced 
HDAC1 histone deacetylase 1 Induced 
HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 Induced 
HES1 hes family bHLH transcription factor 1 Induced 
HGS hepatocyte growth factor-regulated tyrosine kinase substrate Induced 
HIST3H3 histone cluster 3, H3 Induced 
HNRNPA
1 heterogeneous nuclear ribonucleoprotein A1 Induced 
HNRNPF heterogeneous nuclear ribonucleoprotein F Induced 
HRAS Harvey rat sarcoma viral oncogene homolog Induced 
HS1BP3 HCLS1 binding protein 3 Input 
HSP90A
A1 
heat shock protein 90kDa alpha (cytosolic), class A 
member 1 Induced 
HSP90A
B1 
heat shock protein 90kDa alpha (cytosolic), class B 
member 1 Induced 
HSP90B
1 heat shock protein 90kDa beta (Grp94), member 1 Induced 
HSPA12
A heat shock 70kDa protein 12A Input 
HSPA4 heat shock 70kDa protein 4 Induced 
HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) Induced 
HSPA9 heat shock 70kDa protein 9 (mortalin) Induced 
HSPB1 heat shock 27kDa protein 1 Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
HTT Huntingtin Induced 
HUWE1 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase Induced 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein Input 
IGBP1 immunoglobulin (CD79A) binding protein 1 Induced 
IGF1R insulin-like growth factor 1 receptor Induced 
IGFBP3 insulin-like growth factor binding protein 3 Induced 
IKBKAP inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein Induced 
IMPA1 inositol(myo)-1(or 4)-monophosphatase 1 Input 
INVS Inversin Input 
IQGAP1 IQ motif containing GTPase activating protein 1 Induced 
IRS1 insulin receptor substrate 1 Induced 
IRS2 insulin receptor substrate 2 Induced 
IRS4 insulin receptor substrate 4 Induced 
ITCH itchy E3 ubiquitin protein ligase Induced 
KCTD9 potassium channel tetramerization domain containing 9 Input 
KEAP1 kelch-like ECH-associated protein 1 Induced 
KRAS Kirsten rat sarcoma viral oncogene homolog Induced 
KYNU Kynureninase Input 
LAMTOR
3 
late endosomal/lysosomal adaptor, MAPK and MTOR 
activator 3 Induced 
LDHA lactate dehydrogenase A Induced 
LIG3 ligase III, DNA, ATP-dependent Input 
LIN7C lin-7 homolog C (C. elegans) Induced 
LRRK2 leucine-rich repeat kinase 2 Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) Induced 
MAGOH mago homolog, exon junction complex core component Induced 
MAP1LC3A microtubule-associated protein 1 light chain 3 alpha Induced 
MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase Induced 
MAP3K3 mitogen-activated protein kinase kinase kinase 3 Induced 
MAP3K5 mitogen-activated protein kinase kinase kinase 5 Induced 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 Induced 
MAPK1 mitogen-activated protein kinase 1 Induced 
MAPT microtubule-associated protein tau Induced 
MARK2 MAP/microtubule affinity-regulating kinase 2 Induced 
MAVS mitochondrial antiviral signaling protein Induced 
MDC1 mediator of DNA-damage checkpoint 1 Induced 
MET MET proto-oncogene, receptor tyrosine kinase Induced 
MID1IP1 MID1 interacting protein 1 Input 
MLH3 mutL homolog 3 Induced 
MRPS7 mitochondrial ribosomal protein S7 Induced 
MSH2 mutS homolog 2 Induced 
MSI1 musashi RNA-binding protein 1 Induced 
MSI2 musashi RNA-binding protein 2 Induced 
MTMR9 myotubularin related protein 9 Input 
MTOR mechanistic target of rapamycin (serine/threonine kinase) Induced 
MVP major vault protein Induced 
MYH11 myosin, heavy chain 11, smooth muscle Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
MYH9 myosin, heavy chain 9, non-muscle Induced 
NAGK N-acetylglucosamine kinase Induced 
NCOA3 nuclear receptor coactivator 3 Induced 
NDFIP1 Nedd4 family interacting protein 1 Induced 
NDFIP2 Nedd4 family interacting protein 2 Induced 
NEDD4 neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase Induced 
NEDD8 neural precursor cell expressed, developmentally down-regulated 8 Induced 
NMI N-myc (and STAT) interactor Induced 
NOTCH1 notch 1 Induced 
NOTCH2 notch 2 Induced 
NOTCH3 notch 3 Induced 
NR3C1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) Induced 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog Induced 
NSF N-ethylmaleimide-sensitive factor Induced 
NSMCE2 NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase Induced 
NUDT21 nudix (nucleoside diphosphate linked moiety X)-type motif 21 Induced 
NUP153 nucleoporin 153kDa Induced 
NXF1 nuclear RNA export factor 1 Induced 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Induced 
PABPC4 poly(A) binding protein, cytoplasmic 4 (inducible form) Induced 
PARP1 poly (ADP-ribose) polymerase 1 Induced 
PBK PDZ binding kinase Input 
PCNA proliferating cell nuclear antigen Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
 
SYMBOL 
GENE NAME TYPE 
PDGFRB platelet-derived growth factor receptor, beta polypeptide Induced 
PEX19 peroxisomal biogenesis factor 19 Induced 
PEX5 peroxisomal biogenesis factor 5 Induced 
PFAS phosphoribosylformylglycinamidine synthase Input 
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha Induced 
PIP5K1A phosphatidylinositol-4-phosphate 5-kinase, type I, alpha Induced 
PLK1 polo-like kinase 1 Induced 
PLK2 polo-like kinase 2 Induced 
PLK3 polo-like kinase 3 Induced 
PLK4 polo-like kinase 4 Induced 
PML promyelocytic leukemia Induced 
POLB polymerase (DNA directed), beta Induced 
POLR1C polymerase (RNA) I polypeptide C, 30kDa Induced 
POMZP3 POM121 and ZP3 fusion Input 
PPP2CA protein phosphatase 2, catalytic subunit, alpha isozyme Induced 
PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme Induced 
PPP3CC protein phosphatase 3, catalytic subunit, gamma isozyme Input 
PRDX1 peroxiredoxin 1 Induced 
PRKACA protein kinase, cAMP-dependent, catalytic, alpha Induced 
PRKCA protein kinase C, alpha Induced 
PRKCB protein kinase C, beta Induced 
PRKCD protein kinase C, delta Induced 
PRKCZ protein kinase C, zeta Induced 
PRKD1 protein kinase D1 Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
PRKDC protein kinase, DNA-activated, catalytic polypeptide Induced 
PROCR protein C receptor, endothelial Input 
PSMA2 proteasome subunit alpha 2 Induced 
PSMA3 proteasome subunit alpha 3 Induced 
PSMA4 proteasome subunit alpha 4 Induced 
PSMA7 proteasome subunit alpha 7 Induced 
PSMA8 proteasome subunit alpha 8 Induced 
PSMB1 proteasome subunit beta 1 Induced 
PSMB2 proteasome subunit beta 2 Induced 
PSMB4 proteasome subunit beta 4 Induced 
PSMD4 proteasome 26S subunit, non-ATPase 4 Induced 
PSMD6 proteasome 26S subunit, non-ATPase 6 Induced 
PTEN phosphatase and tensin homolog Input 
PTK2 protein tyrosine kinase 2 Induced 
PTMA prothymosin, alpha, prothymosin alpha-like Induced 
PTPN1 protein tyrosine phosphatase, non-receptor type 1 Induced 
PTPN11 protein tyrosine phosphatase, non-receptor type 11 Induced 
PWP1 PWP1 homolog, endonuclein Input 
RAB11A RAB11A, member RAS oncogene family Induced 
RAB11B RAB11B, member RAS oncogene family Induced 
RAB7A RAB7A, member RAS oncogene family Induced 
RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) Induced 
RAD23B RAD23 homolog B, nucleotide excision repair protein Induced 
RAD51 RAD51 recombinase Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
RAF1 Raf-1 proto-oncogene, serine/threonine kinase Induced 
RAN RAN, member RAS oncogene family Induced 
RANGRF RAN guanine nucleotide release factor Input 
RASA1 RAS p21 protein activator (GTPase activating protein) 1 Induced 
RBM3 RNA binding motif (RNP1, RRM) protein 3 Input 
RBX1 ring-box 1, E3 ubiquitin protein ligase Induced 
RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 Induced 
RPL17 ribosomal protein L17 Induced 
RPL5 ribosomal protein L5 Induced 
RPS20 ribosomal protein S20 Induced 
RPS23 ribosomal protein S23 Induced 
RPS27A ribosomal protein S27a Induced 
RPS7 ribosomal protein S7 Induced 
RPTOR regulatory associated protein of MTOR, complex 1 Induced 
RQCD1 RCD1 required for cell differentiation1 homolog (S. pombe) Induced 
RUVBL1 RuvB-like AAA ATPase 1 Induced 
S100A1 S100 calcium binding protein A1 Induced 
S100B S100 calcium binding protein B Induced 
SACS sacsin molecular chaperone Input 
SEC23A Sec23 homolog A, COPII coat complex component Induced 
SGTA small glutamine-rich tetratricopeptide repeat (407)-containing, alpha Induced 
SHARPI
N SHANK-associated RH domain interactor Induced 
SIN3A SIN3 transcription regulator family member A Induced 
SIRT1 sirtuin 1 Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
SKP1 S-phase kinase-associated protein 1 Induced 
SLC25A3 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 Induced 
SLC9A3R
1 
solute carrier family 9, subfamily A (NHE3, cation 
proton antiporter 3), member 3 regulator 1 Induced 
SMAD1 SMAD family member 1 Induced 
SMAD 2 SMAD family member 2 Induced 
SMAD 3 SMAD family member 3 Induced 
SMAD 4 SMAD family member 4 Induced 
SMC1A structural maintenance of chromosomes 1A Input 
SMS spermine synthase Induced 
SMURF1 SMAD specific E3 ubiquitin protein ligase 1 Induced 
SNCA synuclein, alpha (non A4 component of amyloid precursor) Induced 
SNRPA small nuclear ribonucleoprotein polypeptide A Induced 
SPTAN1 spectrin, alpha, non-erythrocytic 1 Induced 
SRC SRC proto-oncogene, non-receptor tyrosine kinase Induced 
SSU72 SSU72 homolog, RNA polymerase II CTD phosphatase Induced 
STAT5A signal transducer and activator of transcription 5A Induced 
STUB1 STIP1 homology and U-box containing protein 1, E3 ubiquitin protein ligase Induced 
STX2 syntaxin 2 Input 
SUMO1 small ubiquitin-like modifier 1 Induced 
SUMO2 small ubiquitin-like modifier 2 Induced 
SUMO3 small ubiquitin-like modifier 3 Induced 
TCP1 t-complex 1 Induced 
TERT telomerase reverse transcriptase Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
TJP1 tight junction protein 1 Induced 
TLR4 toll-like receptor 4 Induced 
TNFRSF1
A 
tumor necrosis factor receptor superfamily, member 
1A Induced 
TNPO1 transportin 1 Input 
TOM1L1 target of myb1 like 1 membrane trafficking protein Induced 
TOMM40 translocase of outer mitochondrial membrane 40 homolog (yeast) Induced 
TOP2A topoisomerase (DNA) II alpha Induced 
TOP2B topoisomerase (DNA) II beta Induced 
TOP3B topoisomerase (DNA) III beta Induced 
TP53 tumor protein p53 Induced 
TP53BP1 tumor protein p53 binding protein 1 Induced 
TPR translocated promoter region, nuclear basket protein Induced 
TRAF1 TNF receptor-associated factor 1 Induced 
TRAF2 TNF receptor-associated factor 2 Induced 
TTC28 tetratricopeptide repeat domain 28 Input 
TUBA1A tubulin, alpha 1a Induced 
TUBA4A tubulin, alpha 4a Induced 
TUBGCP
2 tubulin, gamma complex associated protein 2 Input 
TUBGCP
4 tubulin, gamma complex associated protein 4 Induced 
TXN Thioredoxin Induced 
UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 Induced 
UBB ubiquitin B Induced 
UBC ubiquitin C Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
UBE2D1 ubiquitin-conjugating enzyme E2D 1 Induced 
UBE2D2 ubiquitin-conjugating enzyme E2D 2 Induced 
UBE2I ubiquitin-conjugating enzyme E2I Induced 
UBE2L3 ubiquitin-conjugating enzyme E2L 3 Induced 
UBE2N ubiquitin-conjugating enzyme E2N Induced 
UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 Induced 
UBL4A ubiquitin-like 4A Induced 
UBQLN1 ubiquilin 1 Induced 
UBQLN2 ubiquilin 2 Induced 
UBQLN4 ubiquilin 4 Induced 
UBQLNL ubiquilin-like Induced 
UBR4 ubiquitin protein ligase E3 component n-recognin 4 Induced 
UBR7 ubiquitin protein ligase E3 component n-recognin 7 (putative) Induced 
UBXN7 UBX domain protein 7 Induced 
UCHL3 ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) Induced 
UIMC1 ubiquitin interaction motif containing 1 Input 
USP10 ubiquitin specific peptidase 10 Induced 
USP14 ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase) Induced 
USP34 ubiquitin specific peptidase 34 Induced 
USP39 ubiquitin specific peptidase 39 Induced 
USP7 ubiquitin specific peptidase 7 (herpes virus-associated) Induced 
USP8 ubiquitin specific peptidase 8 Induced 
USP9X ubiquitin specific peptidase 9, X-linked Input 
UVRAG UV radiation resistance associated Induced 
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Supplementary Table II-5 (continued): G1-X-G2 Analysis-Induced EGFRI Resistance 
Network Members that interact with CK2α or CK2α’ within one or two edges.  
 
SYMBOL GENE NAME TYPE 
VIM Vimentin Input 
VPS16 vacuolar protein sorting 16 homolog (S. cerevisiae) Induced 
VPS33B vacuolar protein sorting 33 homolog B (yeast) Input 
WASL Wiskott-Aldrich syndrome-like Induced 
WDHD1 WD repeat and HMG-box DNA binding protein 1 Induced 
WDR48 WD repeat domain 48 Induced 
WRN Werner syndrome, RecQ helicase-like Input 
WWP1 WW domain containing E3 ubiquitin protein ligase 1 Induced 
WWP2 WW domain containing E3 ubiquitin protein ligase 2 Induced 
XIAP X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase Induced 
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining) Induced 
XRCC6 X-ray repair complementing defective repair in Chinese hamster cells 6 Induced 
YAP1 Yes-associated protein 1 Induced 
YBX1 Y box binding protein 1 Induced 
YEATS4 YEATS domain containing 4 Induced 
YKT6 YKT6 v-SNARE homolog (S. cerevisiae) Induced 
YWHAB tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta Induced 
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon Induced 
YWHAH tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta Induced 
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta Induced 
ZC3H14 zinc finger CCCH-type containing 14 Input 
ZEB1 zinc finger E-box binding homeobox 1 Input 
ZYX Zyxin Induced 
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Supplementary Table II-6: G1-X-G2 Analysis-Induced EGFRI Resistance Network 
Members that do not interact with CK2α or CK2α’. Table members were generated 
using the 85 independent Ensembl IDs identified by the FS analysis. Table members 
generated by the STRING analysis considering the scenario G1-X-G2 where G1 and G2 
are from the original list of 85 Ensembl IDs of mRNA found to be upregulated in EGFRI 
resistant NSCLC cells and X is any other node that connects them. Table members are 
from the complete network of 385 proteins that do not interact with CK2α or CK2α’ within 
one or two edges. 
 
SYMBOL GENE NAME TYPE 
ARHGEF9 Cdc42 guanine nucleotide exchange factor 9 Input 
DHRS4 
DHRS4L2 
DHRS4L1 
dehydrogenase/reductase (SDR family) member 4, 
dehydrogenase/reductase (SDR family) member 4 
like 2, dehydrogenase/reductase (SDR family) 
member 4 like 1 
Input 
EGF epidermal growth factor Induced 
FANCF Fanconi anemia, complementation group F Input 
FBXO31 F-box protein 31 Input 
GAB1 GRB2-associated binding protein 1 Induced 
GNG11 guanine nucleotide binding protein (G protein), gamma 11 Input 
KNG1 kininogen 1 Induced 
LDHAL6B lactate dehydrogenase A-like 6B Induced 
MINOS1 mitochondrial inner membrane organizing system 1 Induced 
NRG1 neuregulin 1 Input 
NUBP2 nucleotide binding protein 2 Input 
PLK5 polo-like kinase 5 Induced 
PMP22 peripheral myelin protein 22 Input 
RAB11FIP2 RAB11 family interacting protein 2 (class I) Input 
RNMTL1 RNA methyltransferase like 1 Input 
S100A3 S100 calcium binding protein A3 Input 
TFE3 transcription factor binding to IGHM enhancer 3 Input 
TNFSF9 tumor necrosis factor (ligand) superfamily, member 9 Input 
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Supplementary Table II-7: Induced network members sorted by putative collective 
activity of community members. Communities of genes were determined from the 
induced network using the cluster_walktrap function in igraph v1.0.1 (Described in 
Appendix IV) (385, 386).   
 
Supplementary Table II-7, Community #1: (Putative hallmark/functions: genomic 
instability, replicative immortality) 
 
SYMBOL GENE NAME TYPE 
ATM ATM serine/threonine kinase Induced 
BARD1 BRCA1 associated RING domain 1 Induced 
BLM Bloom syndrome, RecQ helicase-like Induced 
BRE brain and reproductive organ-expressed (TNFRSF1A modulator) Induced 
CHAF1A chromatin assembly factor 1, subunit A (p150) Induced 
DKC1 dyskeratosis congenita 1, dyskerin Induced 
FAM175A family with sequence similarity 175, member A Induced 
FANCA Fanconi anemia, complementation group A Induced 
FANCF Fanconi anemia, complementation group F Input 
FANCG Fanconi anemia, complementation group G Induced 
FANCM Fanconi anemia, complementation group M Induced 
H2AFX H2A histone family, member X Induced 
HES1 hes family bHLH transcription factor 1 Induced 
LIG3 ligase III, DNA, ATP-dependent Input 
MDC1 mediator of DNA-damage checkpoint 1 Induced 
MLH3 mutL homolog 3 Induced 
MSH2 mutS homolog 2 Induced 
NSMCE2 NSE2/MMS21 homolog, SMC5-SMC6 SUMO ligase Induced 
PARP1 poly (ADP-ribose) polymerase 1 Induced 
PCNA proliferating cell nuclear antigen Induced 
POLB polymerase (DNA directed), beta Induced 
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Supplementary Table II-7, Community #1 (continued): (Putative hallmark/functions: 
genomic instability, replicative immortality) 
 
SYMBOL GENE NAME TYPE 
POLR1C polymerase (RNA) I polypeptide C, 30kDa Induced 
PWP1 PWP1 homolog, endonuclein Input 
RAD51 RAD51 recombinase Induced 
SMC1A structural maintenance of chromosomes 1A Input 
SUMO2 small ubiquitin-like modifier 2 Induced 
SUMO3 small ubiquitin-like modifier 3 Induced 
TOP2A topoisomerase (DNA) II alpha Induced 
TOP2B topoisomerase (DNA) II beta Induced 
TOP3B topoisomerase (DNA) III beta Induced 
TP53BP1 tumor protein p53 binding protein 1 Induced 
UIMC1 ubiquitin interaction motif containing 1 Input 
WDHD1 WD repeat and HMG-box DNA binding protein 1 Induced 
WRN Werner syndrome, RecQ helicase-like Input 
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining) Induced 
XRCC6 X-ray repair complementing defective repair in Chinese hamster cells 6 Induced 
 
 
  
APPENDIX II 
202 
 
Supplementary Table II-7, Community #2: (Putative hallmark/functions: growth 
signal autonomy, invasion and metastasis, proteomic instability, EGFRI 
RESISTANCE MECHANISMS) 
 
SYMBOL GENE NAME TYPE 
DVL2 dishevelled segment polarity protein 2 Induced 
EGF epidermal growth factor Induced 
ERBB2 erb-b2 receptor tyrosine kinase 2 Induced 
ERBB3 erb-b2 receptor tyrosine kinase 3 Induced 
ERBB4 erb-b2 receptor tyrosine kinase 4 Induced 
FBXL15 F-box and leucine-rich repeat protein 15 Input 
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein Input 
ITCH itchy E3 ubiquitin protein ligase Induced 
KRAS Kirsten rat sarcoma viral oncogene homolog Induced 
LIN7C lin-7 homolog C (C. elegans) Induced 
NDFIP1 Nedd4 family interacting protein 1 Induced 
NDFIP2 Nedd4 family interacting protein 2 Induced 
NEDD4 neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase Induced 
NOTCH1 notch 1 Induced 
NOTCH2 notch 2 Induced 
NOTCH3 notch 3 Induced 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog Induced 
NRG1 neuregulin 1 Input 
RASA1 RAS p21 protein activator (GTPase activating protein) 1 Induced 
SMURF1 SMAD specific E3 ubiquitin protein ligase 1 Induced 
WWP1 WW domain containing E3 ubiquitin protein ligase 1 Induced 
WWP2 WW domain containing E3 ubiquitin protein ligase 2 Induced 
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Supplementary Table II-7, Community #3: (Putative hallmark/functions: genomic 
instability, deregulating cellular energetics) 
 
SYMBOL GENE NAME TYPE 
GRSF1 G-rich RNA sequence binding factor 1 Induced 
MRPS7 mitochondrial ribosomal protein S7 Induced 
RNMTL1 RNA methyltransferase like 1 Input 
USP39 ubiquitin specific peptidase 39 Induced 
 
 
Supplementary Table II-7, Community #4: (Putative hallmark/functions: growth 
signal autonomy, proteomic instability, EGFRI RESISTANCE MECHANISMS) 
 
SYMBOL GENE NAME TYPE 
AKT1 v-akt murine thymoma viral oncogene homolog 1 Induced 
AKT2 v-akt murine thymoma viral oncogene homolog 2 Induced 
AP2A1 adaptor-related protein complex 2, alpha 1 subunit Induced 
APC adenomatous polyposis coli Induced 
ARHGEF40 Rho guanine nucleotide exchange factor (406) 40 Input 
ARRB2 arrestin, beta 2 Induced 
BCL2 B-cell CLL/lymphoma 2 Induced 
CAV1 caveolin 1, caveolae protein, 22kDa Induced 
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase Induced 
CDC37 cell division cycle 37 Induced 
EGFR epidermal growth factor receptor Input 
EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 Induced 
EPN1 epsin 1 Induced 
EPS15 epidermal growth factor receptor pathway substrate 15 Induced 
GAB1 GRB2-associated binding protein 1 Induced 
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Supplementary Table II-7, Community #4 (continued): (Putative hallmark/functions: 
growth signal autonomy, proteomic instability, EGFRI RESISTANCE MECHANISMS) 
 
SYMBOL GENE NAME TYPE 
GAPDH glyceraldehyde-3-phosphate dehydrogenase Induced 
GLRX glutaredoxin (thioltransferase) Input 
HGS hepatocyte growth factor-regulated tyrosine kinase substrate Induced 
HRAS Harvey rat sarcoma viral oncogene homolog Induced 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 Induced 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B member 1 Induced 
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 Induced 
HSPA12A heat shock 70kDa protein 12A Input 
HSPA4 heat shock 70kDa protein 4 Induced 
HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) Induced 
HSPB1 heat shock 27kDa protein 1 Induced 
HTT Huntingtin Induced 
IGF1R insulin-like growth factor 1 receptor Induced 
IRS1 insulin receptor substrate 1 Induced 
IRS2 insulin receptor substrate 2 Induced 
IRS4 insulin receptor substrate 4 Induced 
KCTD9 potassium channel tetramerization domain containing 9 Input 
LRRK2 leucine-rich repeat kinase 2 Induced 
MAP1LC3A microtubule-associated protein 1 light chain 3 alpha Induced 
MAP3K3 mitogen-activated protein kinase kinase kinase 3 Induced 
MAP3K5 mitogen-activated protein kinase kinase kinase 5 Induced 
MAPK1 mitogen-activated protein kinase 1 Induced 
MAPT microtubule-associated protein tau Induced 
MARK2 MAP/microtubule affinity-regulating kinase 2 Induced 
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Supplementary Table II-7, Community #4 (continued): (Putative hallmark/functions: 
growth signal autonomy, proteomic instability, EGFRI RESISTANCE MECHANISMS) 
 
SYMBOL GENE NAME TYPE 
MET MET proto-oncogene, receptor tyrosine kinase Induced 
MTOR mechanistic target of rapamycin (serine/threonine kinase) Induced 
MVP major vault protein Induced 
PDGFRB platelet-derived growth factor receptor, beta polypeptide Induced 
PRKACA protein kinase, cAMP-dependent, catalytic, alpha Induced 
PRKCA protein kinase C, alpha Induced 
PRKCB protein kinase C, beta Induced 
PRKCD protein kinase C, delta Induced 
PRKCZ protein kinase C, zeta Induced 
PRKD1 protein kinase D1 Induced 
PTK2 protein tyrosine kinase 2 Induced 
PTPN1 protein tyrosine phosphatase, non-receptor type 1 Induced 
PTPN11 protein tyrosine phosphatase, non-receptor type 11 Induced 
RAF1 Raf-1 proto-oncogene, serine/threonine kinase Induced 
RPTOR regulatory associated protein of MTOR, complex 1 Induced 
SNCA synuclein, α (non A4 component of amyloid precursor) Induced 
SRC SRC proto-oncogene, non-receptor tyrosine kinase Induced 
STAT5A signal transducer and activator of transcription 5A Induced 
STUB1 STIP1 homology and U-box containing protein 1, E3 ubiquitin ligase Induced 
TTC28 tetratricopeptide repeat domain 28 Input 
TUBA1A tubulin, alpha 1a Induced 
TUBA4A tubulin, alpha 4a Induced 
USP8 ubiquitin specific peptidase 8 Induced 
YAP1 Yes-associated protein 1 Induced 
YWHAB tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta Induced 
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Supplementary Table II-7, Community #4 (continued): (Putative hallmark/functions: 
growth signal autonomy, proteomic instability, EGFRI RESISTANCE MECHANISMS) 
 
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon Induced 
YWHAH tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta Induced 
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta Induced 
 
 
Supplementary Table II-7, Community #5: (Putative hallmark/functions: invasion 
and metastasis, proteomic instability, replicative immortality) 
 
SYMBOL GENE NAME TYPE 
ACTA1 actin, alpha 1, skeletal muscle Induced 
ACTA2 actin, alpha 2, smooth muscle, aorta Input 
ADSS adenylosuccinate synthase Induced 
CALM1 
CALM2 
calmodulin 1 (phosphorylase kinase, delta), 
calmodulin 2 (phosphorylase kinase, delta) Induced 
CALM2 calmodulin 2 (phosphorylase kinase, delta) Induced 
CAMK1 calcium/calmodulin-dependent protein kinase I Input 
CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 Induced 
CAPZB capping protein (actin filament) muscle Z-line, beta Induced 
CD2AP CD2-associated protein Induced 
CFL1 cofilin 1 (non-muscle) Induced 
DLG1 discs, large homolog 1 (Drosophila) Induced 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 Induced 
EIF3A eukaryotic translation initiation factor 3, subunit A Input 
ELAVL1 ELAV like RNA binding protein 1 Induced 
H2AFV H2A histone family, member V Induced 
HECW2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 Induced 
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Supplementary Table II-7, Community #5 (continued): (Putative hallmark/functions: 
invasion and metastasis, proteomic instability, replicative immortality) 
 
SYMBOL GENE NAME TYPE 
HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 Induced 
HNRNPF heterogeneous nuclear ribonucleoprotein F Induced 
HSPA9 heat shock 70kDa protein 9 (mortalin) Induced 
IQGAP1 IQ motif containing GTPase activating protein 1 Induced 
MYH11 myosin, heavy chain 11, smooth muscle Induced 
MYH9 myosin, heavy chain 9, non-muscle Induced 
NUDT21 nudix (nucleoside diphosphate linked moiety X)-type motif 21 Induced 
PIK3C2A phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha Induced 
PRDX1 peroxiredoxin 1 Induced 
SGTA small glutamine-rich tetratricopeptide repeat-containing, alpha Induced 
SLC25A3 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 Induced 
SPTAN1 spectrin, alpha, non-erythrocytic 1 Induced 
SSU72 SSU72 homolog, RNA polymerase II CTD phosphatase Induced 
TJP1 tight junction protein 1 Induced 
TXN Thioredoxin Induced 
UBC ubiquitin C Induced 
VIM Vimentin Input 
WASL Wiskott-Aldrich syndrome-like Induced 
WDR48 WD repeat domain 48 Induced 
YBX1 Y box binding protein 1 Induced 
YEATS4 YEATS domain containing 4 Induced 
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Supplementary Table II-7, Community #6: (Putative hallmark/functions: invasion 
and metastasis, growth and proliferation, cytoskeletal requirements) 
 
SYMBOL GENE NAME TYPE 
C1QBP complement component 1, q subcomponent binding protein Input 
CKAP5 cytoskeleton associated protein 5 Induced 
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) Induced 
MINOS1 mitochondrial inner membrane organizing system 1 Induced 
PLK2 polo-like kinase 2 Induced 
PLK3 polo-like kinase 3 Induced 
PLK4 polo-like kinase 4 Induced 
PLK5 polo-like kinase 5 Induced 
TOMM40 translocase of outer mitochondrial membrane 40 homolog (yeast) Induced 
TUBGCP2 tubulin, gamma complex associated protein 2 Input 
TUBGCP4 tubulin, gamma complex associated protein 4 Induced 
 
 
Supplementary Table II-7, Community #7: (Putative hallmark/functions: evasion of 
growth suppressors, proteomic instability, evasion of apoptosis) 
 
SYMBOL GENE NAME TYPE 
ACACB acetyl-CoA carboxylase beta Induced 
BABAM1 BRISC and BRCA1 A complex member 1 Induced 
BRCC3 BRCA1/BRCA2-containing complex, subunit 3 Input 
CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase Induced 
CCT4 chaperonin containing TCP1, subunit 4 (delta) Induced 
COPS5 COP9 signalosome subunit 5 Induced 
CUL1 cullin 1 Induced 
DPYSL3 dihydropyrimidinase-like 3 Input 
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Supplementary Table II-7, Community #7 (continued): (Putative hallmark/functions: 
evasion of growth suppressors, proteomic instability, evasion of apoptosis) 
 
SYMBOL GENE NAME TYPE 
ERP44 endoplasmic reticulum protein 44 Induced 
FAM175B family with sequence similarity 175, member B Induced 
HUWE1 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase Induced 
IGBP1 immunoglobulin (CD79A) binding protein 1 Induced 
IKBKAP inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein Induced 
NEDD8 neural precursor cell expressed, developmentally down-regulated 8 Induced 
NUBP2 nucleotide binding protein 2 Input 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Induced 
PABPC4 poly(A) binding protein, cytoplasmic 4 (inducible form) Induced 
PFAS phosphoribosylformylglycinamidine synthase Input 
PLK1 polo-like kinase 1 Induced 
PPP2CA protein phosphatase 2, catalytic subunit, alpha isozyme Induced 
PSMD4 proteasome 26S subunit, non-ATPase 4 Induced 
RAD23B RAD23 homolog B, nucleotide excision repair protein Induced 
RPL17 ribosomal protein L17 Induced 
RPL5 ribosomal protein L5 Induced 
RPS20 ribosomal protein S20 Induced 
RPS23 ribosomal protein S23 Induced 
RPS27A ribosomal protein S27a Induced 
RPS7 ribosomal protein S7 Induced 
SEC23A Sec23 homolog A, COPII coat complex component Induced 
SIN3A SIN3 transcription regulator family member A Induced 
TCP1 t-complex 1 Induced 
UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 Induced 
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Supplementary Table II-7, Community #7 (continued): (Putative hallmark/functions: 
evasion of growth suppressors, proteomic instability, evasion of apoptosis) 
 
SYMBOL GENE NAME TYPE 
UBB ubiquitin B Induced 
UBE2D1 ubiquitin-conjugating enzyme E2D 1 Induced 
UBE2D2 ubiquitin-conjugating enzyme E2D 2 Induced 
UBE2L3 ubiquitin-conjugating enzyme E2L 3 Induced 
UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 Induced 
UBL4A ubiquitin-like 4A Induced 
UBQLN1 ubiquilin 1 Induced 
UBQLN2 ubiquilin 2 Induced 
UBQLN4 ubiquilin 4 Induced 
UBQLNL ubiquilin-like Induced 
UBR4 ubiquitin protein ligase E3 component n-recognin 4 Induced 
UBXN7 UBX domain protein 7 Induced 
UCHL3 ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) Induced 
USP10 ubiquitin specific peptidase 10 Induced 
USP14 ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase) Induced 
USP34 ubiquitin specific peptidase 34 Induced 
USP7 ubiquitin specific peptidase 7 (herpes virus-associated) Induced 
USP9X ubiquitin specific peptidase 9, X-linked Input 
ZYX Zyxin Induced 
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Supplementary Table II-7, Community #8: (Putative hallmark/functions: tumor 
promoting inflammation, evasion of apoptosis) 
 
SYMBOL GENE NAME TYPE 
BIRC2 baculoviral IAP repeat containing 2 Induced 
BIRC3 baculoviral IAP repeat containing 3 Induced 
CASP8 caspase 8, apoptosis-related cysteine peptidase Induced 
MAP3K1 mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase Induced 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 Induced 
MAVS mitochondrial antiviral signaling protein Induced 
RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 Induced 
SHARPIN SHANK-associated RH domain interactor Induced 
TLR4 toll-like receptor 4 Induced 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A Induced 
TNFSF9 tumor necrosis factor (ligand) superfamily, member 9 Input 
TRAF1 TNF receptor-associated factor 1 Induced 
TRAF2 TNF receptor-associated factor 2 Induced 
UBE2N ubiquitin-conjugating enzyme E2N Induced 
XIAP X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase Induced 
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Supplementary Table II-7, Community #9: (Putative hallmark/functions: proteomic 
instability, evasion of apoptosis) 
 
SYMBOL GENE NAME TYPE 
CNOT4 CCR4-NOT transcription complex, subunit 4 Induced 
NSF N-ethylmaleimide-sensitive factor Induced 
PSMA2 proteasome subunit alpha 2 Induced 
PSMA3 proteasome subunit alpha 3 Induced 
PSMA4 proteasome subunit alpha 4 Induced 
PSMA7 proteasome subunit alpha 7 Induced 
PSMA8 proteasome subunit alpha 8 Induced 
PSMB1 proteasome subunit beta 1 Induced 
PSMB2 proteasome subunit beta 2 Induced 
PSMB4 proteasome subunit beta 4 Induced 
PSMD6 proteasome 26S subunit, non-ATPase 6 Induced 
RQCD1 RCD1 required for cell differentiation1 homolog (S. pombe) Induced 
SACS sacsin molecular chaperone Input 
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Supplementary Table II-7, Community #10: (Putative hallmark/functions: genomic 
instability) 
 
SYMBOL GENE NAME TYPE 
EIF4A3 eukaryotic translation initiation factor 4A3 Induced 
EXOSC10 exosome component 10 Induced 
MAGOH mago homolog, exon junction complex core component Induced 
NUP153 nucleoporin 153kDa Induced 
NXF1 nuclear RNA export factor 1 Induced 
RAN RAN, member RAS oncogene family Induced 
RANGRF RAN guanine nucleotide release factor Input 
RBM3 RNA binding motif (RNP1, RRM) protein 3 Input 
SNRPA small nuclear ribonucleoprotein polypeptide A Induced 
TNPO1 transportin 1 Input 
TPR translocated promoter region, nuclear basket protein Induced 
 
 
 
Supplementary Table II-7, Community #11: (Putative hallmark/functions: evasion of 
growth suppressors, evasion of apoptosis) 
 
SYMBOL GENE NAME TYPE 
ANXA6 annexin A6 Input 
IMPA1 inositol(myo)-1(or 4)-monophosphatase 1 Input 
S100B S100 calcium binding protein B Induced 
 
  
APPENDIX II 
214 
 
Supplementary Table II-7, Community #12: (Putative hallmark/functions: growth 
signal autonomy, evasion of growth suppressors) 
 
SYMBOL GENE NAME TYPE 
PIP5K1A phosphatidylinositol-4-phosphate 5-kinase, type I, alpha Induced 
PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme Induced 
PPP3CC protein phosphatase 3, catalytic subunit, gamma isozyme Input 
RAB11A RAB11A, member RAS oncogene family Induced 
RAB11B RAB11B, member RAS oncogene family Induced 
RAB11FIP2 RAB11 family interacting protein 2 (class I) Input 
 
 
 
Supplementary Table II-7, Community #13: (Putative hallmark/functions: 
deregulating cellular energetics) 
 
SYMBOL GENE NAME TYPE 
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 Induced 
ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9) Input 
 
 
 
Supplementary Table II-7, Community #14: (Putative hallmark/functions: 
deregulating cellular energetics) 
 
SYMBOL GENE NAME TYPE 
COX15 cytochrome c oxidase assembly homolog 15 (yeast) Input 
LAMTOR3 late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 Induced 
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Supplementary Table II-7, Community #15: (Putative hallmark/functions: tumor 
promoting inflammation) 
 
SYMBOL GENE NAME TYPE 
MTMR9 myotubularin related protein 9 Input 
NMI N-myc (and STAT) interactor Induced 
POMZP3 POM121 and ZP3 fusion Input 
 
 
 
Supplementary Table II-7, Community #16: (Putative hallmark/functions: tumor 
promoting inflammation, angiogenesis, tumor microenvironment influence) 
 
SYMBOL GENE NAME TYPE 
CTSL cathepsin L Input 
KNG1 kininogen 1 Induced 
 
 
 
Supplementary Table II-7, Community #17: (Putative hallmark/functions: 
deregulating cellular energetics) 
 
SYMBOL GENE NAME TYPE 
BCCIP BRCA2 and CDKN1A interacting protein Input 
CHORDC1 cysteine and histidine-rich domain (CHORD) containing 1 Induced 
GDA guanine deaminase Induced 
KYNU Kynureninase Input 
LDHA lactate dehydrogenase A Induced 
SMS spermine synthase Induced 
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Supplementary Table II-7, Community #18: (Putative hallmark/functions: 
deregulating cellular energetics) 
 
SYMBOL GENE NAME TYPE 
DARS2 aspartyl-tRNA synthetase 2, mitochondrial Input 
DCP2 decapping mRNA 2 Induced 
 
 
Supplementary Table II-7, Community #19: (Putative hallmark/functions: growth 
signal autonomy, invasion and metastasis, genomic instability) 
 
SYMBOL GENE NAME TYPE 
AR androgen receptor Induced 
AURKA aurora kinase A Induced 
BRCA1 breast cancer 1, early onset Induced 
BTRC beta-transducin repeat containing E3 ubiquitin protein ligase Induced 
CCND1 cyclin D1 Induced 
CDH1 cadherin 1, type 1 Induced 
CDK1 cyclin-dependent kinase 1 Induced 
CDK2 cyclin-dependent kinase 2 Induced 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) Induced 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) Induced 
CHUK conserved helix-loop-helix ubiquitous kinase Input 
CREBBP CREB binding protein Induced 
CSNK2A1 casein kinase 2, alpha 1 polypeptide Induced 
CSNK2A2 casein kinase 2, alpha prime polypeptide Induced 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa Induced 
EP300 E1A binding protein p300 Induced 
ESR1 estrogen receptor 1 Induced 
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Supplementary Table II-7, Community #19 (continued): (Putative 
hallmark/functions: growth signal autonomy, invasion and metastasis, genomic 
instability) 
 
SYMBOL GENE NAME TYPE 
FBXO31 F-box protein 31 Input 
FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase Induced 
HDAC1 histone deacetylase 1 Induced 
HIST3H3 histone cluster 3, H3 Induced 
KEAP1 kelch-like ECH-associated protein 1 Induced 
NCOA3 nuclear receptor coactivator 3 Induced 
NR3C1 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) Induced 
PBK PDZ binding kinase Input 
PML promyelocytic leukemia Induced 
PRKDC protein kinase, DNA-activated, catalytic polypeptide Induced 
PTEN phosphatase and tensin homolog Input 
PTMA prothymosin, alpha, prothymosin alpha-like Induced 
RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) Induced 
RBX1 ring-box 1, E3 ubiquitin protein ligase Induced 
RUVBL1 RuvB-like AAA ATPase 1 Induced 
SIRT1 sirtuin 1 Induced 
SKP1 S-phase kinase-associated protein 1 Induced 
SMAD1 SMAD family member 1 Induced 
SMAD 2 SMAD family member 2 Induced 
SMAD 3 SMAD family member 3 Induced 
SMAD 4 SMAD family member 4 Induced 
SUMO1 small ubiquitin-like modifier 1 Induced 
TERT telomerase reverse transcriptase Induced 
TP53 tumor protein p53 Induced 
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Supplementary Table II-7, Community #19 (continued): (Putative 
hallmark/functions: growth signal autonomy, invasion and metastasis, genomic 
instability) 
 
UBE2I ubiquitin-conjugating enzyme E2I Induced 
ZEB1 zinc finger E-box binding homeobox 1 Input 
 
 
 
Supplementary Table II-7, Community #20: (Putative hallmark/functions: genomic 
instability, proteomic instability) 
 
SYMBOL GENE NAME TYPE 
RAB7A RAB7A, member RAS oncogene family Induced 
UVRAG UV radiation resistance associated Induced 
VPS16 vacuolar protein sorting 16 homolog (S. cerevisiae) Induced 
VPS33B vacuolar protein sorting 33 homolog B (yeast) Input 
 
 
 
Supplementary Table II-7, Community #21: (Putative hallmark/functions: growth 
signal autonomy, deregulating cellular energetics, Endo/Exocytosis) 
 
SYMBOL GENE NAME TYPE 
STX2 syntaxin 2 Input 
YKT6 YKT6 v-SNARE homolog (S. cerevisiae) Induced 
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Supplementary Table II-7, Community #22: (Putative hallmark/functions: growth 
signal autonomy, proteomic instability) 
 
SYMBOL GENE NAME TYPE 
CRTAP cartilage associated protein Input 
TOM1L1 target of myb1 like 1 membrane trafficking protein Induced 
 
 
 
Supplementary Table II-7, Community #23: (Putative hallmark/functions: post-
translational gene regulation, proteomic instability) 
 
SYMBOL GENE NAME TYPE 
DAZAP1 DAZ associated protein 1 Induced 
MSI1 musashi RNA-binding protein 1 Induced 
MSI2 musashi RNA-binding protein 2 Induced 
ZC3H14 zinc finger CCCH-type containing 14 Input 
 
 
 
Supplementary Table II-7, Community #24: (Putative hallmark/functions: genomic 
instability) 
 
SYMBOL GENE NAME TYPE 
CSE1L CSE1 chromosome segregation 1-like (yeast) Induced 
SLC9A3R1 solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 1 Induced 
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Supplementary Table II-7, Community #25: (Putative hallmark/functions: 
deregulating cellular energetics, proteomic instability) 
 
SYMBOL GENE NAME TYPE 
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 Input 
UBR7 ubiquitin protein ligase E3 component n-recognin 7 (putative) Induced 
 
 
 
Supplementary Table II-7, Community #26: (Putative hallmark/functions: 
deregulating cellular energetics) 
 
SYMBOL GENE NAME TYPE 
GNS glucosamine (N-acetyl)-6-sulfatase Induced 
LDHAL6B lactate dehydrogenase A-like 6B Induced 
NAGK N-acetylglucosamine kinase Induced 
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Supplementary Table II-7, Proteins with no community affiliation: 
 
SYMBOL GENE NAME TYPE 
PROCR protein C receptor, endothelial Input 
GNG11 guanine nucleotide binding protein (G protein), gamma 11 Input 
ARHGEF9 Cdc42 guanine nucleotide exchange factor (406) 9 Input 
DOCK10 dedicator of cytokinesis 10 Input 
INVS Inversin Input 
DIP2C disco-interacting protein 2 homolog C Input 
S100A1 S100 calcium binding protein A1 Induced 
ADCY9 adenylate cyclase 9 Input 
HS1BP3 HCLS1 binding protein 3 Input 
PMP22 peripheral myelin protein 22 Input 
TFE3 transcription factor binding to IGHM enhancer 3 Input 
DHRS4:D
HRS4L2:
DHRS4L1 
dehydrogenase/reductase (SDR family) member 4, 
dehydrogenase/reductase (SDR family) member 4 like 
2, dehydrogenase/reductase (SDR family) member 4 
like 1 
Input 
MID1IP1 MID1 interacting protein 1 Input 
ANGEL2 angel homolog 2 (Drosophila) Input 
PEX19 peroxisomal biogenesis factor 19 Induced 
S100A3 S100 calcium binding protein A3 Input 
CUTC cutC copper transporter Input 
IGFBP3 insulin-like growth factor binding protein 3 Induced 
DIXDC1 DIX domain containing 1 Input 
FASTKD1 FAST kinase domains 1 Input 
PEX5 peroxisomal biogenesis factor 5 Induced 
GPHN Gephyrin Induced 
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Supplementary Figure II-1: NSCLC cells most sensitive to CX-4945 have decreased 
CSNK2B expression. U133A Affymetrix signal intensity values for (A) CSNK2A1 
(Averaged of three probesets: 212072_s_at, 206075_s_at, and 212075_s_at), (B) 
CSNK2A2 (203575_at), and (C) CSNK2B (201390_s_at) probesets were generated from 
untreated NSCLC cell lines (n=3) with using Affymetrix MAS v5.0 software [Balko, 2006 
#238]. Values for each gene set were normalized to corresponding expression in Small 
Airway Epithelial Cells (SAEC) and is shown as percent change. 
 
 
A       
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Supplementary Figure II-1 (continued): NSCLC cells most sensitive to CX-4945 have 
decreased CSNK2B expression. U133A Affymetrix signal intensity values for (A) 
CSNK2A1 (Averaged of three probesets: 212072_s_at, 206075_s_at, and 212075_s_at), 
(B) CSNK2A2 (203575_at), and (C) CSNK2B (201390_s_at) probesets were generated 
from untreated NSCLC cell lines (n=3) with using Affymetrix MAS v5.0 software [Balko, 
2006 #238]. Values for each gene set were normalized to corresponding expression in 
Small Airway Epithelial Cells (SAEC) and is shown as percent change. 
 
B 
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Supplementary Figure II-1 (continued): NSCLC cells most sensitive to CX-4945 have 
decreased CSNK2B expression. U133A Affymetrix signal intensity values for (A) 
CSNK2A1 (Averaged of three probesets: 212072_s_at, 206075_s_at, and 212075_s_at), 
(B) CSNK2A2 (203575_at), and (C) CSNK2B (201390_s_at) probesets were generated 
from untreated NSCLC cell lines (n=3) with using Affymetrix MAS v5.0 software [Balko, 
2006 #238]. Values for each gene set were normalized to corresponding expression in 
Small Airway Epithelial Cells (SAEC) and is shown as percent change. 
 
C 
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APPENDIX III: SUPPLEMENTARY FIGURES FOR CHAPTER 5 
 
Supplementary Figure III-1: Comparison of CX-4945 treatment on erlotinib 
response. A549 and PC9 samples treated only with ± 1µM CX-4945 from Figures 3 and 
5 to determine the impact of 7-day incubation of CX-4945 on erlotinib sensitivity in cells 
not modulated with TGFβ, LY-2109761, or SB-431542. Unpaired t-test comparing 
untreated and CX-4945 treated curves indicates that the differences between the curves 
are not significant. 
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